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Abstract 
 
Autoimmune inflammatory disorders such as systemic lupus erythematosus (SLE) 
remain debilitating conditions, as many patients are refractory to existing 
conventional and biologic therapies or suffer serious adverse effects, such as 
susceptibility to catastrophic infection. Therapies based on the actions of parasite-
derived immunomodulators that dampen inflammation to promote the survival of 
the parasite without seriously immunocompromising the host, may therefore 
provide alternative strategies for the development of novel and safer drugs. One 
such molecule, ES-62, protects against disease in mouse models of rheumatoid 
arthritis and asthma; in both of these pathologies, suppression of disease is due to 
modulation of pathogenic IL-17A responses. As IL-17A has been implicated in the 
pathogenesis of SLE, in this thesis, the therapeutic potential of ES-62 is explored 
in the MRL/lpr mouse model of SLE. 
  
SLE is characterized by autoantibody responses to dsDNA, as well as other 
nuclear and cytoplasmic antigens, which result in the deposition of autoantibody-
immune complexes that cause localized inflammation in tissues with dense 
capillary networks, most often the skin, joints and kidneys. The MRL/lpr mouse is 
genetically predisposed to develop lupus-like pathology displaying many of the 
characteristics of human disease, including the major cause of morbidity, 
glomerulonephritis. Twice weekly treatment of MRL/lpr mice with ES-62 
significantly suppressed the development of proteinuria, a direct measure of renal 
dysfunction. Despite drastic improvement in renal function, the kidneys from ES-62 
treated mice did not show substantial improvement in histopathology as indicated 
by the overall levels of glomeruloproliferation, cellular infiltration and complement 
or immunoglobulin deposition in the kidneys. However, exposure to ES-62 did 
reduce the expression of complement (C3aR and C5aR) and immunoglobulin 
receptors (FcγRI (CD64)), thus rendering renal cells hypo-responsive to these pro-
inflammatory stimuli. Moreover, by modulating MyD88 signaling, ES-62 likely 
suppresses renal cell responsiveness to chronic DAMP and IL-1 signals as well as 
potentially promoting glomerular barrier stability.  
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Consistent with their hypo-responsive phenotype, renal fibroblasts from ES-62 
treated mice produced less MCP-1 in response to TLR stimulation and this was 
associated with reduced infiltration into the kidney by effector T and B cells and 
granulocytes; along with the ability of the parasite product to modulate the 
production of the pro-inflammatory cytokines IL-17A and IL-22. ES-62 suppressed 
the production of IL-22 both prior to and following onset of disease suggesting a 
key role for this cytokine in lupus pathogenesis, a proposal confirmed by 
neutralization studies which demonstrated that IL-22 played an essential role in 
the development of disease in the MRL/lpr mouse. This was further supported by 
studies showing that recombinant IL-22 significantly accelerated and exacerbated 
disease. By contrast, despite suppressing early IL-17A responses, the production 
of IL-17A was significantly increased in ES-62 treated mice during the established 
phase of disease, suggesting that IL-17A may promote pathogenesis during the 
initiation of pathology, yet act to resolve aberrant inflammation in the kidney. This 
potential dual role for IL-17A in the regulation of kidney inflammation was 
corroborated by studies using neutralizing antibodies and recombinant IL-17A, as 
the early neutralization of IL-17A production slowed the onset and severity of 
proteinuria and the late administration of rIL-17A suppressed disease severity.  
 
Aberrant B cell responses drive pathogenesis both in murine models of SLE and 
also in human disease: reflecting this, B cell depleting therapies have proved 
successful in the clinic. Thus, the effects of ES-62 on the population dynamics of 
effector and regulatory B cell subsets were investigated and these studies 
revealed that ES-62 induced a hypo-responsive B cell phenotype that was 
associated with modulated development, migration and/or activation of pathogenic 
effector B cells. Furthermore, the proportion of IL-10 producing ‘regulatory’ B cells 
were significantly elevated in the ES-62 treated MRL/lpr mice during the 
established phase of disease. Crucially, the protection afforded against the 
development of proteinuria by ES-62 was mimicked by the adoptive transfer of B 
cells from ES-62 treated MRL/lpr mice: moreover, such protection was associated 
with modulation of the IL-17A/IL-22 axis, as observed in MRL/lpr mice treated with 
ES-62. 
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Together with previous reports on the therapeutic potential of ES-62 in arthritis and 
asthma, these studies suggest that therapies based on the parasite product have 
a future in the clinic. ES-62 itself is not suitable as a therapy, due to it 
immunogenic nature and the complexity of its biosynthesis: thus small molecular 
analogues (SMAs) of the parasite product have been synthesized. Two of these 
were tested in the MRL/lpr mouse and found to suppress the development of 
proteinuria, even when administered after the onset of pathology. This protection, 
as with that afforded by ES-62, was associated with a modulation of MyD88 
signaling in the kidney and indicates that novel drugs, based on the safe 
modulation of the immune system by the parasite derived product, ES-62, have 
the potential to treat lupus nephritis in SLE patients.  
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1. General introduction 
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1.1. Immunity: a double-edged sword. 
The immune system has evolved to protect us from disease by developing efficient 
mechanisms to eliminate pathogens whilst limiting host pathology resulting from 
inflammation. The advent of increased sanitation and widespread vaccination 
uptake has resulted in reduced exposure to infectious agents, consequently, 
aberrant or inappropriately strong immune responses are increasingly prevalent, 
resulting in a variety of pathologies and underlining the need for highly regulated 
immune responses. Such aberrant hyper-immune responses can lead to 
conditions associated with autoimmunity or allergy: hence, it is now often thought 
of as a double-edged sword. Increasingly, a major focus in translational medicine 
is to identify novel safe drug targets that allow the suppression of inflammatory 
disease, without compromising the capacity of the immune system to clear 
invading microorganisms and cancerous cells. Relating to this, a core aim of this 
thesis has been to exploit the helminth-derived immunomodulator ES-62, to 
identify key pathogenic inflammatory events in one such autoimmune inflammatory 
disorder, systemic lupus erythematosus (SLE, lupus), in order to increase our 
fundamental understanding of the etiology of this disease and potentially identify 
novel, safer anti-inflammatory drug targets.  
 
1.2. Systemic lupus erythematosus 
Systemic lupus erythematosus (SLE, lupus) is a systemic autoimmune 
inflammatory disease characterized by the production of antibodies recognizing 
cytoplasmic and nuclear self-antigens, characteristically double stranded DNA 
(dsDNA). Complexes of self-reactive antibodies and host antigens circulate 
throughout the body and become trapped in organs with dense capillary networks 
such as the kidney, joints, skin and cardiovascular system: the deposition of these 
immune complexes cause local inflammation and damage. The kidney is a major 
site of disease and glomerulonephritis is one of the most serious manifestations of 
lupus (1,2).  
 
The production of anti-dsDNA autoantibodies is associated with disease severity 
(3). These antibodies usually bind to DNA released from necrotic cells as this 
disorder is also associated with defects in the machinery of apoptotic cell 
clearance. However, in the kidney, circulating DNA can embed in the glomerular 
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matrix due to charge interactions with collagen type IV or heparin sulphate at the 
glomerular basement membrane, providing a reservoir of antigen for circulating 
anti-dsDNA antibodies (4,5). Inflammation in the kidney is driven by the activation 
of antibody  (FcR) receptors(6), complement receptors (7,8) and toll-like receptors 
(TLR) (3,5,6,9); with the subsequent proinflammatory cytokine response inducing 
the recruitment of immune system cells into the kidney that further drive pathology 
by the production of antibodies, cytokines and the attempted clearance of 
apoptotic or antigenic debris (2,10).  
 
It is currently estimated that 5 million people are affected with SLE worldwide; as 
with many autoimmune diseases, it is most common and severe in women (11). 
Lupus is monitored in the clinic by the SLE disease activity index (SLEDAI), a 
method by which clinicians can score the severity of disease by assessing specific 
cell counts, anti-DNA antibody and complement levels in the blood; fever; chest 
pain; mucosal inflammation; inflammatory rash; proteinuria; haematuria; muscle 
weakening; arthritis; vasculitis and CNS complications (12). SLE is typically treated 
by general immunosuppressive regimes and hence, there is an urgent unmet 
clinical need for more specific and less toxic drugs. Several promising drugs that 
have entered clinical trials, failed to show a significant benefit: it is now widely 
accepted that this was due to poor characterization and stratification of the 
heterogeneous SLE patient population preventing establishment of an appropriate 
clinical trial (13). The precise etiology of SLE is as of yet unknown but deregulation 
of multiple aspects of the immune system have been implicated in this complex 
disease (10). Therefore, to develop the required drugs and get them into the clinic, 
a better understanding of the immune system and its role in this disease is 
required.  
 
1.3. Animal models of SLE 
There are multiple mouse models of SLE that can either develop disease 
spontaneously or be induced. The relevance of these models is complicated by 
our lack of understanding of the origin of this autoimmune disease, which to date 
has advanced by investigating observations made in patients and these models 
(14). The classical spontaneous models are those provided by NZB/NZW F1, 
MRL/lpr and BXSB/Yaa mice. The New Zealand Black (NZB) and New Zealand 
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White (NZW) strains of mice are both prone to develop mild autoimmunity, 
however, the F1 cross phenotype exhibits exacerbated disease and these mice 
die of renal failure within 12 months. NZB/NZW F1 progeny develop several of the 
pathologies associated with SLE, such as lymphadenopathy, splenomegaly and 
ANA production, however, they do not produce autoantibody responses to RNA-
containing immune complexes (14). Likewise, the MRL strain of mice, which have 
a complex background due to the crossing of the LG/J mice with C3H/Di, C57BL/6 
and AKR/J strains, contains several genes associated with susceptibility in SLE 
patients (14). Consistent with this, MRL mice exhibit all of the major symptoms 
presented by SLE patients. MRL/lpr mice have a mutation on chromosome 19 that 
alters the transcription of the FAS receptor and these mice develop an accelerated 
version of the disease, relative to the parental MRL/MP strain, and usually die of 
renal failure within 5 months (14). The BXSB/Yaa strain develops a lupus-like 
disease due to duplications of at least 16 genes that contribute to SLE, the most 
prominent of which is TLR7(14). More recently described spontaneous models of 
SLE include the FcγR2b-/-mouse (15), which exhibits hyper-reactive B cell 
responses, and the Ro52-/- mouse that develops a lupus-like disease following 
tissue injury (16). As well as these spontaneous models, there are a number of 
inducible models of SLE that, for example, employ administration of pristine or 
induction of chronic graft versus host disease regimens (14). 
 
1.4: The innate immune system 
1.4.1. First line of defense 
The innate immune system provides a natural form of protection and is present, in 
some form, in all eukaryotic organisms. It provides the first line of defense against 
microorganisms and, in addition to barrier functions; it involves the activation of a 
range of polyspecific extracellular and intracellular receptors. This leads to the 
recognition and/or phagocytosis of foreign particles, resulting in the release of pro-
inflammatory mediators, cellular infiltration and the induction of inflammation. In 
addition, via antigen presentation cells, the innate immune system can trigger the 
activation of antigen specific adaptive immune responses. In SLE, prolonged 
activation of the innate immune system propagates the inflammation associated 
with disease pathology (17). 
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1.4.2. Receptors of the innate immune system  
Our understanding of the innate immune system was revolutionized by the seminal 
findings of Janeway and Madzhitov that immune responses are initiated by the 
recognition of conserved pathogen-associated molecular patterns (PAMPs) 
present on microorganisms, by pattern recognition receptor (PRR). PRRs are 
germ-line encoded receptors expressed on the cell surface or in intracellular 
vesicles. Upon recognition of PAMPs, the innate immune response is often 
sufficient to neutralize and clear the threat of invading pathogens, however, in 
more complex scenaria; PRR activation can result in the triggering of the adaptive 
immune response. PAMPs are present on a variety of molecules expressed by 
pathogens such as bacterial lipopolysaccharide (LPS), fungal carbohydrates and 
viral nucleic acids (18). There are several families of PRRs including the cytosolic 
NOD-like receptors, C-type lectin receptors and RIG-1-like receptors, which 
recognize bacterial products, β-glucans and nucleic acids respectively (19). 
However, by far the most studied and well defined family of PRRs are the toll-like 
receptors (TLR; Fig. 1.1)(20).  
 
1.4.3. Toll like receptors 
TLR signaling is initiated by ligand-mediated homo- or hetero-dimerization of TLR-
ligand-binding subunits: all TLRs, except TLR3, signal via the adaptor protein 
MyD88 to activate the NF-κB pathway and hence drive inflammation (19) (Fig. 
1.1). Deregulation of TLR signaling is associated with the development of 
autoimmune diseases (21). The expression of TLRs is increased on monocytes, T 
and B cells from SLE patients, and their stimulation with endogenous antigen 
leads to the elevated production of pro-inflammatory cytokines (22). Moreover, 
infection often precedes autoimmune responses and has been proposed to trigger 
disease flares via TLR signaling in chronic autoimmune disease.  
 
1.4.4. Danger hypothesis 
The "Danger Hypothesis" proposes that the immune system recognizes 
endogenous antigens that are produced by dying, damaged or corrupted cells 
(23), and in an analogous manner to PAMPs, these damage/danger associated 
molecular patterns (DAMPs or Alarmins) are detected by PRRs. Although infection 
in SLE patients likely exacerbates disease, the ability of PRRs to recognize 
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DAMPs probably provides the major mechanism by which PRRs contributes to 
disease severity (24). One such DAMP that is considered to contribute to disease 
in SLE patients is the high mobility group box 1 (HMGB1) protein. Circulating 
HMGB1 levels are elevated in SLE patients and correlate with disease. Although 
early reports that HMGB1 stimulated TLR4 reflected sample contamination (25), 
HMGB1 has since been shown to stimulate immune system cells via TLR9 and 
TLR2 in addition to RAGE receptors (7,8,26,27). 
 
1.4.5. Apoptosis 
Cell death is a necessary and natural process that occurs during pathological and 
physiological circumstances. The resulting debris must be cleared through a 
controlled process such as apoptosis (controlled non-inflammatory cell death or 
‘suicide’) to avoid overzealous immune responses occurring. Such self-harming 
responses are triggered by tissue damage and/or cellular necrosis (uncontrolled 
inflammatory cell death) (28). The innate immune system acts to regulate this by 
responding to DAMPs expressed on apoptotic cells: an example of this is 
phosphatidylserine, a lipid that is normally expressed on the inner layer of the 
phospholipid bilayer but expressed on the surface of apoptotic cells (28). 
Reflecting this role of the innate system in apoptosis, a major factor in the 
pathogenesis of SLE is the defective apoptotic clearance of cell debris and the 
subsequent over exposure of self-antigens, which, along with a breakdown in 
immune tolerance, drives the activation and generation of damaging autoimmune 
responses. Apoptosis per se is enhanced in SLE patients (29) yet factors that 
control the clearance of cell debris: such as MFG-E8, an integrin that allows 
phagocytes to bind to apoptotic cells; are reduced (30) leading to defective 
clearance.  
 
1.4.6. Complement 
A fundamental component in the clearance of apoptotic debris is the complement 
system, which comprises of a cascade of more than 25 soluble serum proteins 
that recognize pathogenic, immunogenic and apoptotic material (Fig. 1.2). The 
activation of complement initiates a series of events involving the neutralization or 
opsonization of dangerous material and targeting of phagocytosis (31). Defects in 
the classical complement cascade have long been associated with SLE as this 
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pathway is important for the clearance of apoptotic debris (32): the alternative 
pathway on the other hand is increasingly recognized as pathogenic in SLE 
patients and mouse models of the disease !
(2,10,17,33-36). 
 
1.4.7. Type 1 interferons 
Type 1 interferons (IFN) are a family of cytokines best known for their antiviral 
capabilities. They are expressed by a wide variety of cells and are induced by PRR 
activation. In some autoimmune diseases they are protective as they can suppress 
certain aspects of the immune response (37) but they are generally considered to 
be pathogenic in SLE where there is a clear type 1 IFN signature in SLE patients, 
two thirds of which express high serum levels of the cytokine that correlates with 
SLEDAI (38). Such high type 1 IFN expression is associated with enhanced B cell 
survival and auto-antibody production (39) and consistent with they key role of B 
cells in SLE, studies in mice have revealed that IFNα can only exacerbate 
autoimmunity in strains of mice that are genetically susceptible to develop lupus 
(40).  
 
1.4.8. Cells of the innate immune system 
1.4.8.1. Phagocytes 
Phagocytosis is a process by which extracellular material is internalized and then 
degraded as an initial attempt to clear cell debris and limit infection. Neutrophils 
are the first cells are recruited to the site of inflammation; these short-lived, 
terminally differentiated cells designed to phagocytize and kill infectious agents 
and further promote inflammation by secreting cytokines and chemokines; 
however, in autoimmune disease the excessive activation of neutrophils can cause 
extensive collateral damage to the host (41). One example of this is through a 
process unique to neutrophils called NETosis, whereby the neutrophils expel their 
‘sticky’ nucleic material as neutrophil extracellular traps (NETs). Although in a 
normal or healthy context this is an effective way to deal with multiple pathogens 
at once, in SLE patients where the clearance of this nuclear material will be 
defective, perhaps due to reduced DNase 1 levels, NETosis simply increases the 
amount of nucleic self-antigens exposed to the immune system (42,43). 
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Phagocytosis is not restricted to neutrophils and in the case of "professional 
antigen-presenting cells" of the innate system, macrophages and dendritic cells 
(DC), the peptides resulting from the proteolytic degradation associated with 
phagocytosis are presented to T cells via MHC Class II molecules (Fig. 1.3). 
These professional antigen-presenting cells shape the subsequent type of 
adaptive immune response by producing specific combinations of cytokines, 
chemokines and other inflammatory mediators. This response depends on the 
additional signals they receive at the time of phagocytosis: for example, in the 
context of the gut where many harmless foreign particles are found (commensal 
microorganisms and food particles), a phagocyte would express regulatory 
cytokines, such as IL-10, to prevent an immune response: however, if an antigen 
were sampled at the time of a bacterial infection or cell damage then these cells 
would be licensed to secrete proinflammatory cytokines, such as IL-6, to trigger an 
immune response. 
 
Moreover, as tissue resident cells, macrophages are often the first phagocytes to 
respond to cell death and therefore play a pivotal role in the clearance of self-
antigens. In SLE, macrophages are defective in clearing apoptotic cell debris in 
vitro (44) resulting in necrosis and release of a proinflammatory DAMPs, which 
further activate the innate immune system (44). Similarly, monocytes, which 
normally express high levels of scavenger receptors that can bind PAMPs and 
DAMPs (45), are reduced in number and defective in clearing apoptotic debris in 
SLE patients, yet produce elevated levels of the proinflammatory cytokines, TNFα 
and IL-6, compared to monocytes from healthy controls (46,47). Furthermore, 
although these cells express comparable levels of the receptor for the regulatory 
cytokine IL-10, monocytes from SLE patients are less sensitive to IL-10 compared 
to those from healthy controls and this IL-10-hyporesponsive phenotype is 
enhanced in the presence of immune complexes (48). Complementing this, and 
consistent with their role in initiating and controlling T cell responses, both in terms 
of determining the type of T cell response as well as neutralizing the threat of auto-
reactive T cells by inducing anergy or cell death, DC are reported to be 
hyperactive in SLE, producing pro-inflammatory cytokines, for example type 1 IFN, 
in response to circulating complexes of autoantibodies and nucleic acids (49).  
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1.4.8.2. Innate lymphoid cells 
There has been increasing recognition of innate lymphoid cells and reflecting this 
several populations have been recently grouped into the family of "innate lymphoid 
cells” (ILC). For example, ILC1 (which include natural killer (NK) cells) produce 
high levels of IFNγ and are involved in the clearance of cells infected with 
intracellular pathogens including bacteria and viruses. Interestingly, NK cells have 
been implicated as protective in SLE and a decline in their numbers inversely 
correlates with SLEDAI (50). The relevance of other populations of the ILC family: 
the lymphatic tissue inducer (LTi), ILC2 (natural helper or nuocytes), ILC17 and 
ILC22 cells has not been examined in SLE. Invariant natural killer T cells (iNK T 
cells), which respond to glycolipid antigens presented by CD1d, a non-classical 
MHC molecule, by producing a variety of cytokines are functionally and 
numerically reduced in the blood of SLE patients: however they are found to be 
concentrated at the site of cutaneous inflammation (51). The significance of these 
cells in SLE is yet to be determined (52). Other lymphoid cells with "innate-like" 
functions, γδT cells and B1 B cells, are discussed in more detail in 1.5.3.1 and 
1.5.5.4.8.  
 
1.5. The adaptive immune response 
1.5.1. Innate versus adaptive responses 
Whereas the innate immune response offers a rapid, non-specific response to 
contain infection, the adaptive immune system provides a slower but more specific 
response combining effector and memory cells that can target specific pathogens 
more effectively, particularly on re-infection. The principal cells of the adaptive 
immune response are the B and T cells, which develop from a common progenitor 
in the bone marrow (53), to provide the humoral and cellular arms of the adaptive 
immune response, respectively. In SLE, regulation of both of these cell type 
responses is dysfunctional.  
 
1.5.2. Effector regulatory balance 
It is essential during the adaptive immune response that regulatory cells, which 
suppress and control the effector immune response, also develop to ensure a 
controlled immune response that will clear immunogenic material whilst causing 
minimal collateral damage to the host cells. Both of these effector and regulatory 
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cell populations must interact harmoniously to maintain homeostasis. Autoimmune 
disease occurs when effector responses expand to the extent that regulatory cells 
can no longer control them; this may be due to defective regulatory function or 
aberrant and/or excessive levels of immunogen. By contrast, if the regulatory 
network is too strong,, cancer or chronic infection can occur (54).   
 
1.5.3. T lymphocytes 
1.5.3.1. T cell development and activation 
T cell development occurs in the thymus and involves proliferation of progenitors, 
rearrangement of antigen receptor (TCR) genes, and positive and negative 
selection of cells expressing viable TCR (55). Selection is required as the 
specificity of the newly generated TCR is random; T cells therefore undergo a 
negative selection process to prevent the development of self-reactive T cells.  
Negative selection is controlled by stromal cells in the thymus that express self-
antigens; thus, any CD4+CD8+ double positive (DP) thymocytes that recognise 
these antigens in the context of self MHC with strong affinity will be removed by 
either deletion, receptor editing or anergy. Cells expressing a TCR that only 
weakly recognises self-antigen will be positively selected for further differentiation 
(55). Mature T cells therefore exit the thymus as either MHC class II restricted 
CD3+CD4+ T helper cells or MHC class I restricted CD3+CD8+ cytotoxic T cells 
(56). More recently, it has emerged that DP thymocytes recognizing antigen with 
intermediate affinity may differentiate into natural regulatory T cells (Tregs) (57). 
When a mature naive T cell recognizes antigen presented by an APC, it will move 
to the T cell zone of a secondary lymphoid organ, express co-stimulatory 
molecules such as CD40 ligand (CD40L) and ICOS, in order to interact with B cells 
specific for the same antigen. The majority of T cells express a αβ TCR however, 
a small proportion (5%) of T cells express a γδ TCR. These γδ T cells are innate-
like T cells with limited TCR repertoire diversity and are therefore not classed as 
ILC. γδ T cells may contribute towards the pathogenesis of AI by activating B cells, 
conventional αβ TCR T cells and secreting pro-inflammatory cytokines (58). 
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1.5.3.2. TCR signaling  
The cytoplasmic domain of the TCR does not have any capacity to signal and 
therefore is required to form an antigen signaling receptor complex with the 
accessory signal transducing molecules CD3γ, CD3δ, CD3ε and CD3ζ, which have 
the ability to signal through immunoreceptor tyrosine-based activation motifs 
(ITAMs; (59)). The CD4 and CD8 molecules expressed on the surface of naïve T 
cells recognize non-polymorphic regions of the MHC class II and MHC class I 
molecules respectively, and by doing so, strengthen the bond between TCR and 
MHC molecule (60). The CD4 and CD8 molecules aid in TCR signaling further by 
recruiting LCK, a tyrosine kinase important in phosphorylation of the ITAMs in the 
TCR signaling complex (61). TCR signaling is insufficient to activate T cells and 
co-receptor signaling is required for full T cell activation (62). T cells from SLE 
patients usually exhibit amplified TCR signaling that is rerouted through alternative 
signaling pathways (63). For example, rather than simply utilizing the CD3ζ: 
ZAP70 pathway, the TCR in T cells from SLE patients additionally associates with 
the signaling via the common γ-chain: SYK pathway, which normally transduces 
FcR signals, resulting in stronger signaling through the TCR and thus reducing the 
requirement of co-receptor signaling and cytokines for T cell activation (64).  
 
1.5.3.3. Co-receptor signaling 
To ensure the full activation or priming of naïve T cells, 3 signals from APC are 
required: 1) TCR recognition of antigen presented by MHC molecules, 2) 
production of pro-inflammatory cytokines to induce the particular functional 
phenotype of the cells and 3) co-stimulation via interactions between co-receptors 
on APC and T cells (65). APC, mainly DC, that have been activated via PRR and 
cytokine receptor signaling, will migrate to the secondary lymphoid organs and 
express CD80/86 and ICOS-L molecules that will interact with "costimulatory" 
CD28 and ICOS molecules on the T cells, respectively. This signaling amplifies 
and ‘fine tunes’ that of the TCR signal, allowing the T cell to respond (66). 
Consistent with their hyper-responsive phenotype, the level of expression of 
stimulatory co-receptors is usually found to be elevated on the APC and/or T cells 
from SLE patients (67). Moreover, although not all co-receptors transduce positive 
signals, the negative receptor CTLA-4, which binds to CD80/86 molecules with 
higher affinity than CD28 to prevent excessive T cells responses is expressed at 
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lower levels on the surface of T cells in lupus patients (68). Defective CTLA4 
signaling has also been reported in SLE prone mice (69). 
 
1.5.3.4. T cell responses 
CD8+ cytotoxic T cells circulate through the blood and secondary lymphoid organs 
(lymph nodes and spleen) surveying antigens presented by APC. Upon priming, 
the expanded population of CD8+ effector cells will search for and kill target cells 
via the release of cytolytic molecules (granzymes and perforin) and activate the 
innate immune system by secreting pro-inflammatory cytokines such as IFNγ and 
TNFα, in order to drive the clearance of infected cells (65). IFNγ has been 
proposed to be one of the major pathogenic cytokines in SLE and consistent with 
this, IFNγ-producing CD8+ T cells are found in the urine of patients during a lupus 
flare have been associated with disease (70,71). 
 
Like CD8+ T cells, CD4+ helper T cells circulate throughout the body but 
alternatively respond to antigens presented by MHC class II molecules. Depending 
on the cytokine signals they receive at the time of MHC:peptide complex 
recognition, CD4+ helper T cells can develop into at least four effector (Th1, Th2 or 
Th17) or regulatory populations that shape the immune response in a specific 
manner (72). SLE patients present with a mixed CD4+ T helper cell phenotype (73) 
reflected by the elevated levels of a variety of cytokines, including IL-18, IL-12, IL-
17A and IL-4 often observed in SLE patients (74). 
 
1.5.3.5.1. Th1 responses 
Th1 cells are generated to help combat intracellular pathogens and are often 
associated with cytotoxic responses: as they result in the recruitment of CD8+ T 
cells and macrophages, which kill infected cells and phagocytose the resulting cell 
debris respectively (75). The main Th1 polarizing cytokine, IL-12p70, is composed 
of two subunits, p35 and p40(76), and binds to a specific heterodimeric receptor 
containing the IL-12Rβ1 and IL-12Rβ2 subunits (77). This interaction activates a 
JAK: STAT4 pathway resulting in the expression of t-Bet, the signature 
transcription factor associated with Th1 responses (78). The signature cytokine of 
the Th1 phenotype, IFNγ, is elevated in the serum (70) and urine of patients with 
SLE (79); copy number variations of il-12 and t-bet are also elevated in patients 
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and correlate with disease severity (80). Indeed, Th1 induction has been shown to 
be essential for the development of disease in the MRL/lpr mouse model of SLE 
(81). 
 
1.5.3.5.2. Th2 responses  
Th2 cell responses are important in the protection against extracellular pathogens 
as they promote B cell responses by the production of IL-4, IL-5, IL-9, IL-13 and 
IL-25 (IL-17E) (82,83). The transcription factor that drives the development of Th2 
cells is GATA3, and although the exact mechanisms of Th2 activation in vivo are 
not yet known, the in vitro expression of GATA3 can be induced by: IL-4 activation 
of STAT6, IL-2 activation of STAT5, WNT activation by β-catenin, T cell factor 1 
and also by Notch signaling (78,84). Reflecting their mixed inflammatory 
phenotype, Th2 related cytokines have also been found to be elevated in SLE 
patients and although they have not received as much focus as other T helper cell 
responses, it is increasingly recognized that Th2-associated IgE, basophil and 
cytokine responses may play an important pathogenic role in some SLE patients 
(85,86).  
 
1.5.3.5.3. Th17 and IL-17 responses 
1.5.3.5.3.1. Development 
Th17 cells are one of the most recent T helper cell phenotypes to be characterized 
and their discovery led to a readjustment of the T helper cell paradigm as it 
became apparent that T cell responses can still be made in the absence of Th1 or 
Th2 promoting factors (87). Indeed, many responses or diseases previously 
characterized as exhibiting a Th1 phenotype have since been reclassified as being 
Th17-dependent. Th17 cells have been reported to produce a number of cytokines 
belonging to the IL-17 family (IL-17A-F, Table 1.1), which are important in 
protection against bacterial and fungal infections. These responses are also 
implicated in the etiology of inflammatory disease (88,89). Th17 cells are also 
capable of producing and inducing several other cytokines, such as IL-21 and IL-
22, which are involved in the activation and recruitment of other cells to the site of 
inflammation (90).  
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Recent comprehensive analysis has established that development of Th17 cells 
requires three individual stages: (i) ‘induction’ occurs within the first 4 hours 
following stimulation with TGFβ1 and IL-6, the latter of which stimulates the 
expression of the Th17-associated transcription factor RORγt; (ii) ‘amplification’ 
occurs between 4-20 hours and during this period, the cells begin to express 
mRNA of both pro- and anti-inflammatory cytokines such as IL-17A and IL-10 
respectively; and finally, (iii) ‘activation’ occurs following expression of the IL-23 
receptor (after 48 hours) as signaling via this receptor permits the cells to become 
fully activated Th17 cells that express pro-inflammatory cytokines and 
chemokines, but not IL-10 (91). However, FAS and GM-CSF signaling are also 
required for full differentiation of Th17 cells and whilst IL-17A production can be 
stimulated by either IL-1β or IL-23, optimal cytokine release occurs following 
stimulation with both of these proinflammatory cytokines (92).  
 
1.5.3.5.3.2. Innate sources of IL-17 
Although IL-17 responses are often generically described as Th17 responses, IL-
17A can still be made in T cell-deficient RAG-/- mice, suggesting alternative 
sources of this cytokine (93). Furthermore, IL-17A responses can be detected 
within 8 hours following bacterial challenge (94), a time frame that suggests an 
innate, rather than adaptive  immune source, as the latter usually requires 
approximately 3-5 days (24). It is now clear that several populations of the innate 
immune system can produce IL-17A, such as ILC (NK and LTi cells), iNK T cells, 
γδT cells and CD11b+ GR1+ myeloid cells, the latter including neutrophils (24,95-
98).  
 
1.5.3.5.3.3. Transcription factors 
All IL-17A producing cells express RORγt, the transcription factor that controls the 
development of Th17 cells (99), however, expression of RORγt is not essential for 
production of this cytokine by non-Th17 cells (60,81,82)(24) and in the absence of 
RORγt, other transcription factors drive IL-17A responses. One such transcription 
factor is the aryl hydrocarbon receptor (AHR). Th17 cells, γδ T cells and ILC are 
among some of the cells that express AHR, which appears to be important for 
effector responses of fully activated Th17 cells, including the production of IL-22. 
AHR allows cells to respond to environmental stimuli, suggesting that AHR may 
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provide molecular evidence for the epidemiological link between the development 
of autoimmune disease and environment toxins (100,101).  
 
1.5.3.5.3.4. IL-17 in autoimmunity 
IL-17A exhibits multiple functional outcomes that allow this cytokine to orchestrate 
an immune response:  thus, for example, in SLE IL-17A acts in synergy with IL-1, 
IL-6 or TNFα in the recruitment of neutrophils to sites of inflammation (102) and 
with B cell activating factor (BAFF) to promote the survival and activation of B cells 
(103). It may also act to recruit other effector cells, such as Th1 cells, to sites of 
inflammation (104). In addition, IL-17A has been implicated in the regulation of 
mucosal barrier integrity during pathogenesis and homeostasis (105), immune 
homeostasis (106) and the induction of innate anti-microbial agents such as β-
defensins (24).  
 
IL-17A has been proposed to be crucial for the development of autoimmune 
disease and consistent with this, has been shown to play roles in both initiating 
and perpetuating disease in previously considered Th1-biased inflammatory 
(models of) diseases (107). Thus, early IL-17A responses have been reported to 
be important in the development of disease in a collagen-induced model of 
rheumatoid arthritis (CIA) (108) and cooperation between IL-17A-producing γδ T 
cells and Th17 cells enhances disease in a murine model of uveitis (109). IL-17A 
is also essential for the development of experimental autoimmune encephalitis 
(EAE), a model of multiple sclerosis (110). Interestingly, therefore, given its mixed 
inflammatory phenotype, IL-17A is consistently found to be elevated in the serum 
of SLE patients compared to healthy controls (111), IL-17A levels are also found to 
be enhanced in strains of mice that spontaneously develop a lupus-like disease 
(112) and IL-17 signaling is essential for disease in the FcγR2b-/- mouse model of 
SLE (113). Consistent with this, IL-17A producing cells have also been observed 
in the kidneys of patients and murine models of SLE (111,114,115).  
 
IL-17 appears to act as a master regulator of inflammation as it also appears to be 
crucial to the development of Th2-based pathologies (116) and it has been 
proposed that IL-17 may also play protective roles in the resolution of 
inflammation, as reported in murine models of colitis (117) and asthma (118). 
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1.5.3.5.4. Th22 and IL-22 responses 
1.5.3.5.4.1. Development and source 
IL-22 is a cytokine of the IL-10 family that can be produced by cells of both the 
innate (ILC) and adaptive (γδ, CD4+ and CD8+ T cells) arms of the immune system 
(106) as indicated by its production in Rag-/- mice (95,119,120). Interestingly, 
therefore, it is unusual in that whilst being produced exclusively by leukocytes it 
acts predominantly on non-haemopoietic cells (120). The IL-22 receptor is a 
heterodimer consisting the β chain of the IL-10 receptor and a specific IL-22-
binding receptor molecule (121) and the bioavailability of IL-22 is controlled, at 
least in part by a soluble IL-22 binding protein (122). Two cell phenotypes that 
produce IL-22 exclusively, NK22 and Th22 cells, have been reported (123,124).  
As with Th17 cells, Th22 cells can be induced by IL-23, IL1β and IL-6, the latter 
being required for the expression of the IL-22R (125): however, whereas TGFβ is 
also required for the development of Th17 cells, TGFβ inhibits the development of 
Th22 cells (126). Moreover, Th22 cells express the RORγt and AHR transcription 
factors but whilst expression of AHR is essential for IL-22 production, that of 
RORγt is not (99,101).  
 
1.5.3.5.4.2. Function in autoimmunity  
IL-22 can be functionally related to IL-17 in that both cytokines exhibit effects on 
epithelial cells, including epithelial barrier formation (127); however, IL-17 and IL-
22 are generally non-redundant and are functionally distinct (106). IL-22 can often 
act in an anti-inflammatory or tissue repair manner (106), although by working in 
synergy with other pro-inflammatory cytokines, such as TNFα or IFNγ, IL-22 can 
enhance inflammation (128,129). Thus, during mucosal inflammation, IL-22 is 
important in maintaining epithelial barrier integrity and promotes the resolution of 
damage by triggering epithelial cell growth (128,130) and hence acts in a 
protective manner during lung inflammation (131,132). In support of this protective 
role against mucosal inflammation, the transfer of IL-22 producing cells is 
protective in murine models of IBD (133) and there is also evidence for IL-22 being 
protective in mouse models of MS, IBD and hepatitis (134,135). Depending on the 
immunological context however, IL-22 may also be pathogenic in autoimmune 
disease (128,136) and has been reported to play both pathogenic and protective 
roles in an ovalbumin-induced model of airway hyper-responsiveness or asthma. 
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Thus, IL-22-/- mice do not develop airway hyper-responsive and neutralization of 
IL-22 in wild-type mice, at the time of immunization, prevented disease. By 
contrast, neutralization of IL-22 during antigen challenge, enhanced airway 
inflammation whilst at this late stage of disease administration of recombinant 
cytokine suppressed disease. These data suggested both a pathogenic role for IL-
22 during disease initiation and a protective role during antigen challenge (118). 
Indeed, there is increasing evidence that the IL-17A:IL-22 balance may regulate 
pathology, as such relationships have also been reported in experimental models 
of arthritis (Pineda, Harnett & Harnett, unpublished data) (106).  
 
This potential dual functionality of IL-22 may explain why, in SLE, the limited 
studies on the role of IL-22 in pathogenesis have been contradictory. For example, 
levels of Th22 cells have been associated with SLEDAI (137,138) and the copy 
number variations of il-22 are increased in SLE patients (139). Furthermore, 
treatment with hydroxychloroquine was found to decrease serum IL-22 levels (140) 
and TGFβ levels are low in SLE patients, perhaps suggesting that Th22, rather 
than Th17 or Tregs, cells may be pathogenic in SLE (141). By contrast, it has 
been suggested that Th22 levels are an indicator only of cutaneous lupus (142) 
whilst others have reported that IL-22 is decreased in the serum of SLE patients, 
suggesting a potential protective role for this cytokine in SLE (143,144).  
 
1.5.3.5.5. Regulatory T cells  
1.5.3.5.5.1. Development 
Regulatory T cells (Treg) can suppress and therefore homeostatically limit immune 
responses. Thus the loss of Tregs can result in immunopathology, autoimmunity 
and allergy. Tregs provide a major component of the mechanisms contributing to 
the maintenance of peripheral tolerance of T cells, the process by which auto-
reactive T cells that escape central tolerance in the thymus or encounter harmless 
foreign antigen are either removed by apoptosis or rendered anergic. The 
induction of Tregs requires IL-2 and TGFβ, which stimulates the induction of the 
Treg signature transcription factor, FoxP3. It is now clear that there are several 
distinct populations of regulatory T cells. For example, FoxP3+ naturally occurring 
regulatory T cells (nTregs) develop in the thymus and are selected by their 
relatively strong reactivity to self-antigens presented by stromal cells during T cell 
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development. By contrast, induced FoxP3+ Tregs, IL-10-secreting TR1 cells and 
TGFβ-secreting Th3 cells develop in the periphery following recognition of a 
particular antigen in the presence of Treg-inducing cytokines such as TGFβ 
(145,146). Moreover, it appears that regulatory T cells can suppress immune 
responses by at least four mechanisms: (i) production of the regulatory cytokines 
IL-10 and TGFβ; (ii) cytolysis via production of granzymes and perforin; (iii) 
disruption of metabolism by consumption of survival/growth factors or alternatively, 
by production of anti-inflammatory metabolites such as adenosine nucleosides; 
and (iv) by modulation of DC function via their expression of CTLA-4, the negative 
signaling co-receptor molecule (57).  
 
1.5.3.5.5.2. Tregs in autoimmunity 
Several groups have reported an inverse correlation between the level of 
circulating Tregs and SLEDAI (147-151) and consistent with this, Treg levels were 
found to be elevated in patients following treatment with corticosteroids (152,153). 
Moreover, although Tregs from SLE patients were capable of suppressing immune 
responses in vitro, the effectiveness of this suppression was reduced compared to 
the capacity of Tregs from healthy controls (154,155). It is not clear, however, 
whether this ineffective suppression is due to a Treg defect or because the T cells 
from SLE patients are resistant to Treg mediated suppression (156). Nevertheless, 
Treg deficiencies in mice result in a lupus-like disease including 
glomerularnephritis (157) and several studies have reported a Treg defect in 
mouse models of SLE (158). 
 
1.5.4. B cells 
1.5.4.1. B cell development 
B cells are a fundamental component of disease pathology in SLE patients (3); 
underlining this, therapies targeting B cells have proved effective in the clinic. In 
addition to producing the autoantibodies that are characteristic of lupus, B cells 
also present antigens and secrete cytokines that shape the immune response. The 
expansion of B cells in SLE patients correlates with SLEDAI (159) whilst renal 
infiltration by B cells is a predictor of severe disease and clinical outcome (160). B 
cells are also essential for pathology in mouse models of SLE (161-163).  
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B cell development starts in the bone marrow where common lymphoid precursors 
develop into pre-pro-pre-B cells, pro-B cells, pre-B cells and finally immature B 
cells (Fig. 1.4). During development, the B cell will rearrange the variable (V), 
diversity (D) and joining (J) segments of its immunoglobulin genes to form a viable 
B cell receptor (BCR). BCR form an antigen signaling complex with the signal 
transducing molecules, Igα and Igβ (164), which contain cytoplasmic ITAM 
signaling domains that are phosphorylated by the protein tyrosine kinase SYK 
(165) (Fig. 1.5). The rearrangement of the Ig genes is a random process and 75% 
of early B cells are auto-reactive. Several mechanisms exist to prevent the release 
of these cells into the periphery. For example, strong recognition of self antigen 
expressed by stromal cells in the bone marrow will induce cell death of IgM+ 
immature B cells by apoptosis whereas an intermediate BCR signal will induce 
receptor editing (166). Alternatively, self-reactive B cells can enter a state of 
anergy where they will not respond to antigen (167).  
 
BCR signal strength further determines the peripheral development of B cells (168) 
with B cell survival requiring weak ‘tonic’ BCR signaling(169). Consistent with a 
pathogenic role of B cell hyper-responsiveness, BCR signaling is elevated in SLE 
patients (170) whilst inhibition of BCR signaling prevents disease development in a 
lupus mouse model (171). Furthermore, mice that do not express negative 
regulators of BCR signaling, such as Lyn and SHP-1, develop a lupus like disease 
and supporting the physiological relevance of such processes, the expression of 
these signal transducers is reduced in B cells from SLE patients (172). 
 
1.5.4.8. Peripheral B effector cell development 
1.5.4.8.1. The spleen 
The spleen has two major functions in biology (Fig. 1.6): in the red pulp, blood is 
filtered to remove old or damaged cells and antigens: whereas in the white pulp, 
immature (transitional) B cells differentiate into mature-naïve, effector and memory 
B cells (Fig. 1.7). The white pulp has three main architectural features: the 
periarteriolar lymphoid sheath, or the T cell zone; the B cell zone containing B cell 
follicles and the marginal zone (MZ), where blood borne antigens are sampled by 
specialist macrophages and the MZ B cell subset (Fig. 1.6) (173). 
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1.5.4.8.2. Transitional B cells 
B cells expressing a viable BCR leave the bone marrow via the circulatory system 
in an immature form termed transitional type 1 (T1; CD19+CD21-CD23-IgM+IgD-
AA4.1+) and whilst they home to the spleen, they lack the ability to recirculate (Fig. 
1.7) (174). The survival of T1 B cells and their further maturation is heavily 
dependent on BAFF survival signals (175). In the spleen, T1 B cells quickly 
differentiate into a second transitional state termed transitional type 2 (T2; 
CD19+CD21-CD23+IgM+IgD-AA4.1+): these cells enter the B cell follicle where they 
acquire the expression of IgD and CD23 and the ability to circulate around the 
body(176). The development of T2 B cells into either marginal zone precursor cells 
(MZP; CD19+CD21+CD23+IgM+IgD+AA4.1-) or follicular type 1 (Fo1; 
CD19+CD21low/-CD23+IgMlowIgD+AA4.1-) B cells is dependent on four factors: BCR 
signal strength, BAFF survival signals, Notch signaling and NFκB activation (174).   
 
1.5.4.8.3. Marginal zone B cells 
MZP B cells reside in the B cell follicles of the spleen where they develop into 
marginal zone B cells (MZ; CD19+CD21+CD23-IgM+IgD-AA4.1-). MZ B cells 
represent approximately 15% of all B cells (177) and are found between the white 
and red pulp in the marginal sinuses of the spleen: they sample antigens in the 
blood and respond to lipid and T-independent antigens. MZ B cells capture 
antigens that have been opsonized with antibodies or complement via receptors 
expressed on their surface. They also express high levels of CD1d, a non-classical 
MHC molecule that allows the cells to present lipid antigens to iNKT cells (178) as 
well as high levels of TLRs allowing them to respond to PAMPS. MZ B cells 
constantly shuttle between the marginal zone and B cell follicles where they 
present this captured antigen to local follicular DC (179,180). MZ B cells can also 
respond to antigen directly and develop into short-lived antibody producing cells, 
which migrate into the red pulp and produce antibodies. However, recent studies 
suggest that a proportion of activated MZ B cells may also enter the B cell follicle 
and undergo further development in germinal centers (181). It is likely that they 
contribute to the pathogenesis of SLE due to their ability to sense blood borne 
antigens, such as immune complexes, and consistent with this, the proportion of 
MZ B cells in the B cell follicle is elevated in lupus prone mice (182,183). It is 
difficult to examine the role of MZ B cells in patients, as these cells do not leave 
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the spleen. Moreover, there is also evidence that MZ B cells may be protective in 
SLE prone mice as stimulation of TLR9 with DNA results in elevated IL-10 
production that can suppress Th1 responses (184) although it is unclear whether 
immune complexes containing DNA would have the same protective effect.  
 
1.5.4.8.4. Follicular B cells 
As with MZP B cells, Fo1 B cells are also derived from T2 B cells. Fo1 B cells 
comprise the major phenotype of mature B cells in adults, representing 
approximately 70% of all B cells. They circulate around the body in the blood and 
home to B cell follicles in the secondary lymphoid organs, which are situated 
adjacent to T cell zones to allow interactions between B cells and T helper cells. 
Whilst Fo1 B cells are responsible for T cell dependent responses in the B cell 
follicles, they are capable of producing T independent responses outside of the 
follicles and in the bone marrow (174). A second follicular B cell population exists, 
termed follicular type 2 B cells (Fo2; CD19+CD21low/-CD23+IgM+IgD+AA4.1-) that 
develop independently of antigen and likely form a pool of cells that can replenish 
the marginal zone B cell population in the event that it is destroyed by a blood 
borne pathogen (185).  
 
1.5.4.8.5. B cell activation 
Circulating Fo1 B cells migrate around the body in search of antigen. B cells can 
recognize antigens that are soluble or membrane bound such as those tethered to 
the surface of cells via complement or antibody receptors (186). Signaling events 
at the immunological synapse, where the BCR has recognized membrane-bound 
antigen, induce localized spreading of the B cell plasma membrane to maximize 
the number of BCR: antigen interactions. The signaling following such polarization 
of the BCR triggers cytoskeleton rearrangements and the release of lytic enzymes 
from the B cell, which release the antigen from the presenting cell. The B cell then 
internalizes the antigen complexed to its BCR and processes it via the endosomal 
MHC class II pathway (Fig. 1.3). Activated B cells will then migrate towards the T 
cell: B cell border in a secondary lymphoid organ in search for T cell help. If the 
newly acquired antigen, presented by the B cell in the form of MHC-peptide, is 
recognized by the TCR of an activated T cell, the T cell will release pro-
inflammatory cytokines that will fully activate the B cell. At this point the B cell will 
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migrate into the B cell follicle and enter the germinal center reaction (186-188). Co-
receptor expression by B cells dictates their activation and pro-inflammatory 
status, it is important for efficient activation by T cells; in SLE patients, CD71, 
CD80 and CD86 are all elevated on circulating B cells (189). 
 
1.5.4.8.6. Germinal center reaction 
The germinal center (GC) has two histologically distinct regions known as the dark 
and lights zones. The dark zone is densely packed with rapidly proliferating B cells 
known as centroblasts, which are drawn to the dark zone via CXCR5 homing 
towards CXCL13 that is produced by local stromal cells. In the dark zone 
centroblasts proliferate and undergo affinity maturation involving a process known 
as somatic hypermutation (SHM), which introduces mutations into the IgV region 
of already rearranged immunoglobulin genes to modulate the affinity of the BCR 
for a specific antigen. Following SHM, centroblasts leave the dark zone and enter 
the light zone by down regulating CXCR5 and up regulating CXCR4, which homes 
towards CXCL12 that is produced by cells in the light zone. In the light zone of the 
GC, centrocytes expressing the newly mutated BCR with high affinity are selected 
by competitive binding to antigens expressed by, or tethered to, the follicular DC 
(FDC). TLR4 signaling by FDC is essential for the onset of the GC reaction and 
affinity maturation (190).  Following such affinity maturation and selection, the 
centrocytes undergo a process known as class switch recombination (CSR), which 
sees the immunoglobulin genes of the GC B cell can switch isotype with the heavy 
chain of the BCR being irreversibly changed from α or µ heavy chains to γ, α or ε 
to provide IgG, IgA or IgE isotypes respectively. This process depends on the 
composition of cytokines produced in the context of particular antigens, for 
example, high levels of IL-4 will promote the development of IgE responses (187). 
The high levels and random nature of somatic hypermutation in the GC results in 
the development of autoreactive cells: normally these cells are cleared efficiently 
but in SLE patients, who experience enhanced lymphocyte activation and 
proliferation, the GC is a major source of autoantigens (191). Furthermore, the 
specific loss of FAS-mediated cell death in the GC leads to the development of a 
lupus like disease in mice (192). 
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1.5.4.8.7. Plasma cell development 
GC B cells that undergo strong BCR stimulation in the light zone develop into 
antibody producing plasma cells or memory B cells (187). Some memory B cells 
appear to be long lived and can survive without tonic BCR stimulation by their 
specific antigen; upon further challenge these memory B cells reactivate to provide 
a rapid humoral immune response. For plasma cell development, the GC B cell is 
required to down-regulate the expression of B cell lineage transcription factors 
Pax5, Bcl-6 and mTA3 and up-regulate the plasma cell specific transcription 
factor, BLIMP1 along with IRF4 and XBP1. The GC B cells first develop into 
plasmablasts which are rapidly proliferating cells that can also produce antibody 
before becoming long-lived plasma cells, which are non-dividing, terminally 
differentiated antibody producing cells. (193). Plasmablasts can either develop into 
long-lived plasma cells locally or migrate to another part of the body such as a site 
of inflammation or stromal niche such as the bone marrow. 
 
Plasmablasts are defined as short-lived antibody producing cells: their 
development can be promoted by IFNα and perhaps consistent with this, their 
production of anti-dsDNA antibodies are associated with flare responses in SLE 
patients (194,195). The levels of plasmablasts correlate with SLEDAI and are 
raised during flares in SLE patients, this may suggest that they are one of the main 
effector B cell population driving disease in SLE patients. Indeed, although the 
levels of long-lived plasma cells are also elevated in SLE patients during infection, 
their levels do not correlate with SLEDAI (196). However, it should be noted that 
some groups have reported that elevated levels of plasma cells do correlate with 
SLEDAI and anti-dsDNA titres, although in this case these cells were not 
differentiated from plasmablasts (159) 
 
The GC reaction is not essential for the generation of antibody producing cells. 
Indeed, the first antibody producing cells to respond to antigen are the innate B1 
or innate-like MZ B cells, which usually develop into loci of antibody producing 
cells outside of the B cell follicle. However, it has been reported recently that both 
B1 (see 1.5.4.8.8. below) and MZ B cells can also enter the GC reaction. The 
antibodies produced by the initial extra-follicular responses are of the IgM isotype 
that usually have low affinity for antigens. The role of these early ‘natural’ 
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antibodies is to facilitate the immune response, for example, by allowing APC to 
collect antigen via antibody receptors. Moreover, and as stated above, circulating 
Fo1 and memory B cells can also develop into antibody producing cells outside of 
the GC. Thus, when a Fo1 B cell receives T cell help it will either enter the GC and 
begin affinity maturation or develop directly into short lived plasmablasts 
depending on the strength of BCR signaling: weak BCR signals send the cells into 
the GC for affinity maturation whereas strong BCR signals allow the B cells to 
develop into plasmablasts outside of the B cell follicle, thus providing a rapid 
source of antibodies (177). 
 
1.5.4.8.8. B1 B cells 
B1 B cells are a population of innate B cells that represent less than 3% of the B 
cell lineage. They were initially identified as a population of B cells expressing 
CD5, hitherto thought to be a T cell marker, that were elevated in lupus prone mice 
(197). B1 B cells have therefore been associated with autoimmunity but they are 
also present in normal mice and healthy individuals and represent a major B cell 
population in the pleural and peritoneal cavities in mice but are rare in the 
secondary lymphoid organs (198). B1 B cells comprise two major phenotypes that 
can be distinguished by their expression of CD5 into B1a (CD5+) and B1b (CD5-) 
subclasses, which have similar characteristics but develop differently (199). 
Despite first being identified in lupus-prone mice, the role of B1 cells in 
autoimmunity, particularly in SLE, is controversial. For example, B1b cells have 
been suggested to play an important role in the development of nephritis in BAFF 
transgenic mice, which develop a lupus like disease (200). However, although 
CD5 expression is elevated on B cells from SLE patients, recent studies have 
revealed that expression of CD5 on B cells can result in the recruitment of the 
negative regulatory signal transducer, SHP-1 to the BCR, perhaps suggesting a 
protective role for CD5 (201). Furthermore, CD5+ B cells are known to act as 
"regulatory" B cells (see 1.5.4.9), producing IL-10 and thereby suppressing pro-
inflammatory immune responses (202).  
 
1.5.4.3. BAFF and APRIL 
Signaling induced by the B cell activating factor (BAFF) is important for the 
survival, differentiation and activation of B cells; especially those of the immature 
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"transitional" B cell phenotype in the periphery(175). BAFF, and its closely related 
homologue APRIL, both belong to the TNF family of cytokines. Both BAFF and 
APRIL exist in membrane bound forms or can be cleaved at a furin site to produce 
soluble cytokines that normally exist as trimers. BAFF binds to three receptors, 
BAFF-R, TACI and BCMA whereas APRIL can bind to TACI and BCMA (203). 
APRIL is not essential for the development of pathology in lupus prone mice (204) 
and inversely correlates with SLEDAI (205-207). Although levels of BAFF are 
generally considered to be elevated in SLE patients and contribute to 
pathogenesis (208,209), BAFF-R expression is reduced (210).  
 
A pathogenic role has been proposed for BAFF in SLE, as high concentrations of 
this cytokine may act to promote the survival of auto-reactive B cells; indeed BAFF 
has been reported to act in synergy with IL-17 to promote the survival and 
proliferation of B cells (103). Perhaps consistent with this, expression of the IL-17A 
receptor is elevated on circulating B cells from SLE patients (211). Consistent with 
the proposed pathogenic role for BAFF, BAFF-transgenic mice develop a lupus 
like disease (212) and BAFF-R signaling drives a lupus like pathology in BAFF-
transgenic mice, in a manner that is dependent on TLR signaling via the adaptor 
protein MyD88 (200,213). Although blockade of BAFF prevents pathology in lupus 
prone mice (214), a recent study with lupus-prone mice that do not express BAFF-
R, TACI or BCMA revealed that disease can occur in the absence of any individual 
BAFF/APRIL receptor (215,216). Nevertheless, a BAFF targeting therapy was the 
first drug specific for the treatment of SLE granted FDA approval in 50 years (217). 
 
1.5.4.4. TLR signaling in B cells  
TLR signaling appears to be instrumental in the fine-tuning of B cell responses and 
appears to be involved in most aspects of B cell biology through to the 
development into antibody secreting cells; TLR signaling may also influence the 
class of antibody produced (218). Indeed, it has been proposed that certain 
molecules are autoantigens in SLE because they can activate the innate immune 
system, in a sense, acting like auto-adjuvants. Expression of TLR9 is elevated in 
circulating B cells from SLE patients and such increased expression is associated 
with disease (219,220) although the mechanisms involved are complex. For 
example, although the development of anti-dsDNA antibodies is abrogated in tlr9-/- 
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lupus prone mice, disease is exacerbated as TLR9 signaling also acts to suppress 
TLR7 activation (221,222). By contrast, whilst TLR7-deficient mice do not develop 
lupus-like pathology, the Yaa mouse develops lupus like disease, due to 
overexpression of TLR7 (223,224).  
 
1.5.4.6. Antibodies 
A major role of B cells is to produce a soluble form of their BCR called antibodies; 
these molecules bind to antigens or cells and neutralize, opsonize or target the 
cells for deletion. Each antibody contains two pairs of polypeptide chains, a heavy 
chain and a smaller light chain linked via a hinge region to provide flexibility, with 
each pair connected by disulphide bonds (Fig. 1.8). The Fab region contains the 
variable antigen binding domains and this is connected to the Fc domain, which 
binds to antibody Fc receptors (FcR). There are 5 forms of antibodies termed 
isotypes: IgG, IgD and IgE are all monomeric proteins whereas IgA molecules form 
dimers and IgM molecules form pentamers although the BCR expressed by 
immature B cells contains a IgM monomer. There are 4 IgG subclasses in mice: 
IgG1, IgG2a, IgG2b and IgG3 and 2 IgA subclasses (225). SLE patients develop 
autoantibody responses against several nuclear and cytoplasmic antigens such as 
Ro, La and Sm (195), but the autoantibodies most characteristic of SLE in patients 
are those raised against dsDNA, the levels of which correlate with SLEDAI and are 
associated with disease flares (3,226).  
 
1.5.4.7. Antibody receptors 
Antibodies: either free, complexed with antigen or attached to cells can be 
detected by the immune system via a series of Fc binding receptors (FcR) for IgM, 
IgA, IgG and IgE.  For example, there are 4 classes of FcR that recognize IgG 
antibodies in mice: three activating receptors, FcγR1, FcγR3 and FcγR4 and one 
inhibitory receptor called FcγR2b. Other antibody receptors also exist such as 
CD23, which binds IgE with low affinity whereas FceRI is the high affinity receptor 
associated with mast cell function and allergic responses(227,228). FcγR are 
expressed by many cells and their signaling can induce both activating and 
tolerogenic responses. While innate immune effector cells such as DC, 
macrophages and neutrophils, express both activating and inhibitory FcγR, B cells 
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only express the inhibitory FcγR2b and it is unclear whether T cells express FcR 
(229).  
 
Each FcγR has an extracellular antibody binding α chain that signals through an 
adjacent ITAM-containing adaptor molecule; this is normally the FcRγ chain but 
can sometimes be replaced by other adaptor molecule such as CD3ζ. An 
exception is FcγR2b, which signals directly through an immunoreceptor tyrosine 
inhibitory motif (ITIM). Binding of immune complexes to FcR results in the receptor 
crosslinking that is required for signaling, which in the case of the activating 
receptors can result in cell activation, the release of pro-inflammatory mediators 
and proliferation.  By contrast, cross-linking of FcγR2b on B cells results in cell 
death by apoptosis and provides a mechanism of negative feedback inhibition of B 
cell activation and antibody production (230). Consistent with this, FcγR2b is 
required to prevent the generation of self-reactive B cells as knockout mice 
develop lupus-like systemic autoimmunity (229), FcγR2b polymorphisms are also 
associated with SLE (231). 
 
1.5.4.9.5. Antibody independent roles of B cells 
B cells are essential for the development of disease in lupus prone mice: however, 
B cells engineered to lack the ability to secrete antibody still have the capacity to 
induce disease, providing evidence for antibody-independent roles of B cells in 
mediating disease (232,233). The exact mechanisms involved are not clear but B 
cells appear to be important for the activation of T cells in autoimmunity via cell 
contact dependent mechanisms such as the presentation of antigen and 
expression of co-stimulatory molecules.  Moreover, they can influence T cell 
responses by their production of cytokines. When cultured in polarizing conditions, 
B cells have been shown to produce cytokines associated with Th1 and Th2 
responses, these cells have been termed Be1 and Be2 respectively, and are 
thought to promote the effect of B cells during an immune response (234). 
Recently, B cell production of IL-6 has been indicated as important for the 
development of autoimmunity (235): furthermore, B cells have been reported to 
produce IL-17 in response to infection with Trypanosoma: these B cells do not 
express RORγt and are activated by CD45 and BCR signaling (187,236,237). 
Finally, and consistent with the finding that B cells, that cannot secrete antibody 
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are still able to drive disease pathogenesis in mouse models of SLE, in patients 
with autoimmune disease undergoing B cell depletion therapy, beneficial effects 
are noticeable before antibody levels drop (217,238,239).  
 
1.5.4.9. Regulatory B cells 
1.5.4.9.1. Historical overview 
As with T cells, several populations of B cells with regulatory cell characteristics 
have been identified. The lack of a signature regulatory B cell transcription factor 
has restricted the advance of our understanding, although it appears that some B 
cells may express FoxP3 (240). Janeway and colleagues first proposed the 
existence of a regulatory B cell population in 1996 by showing that mice which 
lacked B cells developed severe disease in the EAE model of MS, this was 
subsequently shown to be due to a loss immune regulation by IL-10 producing 
regulatory B cells (Bregs) (241,242). Since then, Bregs have been shown to be 
effective at suppressing disease in mouse models of IBD, RA and SLE (243-245). 
Consistent with this, Breg subsets have been identified in humans that are 
defective in patients suffering from MS or SLE (246,247). Although regulatory B 
cells (Bregs) express some of the phenotypical characteristics of B1 B cells, such 
as CD5, which are known to produce IL-10 (199). Bregs can also express 
phenotypic markers of B2 cells, such as CD21 and CD23. Thus it is unclear 
whether Bregs develop from innate or adaptive progenitor cells, nevertheless, 
several distinct B cell populations have been reported to express IL-10 with T2, 
MZP and MZ cells being reported to be protective in models of lupus (244), 
RA(248) and colitis (249) respectively.  
 
1.5.4.9.2. Breg development 
Several aspects of B cell biology have been identified as potential triggers for the 
development of Bregs. Thus, although BCR, CD40 and TLR signaling are 
important for the development of antibody producing cells, the same signals may 
also influence the development of Bregs (250). For example, the importance of 
BCR signaling in the development of Bregs was highlighted in mouse models of 
autoimmunity, where in EAE the loss of CD19 signaling augmented Breg 
responses (251) whilst B cells expressing a BCR specific for an irrelevant protein 
(hen egg lysosome) failed to suppress disease (242). Furthermore, in the CIA 
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model, IL-10 production was stimulated by antigen (252). Likewise, CD40 
signaling was shown to be required for B cell-mediated suppression of disease in 
the EAE, CIA and MRL/lpr mouse models: such CD40 stimulation can be provided 
in vivo by either innate (iNKT) or adaptive  (CD4+ T helper) cells (242). Moreover, 
as B cells can also express CD40-ligand, in addition to expressing CD40 (253), it 
is also possible that the development of Bregs can be driven by B cells in an 
antigen independent manner as shown in the MRL mouse (253-255). This process 
clearly requires tight control as continuous expression of CD40-L by B cells results 
in a lupus-like disease (250,256). Likewise, the final signal required to induce IL-10 
production by B cells is provided by TLR signaling which is generally thought to 
promote immune responses. Nevertheless, B cells deficient in TLR2, TLR4 or 
MyD88 do not resolve EAE (257) and TLR9 stimulation has been reported to 
induce B cell IL-10 production (178). It may be that TLR signaling is different in B 
cells, compared to other cells such as DCs, and it may be that a certain type of 
TLR signaling in B cells promotes a regulatory phenotype, however, clearly much 
is left to be discovered relating to the activation and development of Bregs (242). 
 
1.5.4.9.3. Bregs control innate and adaptive responses 
IL-10 from Bregs can potentially inhibit T cell responses by suppressing DC 
priming of Th1 or Th17 cells. Supporting this, DC from B cell-deficient mice were 
found to produce more IL-12 (258). Furthermore, IL-10 from B cells has been 
shown to suppress IL-12 and IL-6 production by DC (257). Alternatively, B cells 
can suppress T cell responses by activating Tregs and consistent with this, Breg-
deficient mice exhibit a reduction in foxp3 mRNA (259). Moreover, adoptive 
transfer of B cells can also suppress the spontaneous IBD that develops in 
lymphopaenic mice, this suggests that Bregs can inhibit both innate and adaptive 
immune responses (260). Nevertheless, although IL-10 is protective and regulates 
disease in murine models of lupus (261) it may also be pathogenic via the 
activation of B cells. Thus, injection of NZB/NZW lupus-prone mice with IL-10 
exacerbates disease, neutralization delays disease onset (262). Reflecting this, 
polymorphisms that lead to elevated IL-10 production have been reported in SLE 
patients (263) whilst blocking of IL-10 reduces disease severity in SLE patients 
(264). 
 
! 30!
1.6. Treating SLE 
1.6.1. Steroidal and non-steroidal anti-inflammatory drugs 
SLE has traditionally been treated with a variety of steroidal and non-steroidal anti-
inflammatory drugs. Corticosteroids are the most widely used short-term therapy 
for treating SLE patients; however, due to the toxicity associated with prolonged 
use they are generally reserved for the treatment of patients during flare 
responses (265,266). These drugs have multiple effects on both innate and 
adaptive immune responses including suppression of pro-inflammatory cytokine 
production and lymphocyte proliferation as well as the induction of apoptosis in 
pathogenic lymphocytes and macrophages (267,268). Likewise, 
Cyclophosphamide, which is a very effective agent at causing cell death, is used 
cautiously during the most severe of SLE manifestations (269). A less toxic 
alternative is mycophenolate mofetil (MMF) which is an inhibitor of DNA synthesis 
(270) and inhibits lymphocyte proliferation: it is well tolerated with relatively mild, 
but uncomfortable, side effects such as vomiting diarrhea and increased 
susceptibility to infection (271). Two other commonly used drugs are azathioprine 
and methotrexate which both suppress nucleotide synthesis, therefore 
suppressing the rapid expansion of immune cells such as lymphocytes (272,273). 
By contrast, the anti-malarial drugs, chloroquine and hydroxychloroquine that have 
long been prescribed for SLE patients appear to act by suppressing phagocytosis 
and TLR activation (274,275). Antimalarials have proved particularly useful in 
treating disease flare and suppressing the acceleration of disease in early onset 
lupus patients (276,277).  
 
1.6.2. Biologics 
Some of the most effective and recently developed successful therapies for 
treating autoimmune diseases, including SLE, come in the form of therapeutic 
antibodies. There are currently 25 antibodies approved for use in patients with a 
further 240 in development for diseases as diverse as autoimmunity, cancer, 
organ transplantation and infection (278). They are a mainstay of modern biotech 
companies and in the USA generate more than $27 billion each year (279). 
Therapeutic antibodies work by blocking the action of a specific molecule, such as 
preventing a cytokine from binding its receptor or targeting a specific cell for 
destruction. They can be engineered to either contain toxic enzymes or signaling 
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molecules to kill cells and they can also target cells for destruction naturally by 
activating complement dependent cytotoxicity. Finally, therapeutic antibodies can 
act as agonists by stimulating receptors (225,280).  
 
Therapeutic antibodies targeting B cells have received much focus over the past 5 
years. The surprise success of Rituximab, a drug initially developed for the 
treatment of cancer, in the treatment of rheumatoid arthritis provided the rationale 
for testing in other autoimmune diseases (275,281). Rituximab is a chimeric anti-
CD20 antibody that depletes circulating B cells, but not plasma cells. Consistent 
with this, the beneficial effects of rituximab are not necessarily associated with a 
loss of autoantibodies and several theories have been suggested as to why 
exactly it is protective in autoimmune diseases. Possible explanations are that the 
antibody-labeled B cells distract macrophages and neutrophils away from target 
organs; that the treatment suppresses the antibody-independent inflammatory 
functions of B cells or that by depleting the B cells, the effector: regulatory balance 
can be reset naturally (54,275).  
 
Rituximab is therapeutic in some SLE patients and consequently, its off-label use 
is common: however, two large phase 2/3 clinical trials failed to meet their primary 
endpoints (282). The general consensus appears to be that both of these trials 
were poorly designed, with poorly stratified patient cohorts, and although 
subsequent analysis suggests that Rituximab was in fact beneficial, this drug has 
not been approved for use in SLE patients (283,284). Nevertheless, clinical trials 
utilizing other B cell-targeting agents, for example, anti-CD19 and anti-CD22 
antibodies are currently underway (275). Clinical trials with Belimumab, an anti-
BAFF antibody that clears the B cell survival factor from circulation, have been 
more successful. Belimumab was shown to be moderately successful in treating 
SLE patients and became the first drug to receive FDA approval specifically for the 
treatment of SLE patients in 50 years. Nevertheless, this drug is only effective in 
approximately 14% of patients (38,285).  
 
As cytokines drive many aspects of SLE, targeting them has also long been 
thought of as a viable option for treatment. Consistent with this, treatment with 
monoclonal antibodies specific for IL-6 (Toclizumab) (286) and IL-10 (264) have 
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shown moderate results in phase 1 trials:  however, trials using an anti-TNFα 
antibody (Infliximab) were terminated prematurely as some patients experienced 
exacerbated disease (287).  Moreover, reflecting the clear type I IFN signature in 
SLE patients, an anti-IFNα therapy is to be tested in such patients (288) (38). 
Likewise, targeting of co-stimulatory molecules has also been attempted as their 
expression is usually elevated in SLE patients (254,289). However, although an 
early phase 1 trial of anti-CD40 in SLE patients showed promise (290), a phase 2 
trial did not show any benefit (291). Moreover, Abatacept, which is a fusion protein 
of the CTLA-4 extracellular domain and an Fc portion of immunoglobulin that is 
approved for the treatment of RA, showed a modest benefit to SLE patients with 
mild disease in a phase 2 trial although the primary endpoints were not met (292).  
 
Although such biologics are good at targeting cell surface or soluble molecules, 
this strategy is less effective at targeting intracellular signaling pathways (293) as 
small chemicals that can easily pass through the lipid bilayer can modulate these 
targets more efficiently. In SLE, the signaling molecules involved in the hyper-
activity of immune response cells, particularly T and B cells, have been targeted. 
For example, Fostamatinib which acts to inhibit SYK, a critical component of BCR 
and TCR signaling in SLE patients, suppresses disease in mouse models of lupus 
and may be beneficial in patients when clinical trials begin(294). Fostamatinib is 
currently going through a phase 2 clinical trial for the treatment of rheumatoid 
arthritis and is showing promise with, perhaps surprisingly given the importance of 
its target, relatively few side effects (295).  
 
1.7. Developing drugs from parasites  
1.7.1. Parasites versus autoimmunity 
There is a clear emerging socioeconomic driving factor(s) underpinning the 
increasing prevalence of autoimmune diseases, as they occur significantly less in 
developing countries relative to industrialised nations. Over the past 30 years, 
countries such as Hungary and South Korea have experienced a rise in 
autoimmune disease as their economies have developed (296,297): one possible 
environmental factor that is likely to be altered during the development of a nation 
is improved sanitation and a subsequent reduced exposure to pathogens, such as 
helminths (298). This correlation has been captured by the hygiene hypothesis, 
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which states that increased sanitation and clean living in modern society has 
reduced our exposure to microorganisms that would normally train and hone our 
immune responses, resulting in elevated levels of autoimmune and allergic 
disease (299,300). Indeed, the incidence levels of autoimmunity and allergy, which 
are high in developed nations, inversely correlate with that of helminth infection, 
which is endemic in developing countries. Furthermore, the levels of autoimmunity 
or allergic disease in the offspring of immigrants that have traveled from 
developing to developed nations is much higher compared with disease rates in 
the country of origin (301). An exception to this observation may be SLE, which 
does not seem to be defined by socioeconomic factors.  
 
1.7.2. Helminth immune suppression 
Helminths are parasitic worms that are capable of inducing debilitating disease 
such as severe cutaneous lesions, elephantiasis and blindness (302). Nematodes 
have unusually long life spans for parasites and have been reported to survive for 
up to 10 years: one explanation for this is their ability to suppress the host immune 
response (303). Thus through selective modulation of the immune response, 
helminths can prevent cytolytic immune responses that would normally clear the 
worm whilst ensuring that the host remains relatively healthy with an active 
immune system (304,305). Thus, it is plausible that the immune response evolved 
to optimally function with background immune modulation by helminths: therefore, 
when helminths are removed from the environment the immune system may 
automatically become hyperactive (306). This theory can only partially explain the 
relationship between helminths and autoimmunity, however, as if this was the 
case, one would expect the prevalence of immune mediated inflammatory disease 
to be much higher in developed societies. It is more likely therefore, that this 
contributes as another environmental factor in the development of autoimmunity. 
 
1.7.3. Treating autoimmunity with helminths 
The unique relationship between helminths and the mammalian immune system, 
in particular the ability of worms to modulate the immune response, has led 
researchers around the world to investigate the potential application of these 
parasites or their immunomodulatory products in the treatment of immune 
mediated disease, such as allergy and autoimmunity (298). Various helminth 
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species have been shown to protect against disease in several mouse models of 
intestinal inflammation, allergic disease, and autoimmunity (298,307,308). This 
has culminated in clinical trials examining the therapeutic potential of helminths in 
the treatment of autoimmune disease, most recently the use of Trichuris suis in 
IBD patients. The administration of live parasites is potentially dangerous as these 
are live pathogens and can elicit immune responses that can exacerbate disease 
or cause other pathologies. T. suis  was chosen for the treatment of humans as it 
is a porcine helminth and observations with pig farmers, who by the nature of their 
profession are chronically exposed to T. suis, revealed that this parasite can 
colonize humans but only briefly (309). Patients received live T. suis in an open 
label phase 1 clinical trial and the authors reported an 80% improvement; 
however, subsequent placebo-controlled double-blind clinical trials showed more 
modest, but significant, improvements (298). A recent trial examining the potential 
of the human parasite Necator americanus in Crohn’s disease has also looked 
promising. Due to the risk of infection low parasite numbers were used, 
nevertheless, patients with moderate, but not mild or inactive, disease showed 
some improvement (310). 
 
Perhaps the most optimal and safe way to utilize the potential of the parasites to 
modulate the immune system would be to identify the specific components 
responsible for the immunomodulation. Such molecules may be therapeutically 
and economically viable options for the treatment of autoimmune and allergic 
disease: alternatively they may be used as blue prints for the design of novel 
therapeutics. It is also important to realize the potential of such parasite-derived 
immunomodulators as tools to dissect the immune system and hence identify safe 
mechanisms of immune suppression that have been selected by nature 
throughout evolution (311).  
 
1.7.4. Helminth immunomodulators 
Helminth infections naturally induce a Th2 and regulatory phenotype in order for 
the worms to ‘hide their tracks’ and repair damaged tissue as they migrate 
throughout the host (306,308). Such Th2 responses are not pathogenic however, 
as they are limited or modified by the parasite (312). 
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Helminth-derived immunomodulatory molecules can suppress the immune system 
in a variety of ways, for example, cystatins from Onchocerca volvulus and 
Acanthocheilonema viteae may suppress inflammatory macrophages via 
mechanisms involving the scavenger receptor, CD36 and the TGFβ receptor 
(313,314); whilst calreticulin from Heligmosomoides polygyrus, via interacting with 
scavenger receptor A in mice, can skew Th2 responses (315); and Dirofilaria 
immitis-derived antigen binds to CD40 on B cells stimulating the production of 
antigen non-specific IgE, thus saturating IgE receptors, which has been shown to 
prevent anaphylaxis (316). Several parasite-derived immunomodulators act by 
modulation of TLR signaling, which usually promotes Th1/Th17 responses (308). 
Suppressing TLR signaling therefore prevents the generation of immune 
responses that would clear the helminth (306). However, as such strong immune 
responses also underpin the pathologies of autoimmune disease, 
immunomodulatory molecules from Schistosoma mansoni, Ascaris lumbricoides, 
A.viteae and Fasciola hepatica act, at least in part, to protect against development 
of such inflammatory disorders in mouse models by modulation of TLR signaling 
(311).  
 
1.7.5. ES-62: a parasitic helminth-derived immunomodulator 
One such immunomodulator that acts via subversion of TLR signaling is ES-62, an 
excretory-secretory (ES) protein from the murine filarial nematode A. viteae. ES-62 
has conserved orthologues with the human filarial nematodes Brugia malayi and 
O. volvulus (317) and is a tetrameric glycoprotein comprising 63 kDa subunits 
(317). Although the molecule contains a putative peptidase site that is yet to be 
fully validated, the major immunomodulator functions of ES-62 are due to the 
phosphorylcholine moieties present on the molecule (318). Indeed the addition of 
PC moieties to irrelevant proteins such as BSA, or free PC, can replicate many of 
the immunomodulatory effects of ES-62 (319,320).  
 
TLR4 is required both for the internalization of ES-62 by macrophages (but not B 
cells) and its immunomodulatory activity and consistent with this, it appears to act 
to subvert both immunoreceptor and TLR signaling through a MyD88 dependent 
mechanism. The mutated, LPS-unresponsive TLR4 molecule expressed by 
C3H/HeJ mice is sufficient for ES-62 entry and immunomodulation (321,322). 
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Consistent with its proposed role in subverting TLR-mediated pro-inflammatory 
signalling, ES-62 suppresses Th1 polarising responses following TLR2, TLR4 and 
TLR9 stimulation (322).  
 
1.7.5.1. Immunomodulation by ES-62 
Over the past 15 years ES-62 has been shown to modulate, both directly and 
indirectly, the pro-inflammatory responses of several cell populations. The first 
indication that ES-62 was a putative immunomodulator came from experiments 
that showed the parasite product to suppress B cell activation and proliferation in 
vitro (318,323) and in vivo (324). This was achieved by an uncoupling of the BCR 
from the MAP kinase signaling pathways and recruitment of the negative signaling 
molecules, SHP-1 (tyrosine phosphatase) and Pac-1 (MAP kinase phosphatase) 
(325). This anti-proliferative phenotype was complemented by the finding that ES-
62 increased spontaneous IL-10 production by peritoneal B1 B cells suggesting a 
potential anti-inflammatory role for the molecule (326). The key role of the PC 
moiety of ES-62 in the induction of IL-10 was indicated by the finding that whereas 
native ES-62 induces IgG1 but not IgG2a antibody responses, recombinant ES-62, 
which does not contain PC moieties, induces both IgG1 and IgG2a responses: 
interestingly, this PC-mediated blocking of potentially pathogenic IgG2a responses 
was dependent on IL-10 (327).   
 
ES-62 can suppress TCR signaling and induce anergy in Jurkat T cells by 
modulating the activation of the TCR tyrosine kinases Lck, Fyn and ZAP-70 (328).  
Perhaps reflecting this, ES-62 was also found to suppresses the clonal expansion 
and modulated the functional phenotype of antigen specific T cells (329). However, 
this does not appear to be via direct effects on naive T cells but rather by 
modulation of APC function (Whelan et al 2000). Thus, DC and macrophages 
stimulated with TLR ligands, such as LPS, usually elicit Th1 responses via the 
production of IL-12 and IFNγ. However, ES-62 suppresses the ability of DCs and 
macrophages, even following LPS stimulation, to promote Th1 responses 
(330,331). ES-62 also modulates the secretion of other proinflammatory cytokines 
by macrophages, most notably IL-12p70, IL-23, IL-6 and TNFα, suggesting a 
potential suppression of both Th1 and Th17 responses by the parasite product 
(331,332)  Strikingly, in vivo exposure is sufficient to render bone marrow 
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progenitors prone to an anti-inflammatory phenotype on subsequent ex vivo 
differentiation of DC or macrophages (333). More recently, transfer studies 
suggest that ES-62 may also influences T cell responses by modulating antigen 
specific T cell B cell interactions (334).   
 
1.7.5.3. Therapeutic potential of ES-62 in the treatment of autoimmunity 
The immunomodulatory actions of ES-62 presumably reflect the strategies 
developed by the parasite to evade the host immune response and survive without 
causing pathology. Investigation of whether such anti-inflammatory actions could 
be exploited therapeutically for the treatment of inflammatory disorders in humans 
revealed that ES-62 can suppress pathogenic inflammation in mouse models of 
both allergic and autoimmune diseases. Thus, ES-62 was found to suppress 
disease in the collagen induced arthritis (CIA) model of rheumatoid arthritis by 
suppressing collagen-specific Th1-associated cytokine production (TNFα, IL-6 and 
IFNγ), lymphocyte proliferation and IgG2a production (335). The effect on 
lymphocyte proliferation and cytokine production was later revealed to be due to 
the PC moiety whereas the reduction in collagen-specific antibody production was 
not dependent on the presence of PC (319). More recently, it has become 
increasingly clear that pathogenesis of many autoimmune pathologies such as 
those observed in CIA are mediated by IL-17 responses, and reflecting this, in 
addition to suppressing Th1 responses, ES-62 was found to down-modulate pro-
inflammatory IL-17 production in the paw and draining LN as well as disrupting the 
activation of Th17 or IL-17+ γδ T cells by DC (336).  
 
As infection with helminths usually skews the immune system to a more Th2 
orientation (306), and indeed ES-62 itself elicits Th2 responses (330), it was at first 
rather surprising that ES-62 could also prevent development of Th2-biased allergic 
inflammation (228). However, the mechanisms of action underpinning this have 
now been partially elucidated and reflect functional desensitization of mast cell 
responses by down-regulation of key elements downstream of FcεR1 and TLR4 
signaling (228,337) and also by increasing IFNγ to counter-regulate Th17 and 
(consequent) Th2 responses (338). 
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The realization that IL-17 can promote both Th1/Th17 and Th2 
inflammation(339,340) provides a rationale for the therapeutic potential of ES-62 in 
both autoimmune and allergic disorders. Indeed, the therapeutic potential of ES-62 
appears to be restricted to diseases with a Th17 element as Th1 type-1 diabetes 
like disease in the NOD mouse (W. Harnett & A. Cooke, unpublished 
observations) and the Th1 immune pathology induced by Toxoplasma gondii or 
Plasmodium chabaudi or other filarial nematode antigens are unaffected by ES-62 
(341-343) (W. Harnett unpublished). Likewise, and important in the consideration 
of the therapeutic potential of ES-62, the parasite molecule did not prevent Th1 
immune responses to the BCG vaccine suggesting that patients receiving drugs 
developed from ES-62 would still be responsive to vaccination (344).  
 
1.7.5.4. Thesis Aims: ES-62 and the MRL/lpr mouse  
Previous studies evaluating the therapeutic potential of ES-62 in the MRL/lpr 
mouse model of SLE have revealed that prophylactic treatment with the parasite 
product suppresses the development of proteinuria. Despite such a clear 
improvement in disease outcome, surprisingly no obvious improvement in renal 
histology was observed and cellular infiltration; C3 and antibody deposition of the 
kidneys appeared unaltered. Likewise, no clear immunomodulatory effect in this 
model of a mixed Th1/Th2 phenotype could be detected nor any suppression of 
the associated lymphadenopathy and splenomegaly.  Thus, the core aims of the 
thesis were to identify and characterize the protective mechanisms of action of ES-
62 in the MRL/lpr mouse model of lupus. In particular, although still controversial in 
SLE, given the increasing recognition of the importance of IL-17 in the 
pathogenesis of autoimmune disease it was planned to focus on the effects of ES-
62 on Th17, and associated cytokine responses such as IL-22, in the MRL/lpr 
mouse. As a major role of IL-17 appears to relate to the recruitment of pro-
inflammatory effector cells to sites of inflammation, it was planned to relate any 
modulation of IL-17 responses to renal pathology.  Moreover, given the effects of 
ES-62 on B cell responses and recent reports that regulatory B cells were 
protective in mouse models of arthritis, at least in part by suppressing Th17-
associated responses (345), it was also planned to determine whether exposure to 
ES-62 resulted in resetting of the effector/regulatory balance in the MRL/lpr 
mouse.  
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Table 1.1: The IL-17 family of cytokines, their receptors and implications in 
disease. LTi, lymphoid tissue inducer cells; NK, natural killer cells; iNKT, invariant 
natural killer cells; RA, rheumatoid arthritis; IBD, irritable bowel disease and MS, 
multiple sclerosis. Adapted from Pappu et al. 2011(89) 
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Figure 1.1: TLR signaling. TLRs are composed of extracellular binding domains 
consisting of multiple leucine rich repeats (colored elongated rectangles) and 
intracellular Toll/IL-1R (TIR) domains (yellow circles). Upon ligation by PAMPs or 
DAMPs, TLRs form homodimers (TLR3, TLR4, TLR5 and TLR9) or heterodimers 
(TLR1/2, TLR2/6 and TLR7/8) and recruit the appropriate adaptor proteins, 
MyD88, MAL, TRIM or TRIF. These adaptor molecules then signal through the 
IRAK/TRAF, TBK or RIP1 pathways to induce the activation of transcription factors 
and subsequent gene expression.  
Adapted from Liew et al., Nature Reviews Immunology (2005)(19).  
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Figure 1.2: Complement cascade. C3 is the central component of the 
complement cascade and this can be activated by the (i) classical pathway, in 
response to immune complexes (IC), C-reactive protein (CRP) or serum amyloid 
protein (SAP); (ii) lectin pathway, by specific carbohydrates, including sugar 
groups on IgA or IgM and the (iii) alternative pathway, by direct binding of C3b to 
activating surfaces that initiates a cascade that results in the formation of the 
membrane attack complex (MAC) and the activation of complement receptors on a 
variety of cells.  
Adapted from Sacks et al., Nature Reviews Immunology (2012)(346). 
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Figure 1.3: Antigen presentation via MHC. The MHC class I pathway (A) 
presents endogenous peptides that have been processed via the proteasome, and 
enter the endoplasmic reticulum via the TAP transporter to be loaded onto MHC 
class I molecules, held in the correct conformation by a complex of the MHC 
molecules (α1-3 and β2M) and chaperone molecules (tapasin, calreticulin and 
ERp57). Binding peptide induces release of the chaperone molecules and the 
MHC class I-peptide complex is then trafficked to the cell surface via the golgi 
apparatus. The MHC class II pathway (B) presents exogenous peptides that have 
entered the cell via endocytosis, or endogenous peptides that have been 
generated via autophagy. MHC class II molecules are assembled in the 
endoplasmic reticulum with CLIP blocking the peptide-binding groove. They are 
then exported through the golgi apparatus to vesicles, that fuse with late 
endosomal compartments that contain peptide fragments that are then loaded 
onto the MHC class 2 complex before being exported to the cell surface.  
Adapted from P. E. Jensen, Nature Immunology (2007)(347). 
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Figure 1.4: Early B cell differentiation. The early stages of B cell development 
occur in the bone marrow where, arising from haemopoietic stem cells, common 
lymphoid precursors (CLP) commit to developing into immature B cells through the 
pre-pro-, pro- and pre-B cell stages until they finally develop into IgM-expressing 
immature B cells, at which point they leave the bone marrow and enter the 
circulation to migrate to the spleen where they further mature via transitional 
stages to mature B cells. During the bone marrow stages, the immunoglobulin 
genes are rearranged to form a viable B cell receptor (BCR).  
Adapted from T. Nagasawa, Nature Review Immunology (2006)(348). 
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Figure 1.5: B cell receptor signaling. The BCR forms an antigen receptor 
complex with Igα (CD79a) and Igβ (CD79b) molecules which recruit SYK and LYN. 
These adaptor molecules activate downstream signaling elements such as BLNK, 
BTK and PLCγ2 which promote cell survival, proliferation and development via 
activation of the PI-3kinase, PLCγ and MAP kinase signaling pathways.  
Adapted from Choi et al., Cancer Journal (2013)(349). 
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Figure 1.6: The spleen. The spleen is a secondary lymphatic organ with two 
major functions; the filtration of blood and detection of circulating foreign or 
immunogenic material, which occurs in the red-pulp; and the peripheral maturation 
of immature B cells, which occurs in the white pulp. The structure of the white pulp 
can be separated into three distinct structures: (i) the periarteriolar lymphoid 
sheath (PALS), which contains T cells; (ii) the B cell zone, where B cell follicles 
and germinal centers form and (iii) the marginal zone, which contains specialized 
B cell and macrophage populations that filter the blood in the red-pulp for antigens.  
Adapted from Pillai et al., Annual Review Immunology (2005)(173). 
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Figure 1.7: Peripheral B cell development. Immature B cells that have 
developed in the bone marrow enter the spleen via the blood (Fig. 1.4); these T1 B 
cells lack the ability to recirculate and, once in the spleen (Fig. 1.6), undergo 
several stages of development into mature B cell phenotypes. As T1 B cells 
(CD19+CD21-CD23-IgM+IgD-AA4.1+) enter the white pulp, they pass through the 
PALS into the B cell zone where they first express surface IgD and acquire the 
ability to recirculate and are termed T2 B cells (CD19+CD21-
CD23+IgM+IgD+AA4.1+). Following strong BCR signaling, T2 B cells will develop 
into follicular type 1 B cells (Fo1; CD19+CD21low/-CD23+IgMlowIgD+AA4.1-), which 
circulate around the body searching for antigen presented by APC. Following weak 
BCR signaling, T2 B cells will develop into marginal zone precursor B cells (MZP; 
CD19+CD21+CD23+IgM+IgD+AA4.1-), which reside in the B cell zone before 
developing into marginal zone B cells (MZ; CD19+CD21+CD23-IgM+IgD-AA4.1). 
MZ B cells reside in the marginal zone of the spleen (Fig. 1.6) where they sample 
antigens passing through the blood of the splenic red pulp and respond to T-
dependent and T-independent antigens. If a T2 B cell receives no BCR stimulation 
but can compete successfully for BAFF, it develops into a follicular type 2 B cell 
(Fo2; CD19+CD21low/-CD23+IgM+IgD+AA4.1-). Little is known about Fo2 B cells but 
they may act as reserve cells to replenish the marginal zone under certain stimuli 
such as when the MZ B cell population is rapidly depleted by a blood borne 
pathogen. Transitional 3 cells (T3 CD19+CD21low/-CD23+IgM+IgD+AA4.1+) are a 
third transitional population that exists in the secondary lymphoid organs, they are 
thought represent a population of anergic B cells however their differentiation is yet 
to be delineated.  
Adapted from Pillai et al., Nature Reviews Immunology (2009)(174). 
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Figure 1.8: Antibodies. Antibodies are secreted forms of the B cell antigen 
receptor (Fig. 1.5) that exhibit varying degrees of antigen specificity depending on 
the type of cell that secretes them. An antibody comprises 4 polypeptide chains, 2 
heavy (blue) and 2 light (green), and can be separated into two fragments: the 
antigen binding F’ab fragment and the antibody receptor binding Fc fragment (A). 
This structure is maintained by several disulphide bonds (black lines). The end 
domains of each F’ab fragment contain the variable regions (striped domains) of 
the protein, which bind to specific epitopes (A). Antibodies can be produced in 5 
classes: IgG, IgD and IgE are monomers with a structure similar to that presented 
in ‘A’; IgA is produced as a dimer as represented in ‘B’; and IgM can be produced 
as either a monomer or pentamer as represented in ‘A’ and ‘C’ respectively.  
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2. Materials and Methods 
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2. 1. Mice 
Animals were maintained in the Biological Services Units of the Universities of 
Glasgow and Strathclyde in accordance with the Home Office UK Licenses 
PPL60/3580, PPL60/3119, PPL60/4300, PPL60/3791, PPL60/3810, PIL60/12183, 
PIL60/12950, and PIL60/9576 and the respective Ethics Review Boards of The 
University of Glasgow and Strathclyde University.  
 
2.2. Purification of ES-62 
ES-62 was purified as previously described (335), briefly: ES-62 was purified, 
using endotoxin free reagents, from spent culture medium (endotoxin-free RPMI 
1640; Life Technologies, Paisley, U.K. with added glutamine (2 mM), penicillin 
(100 U/ml), streptomycin (100 µg/ml)) of adult A. vitea. Larval forms were removed 
by filtering the media through 0.22 µm filter (Sigma-Aldridge, Poole, U.K.). The 
media was then transferred to a stirred ultracentrifugation unit containing a YM10 
membrane (Amicon, Stonehouse, U.K.). The sample was then further 
concentrated using a Centricon micro-concentrators with a 30kDa cutoff 
membrane (Amicon) before being applied to a sepharose column fitted to an 
isocratic fast protein liquid chromatography system (Pharmacia). 95% of protein-
containing eluted fractions were shown to contain a single protein band that was 
confirmed to be ES-62 by SDS-page. Endotoxin levels were confirmed to be 
<0.003 U/ml using the Endosafe Kit (Charles River Laboratories, Kent, UK) 
(319,336,338) 
 
2.3.1. MRL/lpr mouse model of SLE 
Male MRL/MP and male or female MRL/lpr mice were obtained from Harlan Olac, 
Bicester, UK at 5-8 weeks of age and maintained until 20-22 weeks of age. 
Proteinuria was monitored twice weekly using Multistix (Bayer, Cambridge, UK). 
ES-62 (2 µg; which reflects the endogenous concentration of ES-62 in a mouse 
during a natural infection with A. vitea (335)) or PBS (100 µl) was administered 
subcutaneously twice weekly from week 7 after birth; recombinant IL-17A (1 µg 
(118)), recombinant IL-22 (1 µg (118)) or neutralizing anti-IL-22 (100 µg (118)) was 
administered twice weekly in 100 µl of sterile PBS from 12-20 weeks; neutralizing 
anti-IL17A (100 µg (118)) was administered twice weekly in 100 µl of sterile PBS 
from 7-12 weeks of age. Mice were sacrificed using CO2 and exsanguination by 
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cardiac puncture using a 23-gauge needle and 1 ml syringe. Serum was collected 
from blood using pediatric blood tubes (LSL, UK). Spleens, kidneys, peripheral 
(popliteal, inguinal, brachial, axillary, cervical), renal lymph nodes and bones were 
harvested.  
 
2.3.2. Collagen induced mouse model of rheumatoid arthritis 
Collagen induced arthritis (CIA) was induced in 8-week old male DBA/1 mice. 
Each mouse received 100 µg of bovine type II collagen (CII, MD Biosciences) in 
complete freunds adjuvant containing 4mg/ml of Mycobacterium tuberculosis 
(CFA, MD Biosciences) by intradermal injection at the base of the tail on day 0 and 
200 µg of CII in PBS via inter-peritoneal injection on day 21. Mice were monitored 
daily for signs of arthritis, which was measured as a total score from 4 limbs 
where: 0 = normal, 1 = digit(s) involvement, 2 = erythema, 3 = erythema and 
swelling, 4 = extension/loss of function. ES-62 (2 µg) or PBS control was 
administered subcutaneously on days -2, 0 and 21. Mice were sacrificed using 
CO2 and exsanguination by cardiac puncture using a 23-gauge needle and 1 ml 
syringe. Spleen, paws and paw-draining LN were harvested. 
 
2.3. Cell culture 
Lymphoid tissue was dissected, mechanically disrupted and passed through a 
nitex gauze (Cadisch Precision Meshes Ltd., UK) to obtain a single cell 
suspension. Spleen samples were treated with 5 ml of red cell lysis buffer 
(eBioscience) for 5 minutes on ice before being diluted 10-fold in PBS and 
centrifuged at 400 xg, 4ºC for 5 minutes. Viable cell counts were obtained using 
cells stained with Trypan blue (0.4%, Sigma) and a haematocytometer (Digital 
Bio.).  B2 B cells were purified as previously described by depletion of CD43+ cells 
using anti-CD43 antibodies conjugated to magnetic micro beads (Miltenyi)(230), 
double negative T cells were purified by depletion of CD19+ CD4+, CD8+ and 
CD11b+ cells (Miltenyi). B cells were cultured in RPMI containing 5% FCS, 50 µM 
β2-Mercaptoethanol, 1% L-glutamine, 1 mM sodium pyruvate, 1% non-essential 
amino acids, 10 U/ml penicillin and 10 µg/ml of streptomycin; and T cells were 
cultured in RPMI containing 10% FCS, 1% L-glutamine, 1 mM sodium pyruvate, 
1% non-essential amino acids, 10 U/ml penicillin and 10 µg/ml of streptomycin.  
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Kidneys were minced in 1 ml of RPMI medium before being passed through nitex 
gauze and centrifuged at 400xg, 4ºC for 5 minutes. The supernatant was stored 
for further analysis of the renal interstitial fluid and the cell pellet was resuspended 
in 5 ml of red cell lysis buffer and incubated on ice for 5 minutes before being 
diluted 10-fold in PBS and centrifuged at 400 xg, 4ºC for 5 minutes. Cells were 
then passed through a cell strainer (BD) to remove any fat and tissue debris still 
present in the sample. 
 
Renal fibroblasts were differentiated by culturing kidney cells (2x106) for two 
weeks in RPMI containing 20% FCS, 1% L-glutamine, 1 mM sodium pyruvate, 1% 
non-essential amino acids,10 U/ml penicillin and 10 µg/ml of streptomycin; media 
was replaced twice weekly and the phenotype of the fibroblasts was confirmed by 
flow cytometry as being CD54+ and CD106+ (Fig. 2.1). 
 
2.4. Purification of lymphocytes  
B2 B cells were purified from whole spleen samples by magnetic bead sorting 
according to manufacturers guidelines (Miltenyi). Briefly, single cell suspensions of 
splenocytes were incubated with anti-CD43 magnetic micro-beads for 15 minutes 
before being washed and massed through an LD column. The purified CD43- cell 
fraction was on average 86% positive for CD19+ cells; which included transitional, 
follicular, marginal zone precursor, marginal zone and germinal center B cells. 
Double negative T cells were also purified by depletion of 
CD4+CD19+CD8+CD11b+ cells from the pLN of 21-week MRL/lpr mice. Population 
purity was confirmed by flow cytometry.  
 
2.5. Generation of bone marrow derived macrophages and DC 
To retrieve bone marrow cells, harvested femurs and tibias were cleaned of all 
tissue and the ends of the bones were removed. A 25G needle was then inserted 
into each bone and 10 ml of media was flushed through into a 50 ml falcon tube. 
Large pieces of bone marrow were then dissociated by gentle pipetting through a 
21G needle. The sample was then centrifuged at 400xg (4oC) for 5 minutes and 
the cell pellet was resuspended in 5 ml of cold red cell lysis buffer (eBiosciences) 
and incubated on ice for 5 minutes. RPMI (35ml) was then added and the cells 
were centrifuged at 400xg (4oC) for 5 minutes. The cell pellet was then 
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resuspended in 5 ml of culture medium and passed through a cell strainer. Culture 
media contained RPMI supplemented with 10% FCS, 1% L-Glutamine, 10 U/ml 
penicillin and 10 µg/ml of streptomycin, 1% pyruvate acid, 1% non-essential amino 
acids (all Life Technologies, UK) and either recombinant GM-CSF (10 µg/ml) for 
DC development or 20% L929-conditioned media, which contains the M-CSF 
required to develop macrophages. The cells were counted and their concentration 
adjusted to 2x106 cells/ml: 1ml of this cell stock was added to a non-tissue culture-
treated petri dish along with a further 9 ml of culture media. DC or macrophage 
cultures were incubated at 37oC with 5% CO2 for 6 days with the media being 
replaced on the third day. On the sixth day the cells were harvested by gentle 
scraping.   
 
2.6. Flow cytometry 
Cells (1x106) were seeded onto round bottom 96-well plates and washed with PBS 
at 400xg for 5 minutes at 4ºC and stained with the Live/Dead® fixable aqua dead 
cell dye (Invitrogen) following the manufacturers protocol. Cells were then 
resuspended in FACs staining buffer (PBS containing 1% FCS and 2.5 mM EDTA 
at 4ºC) and Fcγ Receptors were blocked by incubation with 100µl of αCD16/CD32-
specific antibody containing 2.4G2 supernatant for 15 minutes. Primary antibody 
cocktails with relevant isotype controls (Table 2.1) were added to the wells and 
incubated for 30 minutes at 4ºC. The cells were then washed twice before 
incubation with secondary antibodies or streptavidin conjugated fluorophores, if 
necessary. The cells were washed a final 3 times before being passed through a 
nitex gauze into labeled FACs tubes. FACs analysis was carried out on a BD LSR 
II. 
 
For the detection of intracellular cytokines or transcription factors, commercial kits 
were utilized according to the manufacturers’ protocols. Cytokine production was 
detected by intracellular cytokine staining as previously described (336). Briefly, 
lymphocytes (106/ml) were stimulated with 50 ng/ml PMA (Sigma-Aldrich, UK) plus 
500 ng/ml ionomycin (Sigma-Aldrich, UK) and 10 µg/ml LPS (E. coli O111:B4, 
Sigma-Aldrich, UK (350)) for 1 h before addition of 10 µg/ml Brefeldin A (Sigma-
Aldrich, UK), cells were the incubated for a further 5 h at 37oC with 5 % CO2. Cells 
were fixed and washed several times in permeabilization buffer before primary 
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antibodies were added in permeabilization buffer, incubated at 4oC for 30 minutes. 
Cells were then washed three times with permeabilization buffer and finally with 
FACs staining buffer.  
 
2.7. Analysis of peripheral B cell subsets  
The study of peripheral B cell subsets is complicated by the multiple stages of 
development from immature transitional cells to functionally mature marginal zone, 
follicular or antibody producing B cells. For this analysis the phenotypic markers 
defined by Allman and Pillai (351) were used (Table 2.2); however, the gating 
strategy suggested was modified to improve cell subset resolution and 
experimental efficiency as follows (Fig. 2.2).  
 
Cell populations were initially selected on the basis of size and granularity using 
the forward scatter (FSC) and side scatter (SSC) parameters respectively (Fig. 
2.2A). Doublets, events where two cells are connected and pass through the laser 
beam at the same time, were excluded by comparing FSC-Height and FSC-Area 
(Fig. 2.2B). As antibodies can bind non-specifically to dead or dying cells, which is 
partially due to expelled DNA during cell death, these cells were excluded from 
analysis using the Live/Dead® fixable aqua dead cell dye (Invitrogen), which binds 
to free amines on the cell surface: as dead cells have compromised cell 
membranes the dye can permeated the cell and bind to free amines inside the cell, 
thus dead cells have a higher staining intensity (Fig. 2.2C). 
 
The conventional method for the separation of marginal zone precursor (MZP), 
marginal zone (MZ) and follicular B cells is to separate CD19+ cells by CD21 and 
CD23 expression (Fig. 2.3A). Using this method, the position of the MZP gate is 
difficult to accurately define and the clarity of this population varies between 
experiments, mouse strains and disease states. To improve the resolution of these 
populations, CD19+CD23- and CD19+CD23+ cells were initially separated (Fig. 
2.3B), with the CD19+CD23+ gate containing the MZP (CD21hiCD1dhi), follicular 
and transitional (Fo & T; CD21low/-CD1dint/-) B cells (Fig. 2.3C); whereas the 
CD19+CD23- gate contains the MZ (CD21+IgM+) and T1 (CD21-IgM+) B cells (Fig. 
2.3D). MZP, MZ and Fo have specific IgM and IgD expression profiles. Using the 
conventional method of separating these subsets, MZ B cells are IgMhiIgDlow/-, 
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MZP are IgMhiIgDhi and Fo are IgMlow/-IgDhi (Fig. 2.3E); these populations are more 
clearly defined using the modified protocol (Fig. 2.3F).  
 
The follicular population identified (Fig. 2.3C) is a hetrogenous population that 
contains the functionally distinct follicular type 1 (Fo1: IgDhiIgMlow/-AA4.1-) and 
follicular type 2 (Fo2: IgDhiIgMhiAA4.1-) B cells as well as the transitional 2 (T2: 
IgDhiIgMhiAA4.1+) and transitional 3 (T3: IgDhiIgMlow/-AA4.1+) populations. These 
populations are first separated on the basis of their IgM and IgD expression (Fig. 
2.3G) and then by the expression of the immature marker AA4.1 (Fig. 2.3H & I).  
 
For the identification of germinal centre (GC) B cells, CD19+CD43- cells (Fig. 2.4A) 
were examined for the expression of the GC cell specific marker GL7 along with 
the pan B cell marker CD24 to ensure that no contaminating non-B cells are 
selected in the initial gate (Fig. 2.4B). The presence of FAS is then confirmed (Fig. 
2.4C) however, in this study FAS is treated as a redundant marker and was not 
included in the analysis of GC B cells, as essentially all of the CD19+CD43-
CD24+GL7+ cells are positive for FAS (~90%) and FAS is not expressed in MRL/lpr 
mice. 
 
GC B cells develop into antibody producing cells. The phenotype of these cells is 
usually defined by the ability to produce antigen specific antibodies and their rate 
of proliferation: plasmablasts are rapidly dividing antibody-producing cells whereas 
plasma cells are sessile antibody producers. The most commonly used method to 
identify plasma cells by flow cytometry is to compare the expression of CD138 to 
that of B220 (Fig. 2.5A) (352) or CD19 (Fig. 2.5B) (353) as plasma cells are 
generally thought to be CD138+CD19-B220-. This method of separation is not 
appropriate for the MRL/lpr mouse model for three reasons: firstly, the majority of 
CD138 is expressed by the B220+CD4-CD8- double negative (DN) T cell population 
(McGrath, Harnett & Harnett unpublished data and data not shown), which 
accounts for up to 80% of lymphocytes from 16 weeks of age; secondly, as 
several populations of B220+ and CD19+ B cells, myeloid cells and T cells express 
CD138, a dump channel to exclude cells positive for CD4, CD8, GR1, F4/80, 
CD11b and CD11c (Fig. 2.5C) is applicable to all plasma cell analysis by flow 
cytometry; and finally, as the MRL/lpr mouse develops a spontaneous disease that 
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is not driven by any specific auto-antigen, it is difficult to identify antigen specific 
antibody producing cells. The CD138+ populations were therefore characterized as 
precisely as possible, initially by selecting the Dump-CD138+ cells (Fig. 2.5C) as 
this excludes any CD4, CD8, GR1, F4/80, CD11b and CD11c positive cells from 
the analysis and provides a clear population that can be further dissected on the 
basis of CD19 and B220 expression (Fig. 2.5D). Based on the current literature 
the B220-CD19- population contains fully differentiated plasma cells, the B220low/-
CD19+ population contains either short-lived plasma cells or plasmablasts and the 
B220+CD19+ population contains either pre-plasma cells or plasmablasts 
(352,354). Examination of the expression of B220 and CD19 on the populations 
isolated by conventional plasma cell gating reveals a mixed population (Fig. 2.5E) 
where the CD138+B220low/- population (Fig. 2.5A) contains CD19+ and CD19- 
populations (Fig. 2.5E), the CD138+CD19- population (Fig. 2.5B) contains B220+ 
populations (Fig. 2.5E), the CD138hiCD19hi population (Fig. 2.5D) contains B220+ 
and B220low populations (Fig. 2.5E) and the CD138lowCD19+ population (Fig. 2.5D) 
are all B220hi (Fig. 2.5E). 
 
The final population examined represents B1 B cells. These innate B cells develop 
independently of B2 B cells and are generally defined as being 
CD19hiCD43+IgMhiIgD- and can be separated into CD5+ B1a cells and CD5- B1b 
cells (199) (Fig. 2.5F & G).  
 
2.8. Organ histology 
Whole organs from MRL/lpr mice were harvested and fixed with 10% Formalin for 
24 hours followed by 30% sucrose for an additional 24 hours before being snap 
frozen in OCT embedding media (Raymond A Lamb) and stored at -80oC. 
Sections, 7µm thick, were cut from the frozen tissues using a Cryostat (Thermo 
Scientific), and mounted onto Super Frost® Plus slides (VWR). Slides were 
wrapped in metallic foil and stored at -20oC. Haematoxylin and eosin (H&E) 
staining was done as described by Fischer et al, 2008. Briefly, sections were 
removed from -80OC storage and equilibrated to room temperature before being 
uncovered and fixed in ice-cold acetone/ethanol (3:1). The slides were then air 
dried and stained with Harris haematoxylin (a nuclear stain) and 1% eosin (a 
connective tissue stain). Alternatively, to detect basement membranes in the 
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kidney glomerulus, kidneys were stained with periodic acid and Schiffs stain 
(PAS). Briefly, fixed sections were oxidized by submersion in periodic acid for 10 
minutes before being washed for 5 minutes and then submerged in Schiff’s 
solution for 20 minutes. Sections were then washed in slightly warm running water 
until the stain had receded enough so that the basement membrane was visible 
around the glomerulus by light microscopy. Cell nuclei were then briefly stained 
with Harris haematoxylin (5-10 seconds) and washed. H & E or PAS stained 
sections were dehydrated in increasing concentrations of ethanol and xylene 
before being mounted in DPX and covered with a glass cover slip. Sections were 
visualized using an Olympus BX41 light microscope. 
 
2.9. Immunohistochemistry and ANA staining 
For immunohistochemistry, tissue sections were fixed in ice-cold acetone for 10 
minutes before being air-dried for a further 30 minutes; tissues were outlined with 
a wax pen and allowed to air-dry for 1 hour before being rehydrated in PBS-tween 
(PBS-T) for 5 minutes and blocked in 1% BSA in PBS-T for 1 hour. Slides were 
washed three times in PBS-T for 5 minutes before being incubated with primary 
antibody for 2 hours at room temperature. Slides were then washed three times in 
PBS-T and then transferred to a dark staining box and incubated with secondary 
fluorochrome conjugated antibodies for 2 hours at room temperature. Slides were 
washed three times in the dark and then incubated with DAPI for 5 minutes. Slides 
were then washed for a final time before being mounted in ProlonGold (Invitrogen) 
and covered with a glass cover slip. Serum anti-nucleic acid antibodies (ANA) 
were detected using Hep-2 slides (Antibodies incorporated, CA) in accordance 
with manufacturers guidelines with the following modifications. Briefly, slides were 
incubated with 40 µl of diluted serum samples (1:40) for 30 minutes in a moist 
staining box before being washed thoroughly with PBS. Slides were then 
incubated with affinity purified rabbit-anti-mouse-IgG (heavy and light chain) 
antibodies (diluted 1:200 in PBS; Jackson Laboratories) diluted in PBS and 
incubated for a further 30 minutes in a moist staining box. Slides were then 
washed thoroughly once again with PBS before being incubated with a FITC-
conjugated goat-anti-rabbit-IgG antibody (diluted 1:200 in PBS) for 30 minutes. 
Slides were washed a final time in PBS before being mounted with the mounting 
solution provided and covered with a glass cover slip. Slides were viewed using a 
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Axiovert S100 fluorescent microscope (Zeiss). Fluorescence staining intensity was 
subjectively assessed and where appropriate scored in the nucleus and cytoplasm 
as: none (0), ± (1), positive (2) and bright (3) (Fig. 2.6). 
 
2.10. ELISAs 
Cytokines were detected by ELISA using 96-well plates (Corning) and the 
following commercially available and validated kits: TNFα, IL-1β, IL-6, IL-12p70, 
IL-27, MCP-1 and IL-10 (all from eBioscience, CA); IFNγ (BD, NJ); IL-17A 
(BioLegend, CA); IL-22 and IL-23 (R&D, MN). Serum antibody concentrations 
were determined by sandwich assay. Mouse serum was serially diluted in PBS 
(103-1010) in a 96-well plate and incubated over night at 4oC. Samples were then 
washed, and non-specific binding blocked using 10% FCS in PBS before being 
incubated with biotinylated mouse- anti-IgG1, -anti-IgG2a, -anti-IgM or -anti-IgE (all 
from BD, NJ, and diluted 1:200) for 1 hour at room temperature. Samples were 
washed and incubated with streptavidin conjugated horseradish peroxidase for 30 
minutes before being washed one final time and then incubated with TMB 
substrate and stop solutions (KPL, MD). Absorbance read at 450nm using a Tecan 
Sunrise plate reader. 
 
2.11. Western blot  
Cells were washed with cold PBS twice and centrifuged at 400xg for 5 minutes at 
4oC, the cell pellet was air-dryed and disrupted (by vortex) in 30-50µl of modified 
RIPA cell lysis buffer (50 nM Tris buffer (pH 7.4), 150 mM sodium chloride, 2% 
(v/v) NP40, 0.25% (w/v) sodium deoxycholate, 1 mM EGTA, 1x HaltTM protease 
inhibitor and 1x HaltTM phosphatase inhibitor (Pierce)) and incubated for 30 
minutes on ice. Cell debris was then separated from the protein extract by 
centrifugation at 16,000xg for 15 minutes at 4oC. The supernatant was then 
removed and protein concentration was measured using the BCA protein assay kit 
(Pierce). Proteins were separated by gel electrophoresis using the NuPAGE 
Novex system (Invitrogen). Protein extract (20-50 µg) was heated with NuPAGE 
LDS sample buffer and NuPAGE reducing agent for 10 minutes in a heat block set 
at 72oC. Sample (20 µl) was then injected into pre-cast 4-12% Bis-Tris gradient 
gels along with 5 µl of Kaleidoscope protein ladder (Bio-Rad). Gels were run in 
NuPAGE MOPS buffer supplemented with antioxidant at 180V until the protein 
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bands were well resolved. Proteins were then transferred to nitrocellulose 
membranes (GE) using the NuPAGE system. Protein transfer was confirmed by 
ponseau-red (Thermo Scientific) staining of the membrane, which was then 
washed with TBS-Tween (TBS-T: 0.5 mM sodium chloride, 20 mM Tris-HCl 
(pH7.4) and 0.1% (v/v) Tween-20) and then blocked with 5% non-fat milk protein 
in TBS-T for 1 hour. The membrane was then incubated with a pre-titrated primary 
antibody suspended in 1% BSA in TBS-T for 16-18h at 4oC. The membrane was 
washed three times with TBS-T before being incubated with a pre-titrated 
secondary antibody suspended in TBS-T with 5% milk for 1 hour at room 
temperature. The membrane was washed for a final 3 times before being 
incubated in ECL Western blotting substrate (Thermo Scientific) and exposed to X-
ray film (Kodak).   
 
2.12. Purification of neutralizing antibodies 
Antibody producing hybridoma cell lines (kindly provided by Drs Renauld and Van 
Snick, Ludwig Institute for Cancer Research, Belgium) were cultured at 80-90% 
confluency for 2 weeks and the supernatant was harvested and filter sterilized. A 
standard purification column was seeded with sepharose beads covered with 
Protein G, a bacterial antibody binding protein, and washed with 5 column volumes 
of binding buffer (0.2 M NaH2PO4 and 0.2 M Na2HPO4 at pH7). Cell supernatants 
were then run through the column at 4oC using capillary action. The column was 
then washed with a further 50ml of PBS and protein was eluted from the column 
by adding 8ml of elution buffer (0.1 M glycine at pH 2.7) and collected in 15 x 1ml 
fractions in eppendorf tubes. Each tube contained 500 µl of 1M Tris-HCl at pH 8.5 
to bring the eluted proteins back to physiological pH. The concentration of protein 
in each fraction was measured using a nanodrop and fractions containing >0.1 
mg/ml of protein were pooled. Purified protein samples were dialysed overnight in 
5 liters of sterile PBS at 4oC. Protein concentration was measured using a 
nanodrop and the purity of the sample and integrity of the protein was confirmed 
by protein gel and Coomassie blue staining. Endotoxin was removed from the 
sample using the Endosafe Kit (Charles River Laboratories, Kent, UK). Endotoxin 
levels were confirmed to have <0.003 endotoxin units/ml before samples were 
filter sterilized and stored in concentrated aliquots.   
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2.13. Statistics 
Statistical analysis was preformed on all data sets using the Prism software 
(GraphPad Software, La Jolla, CA) and statistical significance is shown as 
*=p<0.05, **=p<0.01 and ***=p<0.001. For data sets with two groups: parametric 
data was analyzed using the one-tailed Student’s t-test; for the analysis of non-
parametric data, the Mann-Whitney test was used. For data sets with more than 2 
groups, the one-way ANOVA with Tukey’s post test was used and in experiments 
where two variables were measured, the two-way ANOVA test was used with the 
Bonferroni’s post test.    
! 69!
Table 2.1. List of antibodies used in this study. 
 
Antigen Fluorophores Clone Co. Optimal Concentration (µg/µ l)  
 
 
 
 
 
 
 
AA4.1 APC AA4.1 eB 0.1 
B220 E450 RA3-6B2 BL 0.05 
CD11b E450 M1/70 BL 0.05 
CD138 PE 281-2 BD 0.05 
CD19 AF488 6D5 BL 0.05 
CD19 Biotin ID3 BD 0.05 
CD19 PE/Cy7 6D5 BL 0.05 
CD1d PE 1B1 BL 0.05 
CD2 Biotin RM2-5 BL 0.1 
CD21 E450 eBio4E3 eB 0.05 
CD23 PE/Cy7 B3B4 BL 0.05 
CD25 APC PC61 BL 0.1 
CD28 Biotin 37.51 BL 0.1 
CD3 AF488 145-2C11 BL 0.05 
CD3 PE 145-2C11 BL 0.05 
CD4 Biotin L3T4 BD 0.1 
CD4 PE RM4-5 BD 0.1 
CD4 PerCP RM4-5 BD 0.1 
CD43 PE 1B11 BL 0.05 
CD43 PE/Cy7 1B11 BL 0.05 
CD5 Biotin 53-7.1 BL 0.1 
CD8 APC 53-6.7 BL 0.2 
CD8 PE/Cy7 53-6.7 BL 0.05 
CD9 PE MZ3 BL 0.05 
CTLA-4 Biotin UC10-4B9 BL 0.1 
FoxP3 PE FJK-165 eB 0.2 
GL7 FITC 553666 BD 0.05 
HSA PerCP-Cy5.5 M1/69 BL 0.05 
IFNγ PE XMG1.2 BL 0.2 
IgD PerCP/Cy5.5 11-26c.2a BL 0.05 
IgM APC/Cy7 RMM-1 BL 0.05 
IL-10 APC JES5-16E3 eB 0.2 
IL-17A APC TC11-18H10.1 BL 0.2 
IL-22 PE Poly5164 BL 0.2 
IL-4 PE 11B11 BL 0.2 
TLR4 APC 67518 R&D 0.2 
BAFF-R FITC eBio7H22-E16 eB 0.05 
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Table 2.2. Cell surface markers used to phenotype B cell populations: as 
defined by Allman and Pillai (351,352,355,356). 
 
Population Phenotype 
T1 CD19+ CD93+ CD21- CD23- IgDlow/- IgMhi 
T2 CD19+ CD93+ CD21int CD23+ IgDhi IgMhi 
T3 CD19+ CD93+ CD21int CD23+ IgDhi IgM low/- 
MZP CD19+ CD93- CD21hi CD23+ CD1dhi IgDhi IgMhi 
MZ CD19+ CD93- CD21hi CD23- CD1dhi IgD- IgMhi 
Fo1 CD19+ CD93- CD21 low/- CD23+ IgDhi IgM low/- 
Fo2 CD19+ CD93- CD21 low/- CD23+ IgDhi IgMhi 
GC CD19+ CD43- CD24+ GL7+ 
Pre-plasma (CD4, CD8, GR1, CD11b, CD11c & F4/80)- CD138+ CD19+ B220+  
Plasmablast (CD4, CD8, GR1, CD11b, CD11c & F4/80)- CD138+ CD19+ B220-/low 
Plasma (CD4, CD8, GR1, CD11b, CD11c & F4/80)- CD138+ CD19- B220-/low 
B1a CD19+ CD43+ IgMhi CD5+  
B1b CD19+ CD43+ IgMhi CD5- 
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Figure 2.1. Gating strategy for the detection of fibroblasts. Fibroblasts were 
confirmed as being double positive for CD54 (ICAM-1) and CD106 (VCAM-1) 
(357). Isotype staining is shown in panel (A) and the positive stain is shown in 
panel (B). 
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Figure 2.2. Gating strategy for the detection of live cells  
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Figure 2.3. Gating strategy for the detection of live transitional, marginal 
zone precursor, marginal zone and follicular B cells.  
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Figure 2.4. Gating strategy for the detection of germinal centre B cells. 
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Figure 2.5. Gating strategy for the detection of antibody producing B cells.  
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Figure 2.6. Representative images of ANA stained Hep-2 slides. Hep-2 slides 
(Antibodies incorporated) were stained with 40µl of negative (A) and positive (B) 
control serum that is provided with the kit. Hep-2 slides were stained with 40µl of 
diluted (1:40) serum from MRL/lpr mice (C). 
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3. ES-62 prevents development of proteinuria in the 
MRL/lpr mouse by modulation  
of the IL-17A and IL-22 axis 
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3.1. Introduction 
 
In recent years, much interest has focused on exploiting the relationship between 
parasitic worms and the immune system, as helminths can actively regulate 
immune responses via the production of immunomodulatory molecules. The safe 
modulation of the immune system by helminth products has developed through the 
co-evolution of parasite and host, and may provide the basis for the design of 
novel therapeutics for the treatment of diseases where the immune system is 
aberrantly hyper-responsive, such as in autoimmune and allergic inflammatory 
conditions (311). ES-62 is one such helminth-derived immunomodulator, secreted 
by the rodent filarial nematode Acanthocheilonema viteae, that protects against 
the development of collagen-induced arthritis and ovalbumin-induced airway 
hypersensitivity in mice via the modulation of Th17/Th1 and Th17/Th2 effector 
cytokine responses, respectively (305,336,338). In this chapter the therapeutic 
potential of this molecule in a mouse model of systemic lupus erythematosus 
(SLE), a disease which exhibits a mixed cytokine phenotype is explored (74,358). 
 
T helper cell responses have been widely studied for their pathogenic role in 
driving renal pathology, as both Th1 and Th2 phenotypes are characteristically 
unbalanced in SLE patients (73). More recently, the implication of Th17 cells in 
driving rheumatoid arthritis, and other autoimmune pathologies, has led to scrutiny 
of the role of this cell type in SLE (111). Consistent with a role for Th17 cells in 
pathogenesis, IL-17A levels have been found to be raised in SLE patient serum; 
furthermore, IL-17A producing cells infiltrate the inflamed kidneys of SLE patients 
(103,359). Recent findings in mouse models of SLE have further supported a role 
for IL-17A in renal pathology (112-114) although the importance of other Th17 
related cytokines, such as IL-22, which may act in synergy with IL-17A in SLE, 
remain to be determined (137,138,142). As ES-62 appears to be protective in 
models of inflammation that are regulated by IL-17, the aims of this chapter were 
therefore to determine: whether ES-62 is protective in the MRL/lpr mouse model of 
SLE and if so, which parameters of pathology are reduced; whether IL-17, and 
associated cytokines such as IL-22, play a pathogenic role in SLE; and whether 
suppression of lupus-associated pathology in the MRL/lpr mouse by ES-62 is 
associated with a modulation of the IL-17A/IL-22 axis.   
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3.2. Results 
 
3.2.1. ES-62 suppresses the development of proteinuria in the MRL/lpr 
mouse  
MRL/MP mice develop a lupus-like disease over 12-18 months that recapitulates 
most of the immunopathology and serology of SLE patients. However, the loss of 
FAS signaling in the MRL/MPlpr/lpr, herein referred to as MRL/lpr mice, results in an 
accelerated disease where the mice develop high titres of anti-nuclear antigen 
(ANA) autoantibodies, glomerulonephritis, arthritis-like footpad inflammation, 
systemic vasculitis, splenomegaly, lymphadenopathy and neurological/behavioral 
changes within 4 months (Fig. 3.1). Consistent with this, analysis of the intensity 
and characteristic nuclear staining of Hep-2 cells revealed the presence of 
autoantibodies with specificities for both cytoplasmic and nuclear antigens in 
MRL/lpr mice; whilst MRL/MP mice also displayed some nuclear staining, this was 
found at much lower levels (Fig. 3.1A). Likewise, assessment of kidney pathology 
showed much higher levels of glomeruloproliferation (Fig. 3.1B) and cellular 
infiltration (Fig. 3.1C) in kidneys from MRL/lpr, relative to MRL/MP mice at this time 
point. Moreover, the MRL/lpr mice exhibited clear splenomegaly and 
lymphadenopathy (Fig. 3.1D) that reflected substantial increases in cell numbers 
(Fig. 3.1E & F). Glomerulonephritis is the major lupus-associated pathology 
observed in the MRL/lpr mouse and the progression of kidney damage is 
assessed by twice weekly measurements of proteinuria. MRL/lpr, but not MRL/MP, 
mice develop high levels of proteinuria (>3 mg/ml) within 16 weeks and are culled 
around 20-22 weeks due to the severity of the renal disease (~20 mg/ml) (Fig. 
3.2). Prophylactic treatment of MRL/lpr mice with twice-weekly (from week-7) 
subcutaneous (s.c) injections of ES-62 (2 µg/dose) significantly reduced the 
concentration of proteinuria (Fig. 3.2). Despite the reduction of proteinuria by ES-
62, histological evaluation of renal tissue sections stained using haematoxylin and 
eosin (H & E) or staining with periodic acid and Schiff’s stain (PAS) protocols 
revealed no clear improvement in glomerular nephritis, cellular infiltration (H & E) 
or basement membrane thickening (PAS). Furthermore, treatment with ES-62 did 
not appear to reduce the level of immune complex or complement deposition (Fig. 
3.3). 
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3.2.2. ES-62 and T cell dynamics in the MRL/lpr mouse 
As exposure to ES-62 did not result in any substantial improvement in renal 
pathology, it was hypothesized that ES-62 was acting to modulate the autoimmune 
response; in particular, the composition of the inflammatory cell infiltrate and the 
cytokines that control inflammation in the kidney. A striking feature of the lupus-like 
disease that develops in MRL/lpr mice is the enlargement of the spleen and lymph 
nodes (LN), termed splenomegaly and lymphadenopathy respectively. This is 
largely due to a loss of peripheral FAS-mediated cell death and exacerbated 
proliferation of lymphocytes (Fig. 3.1D-F). ES-62 did not prevent the development 
of splenomegaly or lymphadenopathy and may even have exacerbated it, as the 
spleens of 12- and 20- week old MRL/lpr mice treated with ES-62 were found, if 
anything, to contain more cells, although lower total numbers of renal cells were 
found at 12-weeks in the kidney (Fig. 3.4A & B).  
 
Dysregulation of T cell responses have been strongly implicated in the pathology 
of SLE reflecting the ability of T cells to orchestrate immune responses(73). 
Consistent with this, characterization of the dynamics of CD3+CD4+ helper T cell, 
CD3+CD8+ cytotoxic T cell and CD3+CD4-CD8-B220+ double negative (DN) T cell 
populations throughout the course of the MRL/lpr model (Fig. 3.4C) revealed that 
whilst the proportion of CD4+ and CD8+ T cells declined throughout the course of 
disease, despite their numbers remaining relatively constant, the proportion and 
number of DN T cells, drastically increased from week 13 such that by week 20, 
DN T cells represented ~80% of the lymphocyte population (Fig. 3.4D & E). This 
expansion of the DN T cell population was therefore the major cause for the 
lymphadenopathy and splenomegaly observed in these mice (Fig. 3.1D-F) and the 
onset of their expansion correlated with the development of proteinuria (Fig. 3.2).  
 
Interestingly, therefore, prior to the onset of disease (at 12 weeks of age) the 
levels of CD4+, CD8+ (number) and γδ (proportion and number) T cells were 
reduced in the pLN of ES-62 treated mice (Fig. 3.5A). The proportion and number 
of CD4+ and CD8+ T cells were also reduced in the rLN of 12-week MRL/lpr mice 
treated with ES-62 whereas the proportion of DN T cells was enhanced (Fig. 
3.5B). None of these effects, however, were observed in either the peripheral 
lymph nodes (pLN) or renal lymph nodes (rLN) by 21-weeks (Fig. 3.5C & D). 
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Nevertheless, these data are perhaps suggestive of ES-62 modulating the early 
initiation of pathogenic T cell responses; interestingly, both CD4+ and γδ T cells 
have been proposed to mediate pathogenic IL-17A responses in lupus 
(58,360,361). Despite significantly increasing the number of DN T cells at 21-
weeks, treatment with ES-62 did not appear to affect T cells in the spleen either 
prior to or during the onset of disease (Fig. 3.6A & B). Moreover, although no 
differences were apparent at 12-weeks (Fig. 3.6C), exposure to ES-62 tended to 
decrease the levels of all the T cell populations infiltrating the kidneys at 21-weeks, 
although this only reached significance in terms of the proportions of DN and gd T 
cell (Fig. 3.6D). Interestingly, the reduction of the T cell and B220+CD3- B cell 
populations in the kidney at 21-weeks was associated with a tendency to observe 
increased proportions of CD4+, CD8+ and DN T cells in the blood and bone 
marrow of ES-62 treated mice, supporting the possibility that the parasite product 
suppressed the migration of lymphocytes to sites of inflammation (Fig. 3.7). 
Furthermore, ES-62 appeared to reduce the proportion of B220-CD3+CD8low cells, 
which may either represent a population of activated cytotoxic T cells(362) or a 
population of MHC class I restricted T cells found in B cell follicles(363). These 
cells were significantly increased in the spleens of ES-62 treated 21-week MRL/lpr 
mice (mean % of live cells ± SEM: PBS, 0.5 ± 0.07; ES-62, 0.77 ± 0.09; p=0.044) 
whilst being significantly decreased in the kidneys (mean % of live cells ± SEM: 
PBS, 0.82 ± 0.23; ES-62, 0.19 ± 0.04; p=0.021). 
 
3.2.3. ES-62 modulates the levels of lineage negative cells in the MRL/lpr 
mouse  
There has been increasing recognition in recent years of the importance of innate 
lymphocytes(364) and this has led to the identification of novel classes of 
lymphocytes (LTi, ILC1, ILC2, ILC17 and ILC22) delineation of their roles in the 
immune system(364). During this investigation, in addition to modulating T cell 
dynamics, it became clear that exposure to ES-62 also modulated cells in the 
lymphocyte gate that were negative for lineage specific markers (CD3-CD19-CD64-
CD11b-) and are likely to represent populations of innate lymphoid cell (ILC). 
Interestingly, therefore, it has became apparent over the past 4 years that ILC 
appear to be involved in the regulation of immune-mediated disease (364) and 
indeed, studies with SLE patients have suggested they may play a protective role 
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in Lupus (50). The dynamics of 3 potential ILC populations based on their Lin- 
status in concert with their expression of CD25 and/or CD127 were characterized 
in the MRL/lpr mice. Two small populations that were either Lin-CD25+CD127- 
(ILC2-like) or Lin-CD25-CD127+ (LTi-like) were detected in the blood of MRL/lpr 
mice but no clear population of Lin-CD25+CD127+ (natural helper- or neuocyte-like) 
cells was found (364,365). Nevertheless, all of these populations were found at 
reduced levels in the blood of ES-62 treated mice (Fig. 3.8A & B).  By contrast, 
although all three of these populations were also detectable in the bone marrow, 
their levels did not appear to be modulated by the parasite product (Fig. 3.8C & D).   
 
Likewise, all three Lin- populations were detectable in the spleen, pLN, rLN and 
kidneys of 12- and 21-week old MRL/lpr mice. Prior to the onset of disease, at 12-
weeks), the proportions of Lin-CD25+ and Lin-CD127+ cells were reduced in the 
spleen, pLN and rLN of ES-62 treated mice but not in the kidney (Fig. 3.9A-D), 
perhaps suggesting that they were involved in the initiation of pathogenesis. By 
contrast, whilst these populations were not significantly changed in the spleen, 
pLN and rLN of 21 week old mice (Fig. 3.9E-G), in the kidney, the proportions of 
the Lin-CD127+ and Lin-CD25+CD127+ populations were significantly reduced in 
mice exposed to ES-62 (Fig. 3.9H) suggesting that these cells may also play a 
pathogenic role in the kidney during established disease; reflecting their 
suppression by ES-62 observed in the spleen and pLN at 12-weeks (albeit the 
CD25+CD127+ populations were not significantly reduced) rather than a defect in 
migration.  
 
3.2.4. ES-62 does not appear to modulate IFNγ  production 
To address whether the ES-62-mediated modulation of T cell dynamics reflected 
modulation of immune phenotype, the effects of exposure to ES-62 on cytokine 
production by MRL/lpr mice were assessed. IFNγ producing Th1 cells have 
traditionally been associated with the pathogenesis of SLE and IL-12p40 appears 
essential for the development of proteinuria in the MRL/lpr mouse (366). However, 
preliminary data on the dynamics of IFNγ production throughout the MRL/lpr model 
in mice treated with or without ES-62 suggested that the parasite product did not 
modulate IFNγ production (McGrath and Harnett, unpublished data). To confirm 
this, the effect of ES-62 on the production of IFNγ in the pLN, rLN and kidneys of 
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21-week old MRL/lpr mice was determined (Fig. 3.10A-D) and indeed, no 
significant effects of ES-62 were detected (Fig. 3.10B-D).  
 
3.2.5. IL-17A may have a dual role in pathogenesis in the MRL/lpr mouse and 
is modulated by ES-62  
Since the study by Kikawada et al. which revealed that IL-12p40 was essential for 
the development of disease in MRL/lpr mice, leading to the proposal of a key role 
for IFNγ in pathogenesis of lupus, it has become apparent that IL-12p40 is also a 
component of IL-23, a cytokine required for the maintenance of IL-17A producing 
cells (91,366). Interestingly, therefore, IL-17A-producing cells have recently been 
implicated in the pathogenesis of SLE (113,367) and can be found in the kidneys 
of both lupus-prone mice and SLE patients (359). Furthermore, IL-23 stimulated 
IL-17A producing T cells from B6lpr/lpr mice can transfer lupus-like renal disease to 
RAG-/- mice (112).  
 
Preliminary data had suggested that ES-62 suppressed a spike in IL-17A prior to 
the onset of disease and it was hypothesized that this may act to initiate 
pathogenesis (McGrath & Harnett, unpublished data). This was confirmed as prior 
to the onset of disease, in 12-week old MRL/lpr mice, ES-62 reduced the levels of 
IL-17A producing cells in the pLN and rLN (Fig. 3.11A & B). At this stage, no IL-17-
producing cells were detected in the kidney (data not shown). Surprisingly, 
however, analysis at 21-weeks revealed that treatment of MRL/lpr mice with ES-62 
increased the proportion and number of IL-17A producing cells in the pLN (Fig. 
3.11C) but not the rLN or kidney (Fig. 3.11D & E). Nevertheless, the concentration 
of IL-17A was significantly elevated in the renal interstitial fluid of ES-62 treated 
mice (Fig. 3.12A) and IL-17A was detected in the renal interstitial fluid from 
MRL/MP mice although this was significantly less that in that of the MRL/lpr mice. 
IL-17E and IL-17F were also detectable in the renal interstitial fluid of 21-week 
MRL/lpr mice however, no difference was observed between mice treated with or 
without ES-62 (data not shown). Interestingly, the number of IL-17+ lymphocytes 
was significantly increased in asymptomatic 21-week MRL/MP mice compared to 
age-matched MRL/lpr mice (Fig. 3.12B); however there was no correlation 
between proteinuria and IL-17 production (Fig. 3.12C). 
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Collectively, these data suggested a potential dual role for IL-17A in the MRL/lpr 
mouse, as ES-62 mediated protection against disease was associated with 
reduced IL-17A production prior to the onset of pathology and elevated IL-17A 
production during established disease. To explore this theory IL-17A responses 
were neutralized by treatment with an anti-IL-17A neutralizing antibody from 7-12 
weeks of age whilst recombinant IL-17A (rIL-17) was administered from 12-21 
weeks of age; replicating the effect of ES-62 on enhancing late IL-17A production. 
Consistent with a dual role for IL-17A, the administration of rIL-17A from 12-weeks 
resulted in significantly reduced proteinuria levels whilst although it did not prevent 
development of proteinuria, the neutralization of early IL17A production slowed the 
onset and reduced severity of the early phase of disease (Fig. 3.13A). Thus it 
appeared that IL-17A contributed to pathogenesis prior to onset of proteinuria yet 
acted to reduce the severity of inflammation during established disease in the 
MRL/lpr mouse (Fig. 3.13A). The inability of anti-IL-17A to fully suppress the 
development of proteinuria may suggest that IL-17A is not sufficient for 
pathogenesis and/or reflect the long half-life of the antibody, which as it was 
administered up until 12 weeks, may also have blocked some of the protective 
effects resulting from IL-17A produced during the established phase of disease. 
Nevertheless, treatment with anti-IL-17A or rIL-17A did not appear to substantially 
affect either renal histology or the production of ANA (Fig. 3.13B & C).  
 
3.2.6. IL-22 is essential for the development of proteinuria in the MRL/lpr 
mouse 
These IL-17-related data are therefore somewhat at odds with recent studies by 
Kyttaris et al. showing that early neutralization of IL-23 suppresses disease in the 
MRL/lpr mouse whilst IL-23R deficiency prevents disease development in the 
B6lpr/lpr model of SLE (368,369).  However, IL-23 is not only crucial for the 
maintenance of IL-17A producing cells, but is also important for production of IL-22 
by cells of both the adaptive and innate immune systems (126). Thus, the 
neutralization of IL-23 that was shown to suppress disease in MRL/lpr mice 
(368,369) may also affect IL-22 production, suggesting that IL-22 may have a 
pathogenic role in SLE that may be modulated by ES-62 (137,138). Preliminary 
data from this lab identified that cells produced either IL-17A or IL-22 exclusively, 
and double producing cell populations were not detected in vivo (McGrath and 
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Harnett unpublished observations). IL-22 producing cells were therefore analyzed 
independently of other cytokine production. Prior to the onset of disease, as with 
IL-17, ES-62 reduced the levels of IL-22-producing cells in the pLN and rLN of 
MRL/lpr mice (Fig. 3.14A & B). However, ES-62 also reduced the proportion of IL-
22 positive cells in the pLN of 21-week old mice (Fig. 3.14C).  Although the levels 
of IL-22-producing cells were not significantly reduced in the rLN (Fig. 3.14D), 
those in the kidneys of MRL/lpr mice were significantly reduced in mice treated 
with ES-62 (Fig. 3.14E). The concentration of IL-22 in the renal interstitial fluid of 
ES-62 treated mice was significantly reduced and was undetectable in the renal 
interstitial fluid from MRL/MP mice (Fig. 3.15A). Furthermore, the number of IL-22-
producing lymphocytes in the pLN positively correlated with proteinuria in MRL/lpr 
mice whilst IL-22-producing cells were not detectable in age-matched MRL/MP 
mice (Fig. 3.15B & C).  
 
Taken together, these data suggested that IL-22 was associated with 
pathogenesis in the MRL/lpr mouse. To test this theory recombinant cytokines and 
neutralizing antibodies were employed: as in preliminary experiments IL-22 
production was not detectable in the serum of MRL/lpr mice prior to the onset of 
disease, both anti-IL-22 and rIL-22 were administered from 12-21 weeks of age. 
Administration of recombinant IL-22 indeed significantly accelerated and 
exacerbated disease whereas neutralization of this cytokine suppressed the 
development of proteinuria: collectively, these data are consistent with the 
proposal that IL-22 is sufficient and essential for the development of renal disease 
in the MRL/lpr mouse (Fig. 3.16A). Despite its profound effects on proteinuria, 
treatment with neutralizing anti-IL-22 antibodies, or rIL-22, had no significant affect 
on renal histology or ANA production (Fig. 3.16B& C).  
 
3.2.7. Analysis of the phenotype of the cytokine producing cells 
As reported above, ES-62 clearly modulated the capacity of cells to produce 
various cytokines in MRL/lpr mice: however, it was unclear whether this 
modulation reflected a general suppression of cytokine production or targeting of 
specific cell populations. Although IFNγ was largely unaffected by ES-62 (Fig. 
3.10), the proportion of IFNγ+ DN T cells was reduced in pLN and rLN of ES-62 
treated mice (Fig. 3.17A-C); whilst in the pLN, the proportion of IFNγ+ Lin- cells 
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were elevated significantly (Fig. 3.17A & B). Moreover, although only a small 
component, the proportion of IFNγ-producing CD4+ T cells was significantly 
decreased in the kidneys of ES-62 treated mice (Fig. 3.17D).  
 
By contrast, prior to the onset of disease, the levels of IL-17-producing cells were 
significantly decreased in ES-62 treated MRL/lpr mice (Fig. 3.11). Whilst the 
conventional IL-17A-producing populations, CD4+ (Th17) and DN T cells, were 
elevated in the pLN, and perhaps in the rLN, of these mice; the proportion of B 
cells, NK cells, γδ T cells and ILC were significantly reduced and likely accounted 
for the overall decline in IL-17A production (Fig. 3.18A&B). The proportion of IL-
17+ cells in the pLN of PBS treated 21-week MRL/lpr mice (mean ± SEM; 1.72 ± 
0.27) was significantly reduced (p=<0.0001, student’s t-test) compared to that of 
the PBS treated 12-week old mice (mean ± SEM; 20.36 ± 0.96); and surprisingly, 
the proportion and number of IL-17+ cells was elevated in the pLN but not the rLN 
of ES-62 treated mice (Fig. 3.11C&D). This increase in IL-17A-producing cells in 
the pLN appears to be due to a significant rise in the levels of IL-17+Lin- cells (Fig. 
3.18C) that was mirrored by a similar increase in the rLN (Fig. 3.18D). However, in 
the rLN, and consistent with their proposed role in initiating pathogenesis 
(112,359), the proportion of Th17 cells was decreased (Fig. 3.18D) perhaps 
suggesting that their elevated levels in the LN of 12-week old mice (Fig. 3.18B & 
C) represented their sequestration away from the site of inflammation.  During 
established disease IL-17+ cells were detectable in the kidneys of MRL/lpr mice 
(Fig. 3.11E) and at similar levels to those previously reported by Tsokos and 
colleagues (112). Treatment with ES-62 did not appear to modulate the overall 
proportion of IL-17+ cells in the kidney (Fig. 3.11E), perhaps reflecting that 
although it did not reach significance, the increase in IL-17-producing DN T cells 
would likely cancel out the significant decrease in the proportion of IL-17+Lin- cells 
(Fig. 3.18F). Although ILC have been proposed to be protective in SLE, these data 
could suggest that IL-17+ILC may be pathogenic and that their reduction in the 
kidney may reflect their ES-62-mediated retention in the pLN and rLN (Fig. 3.18D 
& E) to sequester them from the site of inflammation. These data suggest that IL-
17+Lin- may be a pathogenic source of IL-17A in the MRL/lpr mice. 
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In contrast to what was observed with IL-17, ES-62 suppressed the levels of IL-22-
producing cells both prior to the onset of pathology and during established 
disease. The early suppression of IL-22 production appeared to be due to a 
significant reduction in the proportion of the ILC populations, IL-22+ Lin- and IL-
22+NK cells, in the pLN, and CD4+ Th22 cells in the rLN (Fig. 3.19A-B): whereas 
the cells targeted in both pLN and rLN during established disease were DN T cells, 
which constitute the predominant source of this cytokine at this stage (Fig. 3.19D 
& E). By contrast, the major phenotype of IL-22+ cells in the kidney was that of Lin- 
ILC-like cells: however, ES-62 did not appear to significantly modulate the 
proportion of any particular IL-22+population, but rather appeared to suppress 
levels overall (Fig. 3.19F).  
 
The expansion of the DN T cell population correlates with the development of 
proteinuria in the MRL/lpr mouse. These cells have also been identified in SLE 
patients and found to infiltrate the kidney where they produce IL-17 (359). 
Interestingly, therefore, exposure to ES-62, albeit not significantly, increased the 
levels of such IL-17-producing cells in kidney during established disease 
suggesting, that in keeping with previous reports (112,359), DN could play a 
protective role in limiting inflammation. However, DN T cells also appear to be a 
major potential source of IL-22 in MRL/lpr mice that is targeted by ES-62 (Fig. 
3.19). As DN T cells produce either IL-17A or IL-22, they may comprise a 
functionally heterogeneous group, a proposal that may go some way to resolving 
the contradictory evidence about their role in the MRL/Lpr mouse (370). 
Nevertheless, as the total DN T cell population was elevated in the spleen and 
blood of ES-62 treated mice but reduced in the kidneys (Fig. 3.6 & 3.7), these data 
suggest that ES-62 may have been targeting a pathogenic DN T cell population or 
inducing a switch in their functional phenotype. To address this, DN T cells were 
adoptively transferred from the pLN of 21-week old PBS or ES-62 treated MRL/lpr 
mice into 7-week old recipient MRL/lpr mice: no significant effect of DN T cells 
from either PBS- or ES-62-treated mice could be observed in terms of proteinuria 
relative to that observed in mice simply receiving PBS i.v. (Fig. 3.20).  
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3.3. Discussion 
 
Parasitic helminths can survive within the host for up to 10 years; one strategy that 
enables them to do so is the secretion of molecules that modulate the immune 
system. Such immunomodulatory molecules may have therapeutic potential in 
inflammatory diseases where the hyper-activation of the immune system results in 
damage to the host, such as allergy and autoimmunity (311). ES-62 is one such 
immunomodulatory glycoprotein, secreted by the murine filarial nematode A. 
viteae, that has been shown to modulate the immune system via TLR4 and MyD88 
dependent mechanisms (322) and can suppress pathogenesis in mouse models of 
rheumatoid arthritis (335,336) and asthma (228,305,335). ES-62 mediated 
protection, in both of these pathologies, is associated with modulation of the T 
helper cell balance by suppression of IL-17A production(336,338). Although SLE 
exhibits an ambiguous immunological phenotype (63,73), Th17 and γδ T cell-
derived IL-17A has been implicated in disease pathogenesis both in mouse 
models and also in SLE patients (111) and thus, the therapeutic potential of ES-62 
was investigated in the MRL/lpr mouse model of SLE.  
 
The major pathology in MRL/lpr mice is lupus nephritis (14) which is monitored 
experimentally by measurement of proteinuria. Prophylactic treatment with ES-62 
(twice-weekly from 7-weeks of age) was found to significantly reduce the 
development of proteinuria in MRL/lpr mice. Rather surprisingly, therefore, it did 
not appear to substantially improve renal histology in terms of inflammation, 
cellular infiltration or the deposition of antibody and complement. Although this 
was surprising given the drastic effects on proteinuria levels that were observed, it 
was consistent with other studies in the literature which similarly failed to show 
global improvements in histology (112,244). Nevertheless, analysis of infiltrating 
cells extracted from whole kidneys revealed that the migration of certain perhaps 
pathogenic populations into the kidneys of MRL/lpr mice might be prevented by 
treatment with ES-62. Supporting this blocked migration theory, whilst the 
proportions of lymphocytes and granulocytes circulating in the blood were elevated 
in ES-62-treated mice; these cells were reduced in the kidneys. Unfortunately, the 
effect of ES-62 on the production of chemokines and/or the expression of their 
receptors was not comprehensively evaluated in these MRL/lpr mice: however, 
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preliminary findings suggested that ES-62 increased CD69 expression (data not 
shown), which may act as a retention marker for lymphocytes (371); and reduced 
expression of CD44 on γδ T cells (336), a marker that is associated with 
lymphocyte migration in vivo.   Furthermore, the expression of CXCR5 on B cells 
was reduced in ES-62 treated MRL/lpr mice (see chapter 4). 
 
ES-62 suppresses the development of pathogenic IL-17A responses in collagen-
induced arthritis and ovalbumin-induced airway hypersensitivity (336,338). Thus, 
as IL-17A had also been strongly linked to SLE pathogenesis and the 
development of lupus-like disease in mice, it was hypothesized that the protection 
afforded by ES-62 might reflect suppression of the pathogenic effects of IL-17A in 
the MRL/lpr mouse. Recent studies using mice deficient in IL-23, a crucial cytokine 
in the maintenance of Th17 development supported the proposed pathogenic role 
of such cells in the development of lupus-like disease in the MRL/lpr and B6lpr/lpr 
mice(368,369): however, IL-23 was not consistently detected in the serum or renal 
interstitial fluid of MRL/lpr mice (results not shown) and consequently the effect of 
ES-62 on IL-23 production or function in the MRL/lpr mouse remains unknown. 
Nevertheless, consistent with these studies, ES-62 suppressed IL-17A and IL-22 
responses prior to the onset of disease. By contrast, ES-62 also suppressed IL-22, 
but not IL-17A responses, during established disease perhaps suggesting that 
protective effects of IL-23 deficiency were predominantly targeting IL-22 
responses.  
 
The role of IL-22 in human SLE patients has not yet been established as whilst 
some reports conclude that IL-22 is associated with pathogenesis (137-139), 
others report a negative correlation with disease activity (143,144) or suggest that 
IL-22 levels may be predictive of specific pathologies, such as tissue involvement, 
in certain SLE patient groups (142). Interestingly, IL-22 is reduced in SLE patients 
treated with hydroxychloroquine (140), a report consistent with the finding that IL-
22 is required for pathogenesis in the MRL/lpr mouse.  
 
Although IL-22 has been proposed to exhibit dual roles in some inflammatory 
diseases (118,372), this is unlikely to be the case in the MRL/lpr mouse as IL-22 
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production is not detectable in MRL/MP mice and treatment with ES-62 reduced 
IL-22 production both prior to and following onset of disease.  
 
As DN T cells were the major IL-22-producing population that was targeted by ES-
62 during established disease, these cells were adoptively transferred into young 
MRL/lpr mice on the basis that those from PBS-treated mice might accelerate 
and/or exacerbate onset of pathology whilst those from ES-62 might potentially 
ameliorate disease when compared to those mice receiving only PBS. Rather 
surprisingly, no significant differences were detected amongst the 3 groups 
although it appeared that the onset of proteinuria was slightly slower and less 
severe in mice receiving either set of DN T cells. Although difficult to interpret, 
these data, which exhibited a rather remitting and relapsing profile especially with 
respect to the DN T cells from PBS-treated, presumably reflected the 
heterogeneous (functional) phenotype of DN T cells in MRL/lpr mice.  Moreover, 
and quite surprisingly, it proved difficult to further purify this abundant population of 
cells with the post-sort cohort of cells from ES-62-treated mice in particular 
showing substantial B cell contamination, perhaps indicating some DN T cell-B cell 
interactions in these mice.  
 
At first sight, the finding that IL-17A may potentially exhibit a protective role in the 
MRL/lpr mouse contradicts the general perception of a solely pathogenic role for 
IL-17A in SLE (103,373,374). However, although levels of IL-17A have been 
widely shown to be elevated in SLE patients, very few of these studies have 
concluded that IL-17A positively correlates with SLEDAI (114,375-378). Rather, 
more studies have concluded that IL-17A levels do not correlate with SLEDAI or 
indeed, are inversely correlated with disease score (379-386). Consistent with 
these latter findings, SLE patients treated with corticosteroids exhibit increased IL-
17A production (387). Moreover, Szeto and colleagues, not only reported that 
elevated levels of IL-17A mRNA in the urine of SLE patients inversely correlated 
with disease severity, but also that such IL-17A mRNA levels declined in the urine 
of SLE patients in the weeks preceding a lupus flare (388,389). Collectively, these 
data provide compelling evidence for a protective role for IL-17A in SLE. 
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Further evidence of a dual role for IL-17A in kidney disease can be found in the 
field of renal transplant rejection, where it is widely accepted that IL-17A is 
responsible for acute graft rejection (390) as high levels of IL-17A are associated 
with end stage renal failure (391-396). Moreover, mouse models of acute renal 
injury have provided experimental evidence that IL-17A drives renal damage (397-
399). For example, in acute renal graft rejection, neutrophils are the major 
population of IL-17A-producing cells (400) and it appears that these cells are 
required for the recruitment of IFNγ-producing neutrophils (98) that drive 
inflammation during the late stage leading to rejection; perhaps counter-intuitively, 
at this stage IL-17A appears to act to limit and resolve inflammation by 
suppressing IFNγ production (401,402). These findings may therefore go some 
way to explaining the proposed dual role of IL-17A in the MRL/lpr mouse as the 
data are consistent with pathogenic IL-17A responses driving initiation of 
autoimmune responses, perhaps by recruiting and/or inducing IL-22-producing 
cells, as indicated by the slower kinetics of serum IL-22 kinetics (McGrath & 
Harnett, unpublished data). Interestingly, whilst 21-week-old MRL/MP mice 
displayed little or no evidence of IL-22-producing cells or serum IL-22, these mice 
had high levels of IL-17A producing cells and serum IL-17A (McGrath, Harnett & 
Harnett, unpublished data).  
 
Another mechanism by which IL-17A may be protective in SLE is through the 
promotion of germinal center formation and the production of long-lived plasma 
cells (403) rather than the GC-independent short-lived plasma cells, or 
plasmablasts, that produce anti-dsDNA antibodies and are associated with flare 
responses in SLE patients (3,195,226). Consistent with this, the decreased levels 
of IL-17A mRNA, found in the urine of SLE patients preceding flares, inversely 
correlate with anti-dsDNA titers (388). Thus, prior to the onset of disease, IL-17A 
may contribute towards pathogenesis by driving the development of the germinal 
centre reaction and the generation of self-reactive B cells, whilst during the later 
stages of disease, IL-17A may act to suppress the extra-follicular development of 
circulating anti-dsDNA specific memory B cells into short-lived plasma cells, thus 
preventing the generation of pathogenic anti-dsDNA responses (see chapter 4). 
As IL-22R is expressed by stromal cells in the germinal centre dark zone (404) IL-
17A and IL-22 may cooperate in the initiation of GC responses. Rather surprisingly 
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therefore, treatment with anti-IL-17, rIL-17, anti-IL-22 or rIL-22 did not appear to 
have an effect on ANA production.  
 
Nevertheless, and regardless of the relevance of these data to the findings with 
human disease, at first sight the findings presented here appear to conflict with 
previous reports on the role of IL-17A in mouse models of SLE. For example, 
Tsokos and colleagues showed that Rag-/- mice, which received IL-23 stimulated T 
cells from B6lpr/lpr mice, developed a lupus like disease that was associated with IL-
17+ cells in the kidney (112). Furthermore, Ro52-deficiency in C57BL/6 mice 
results in the development of a lupus-like disease that is IL-23/IL-17A dependent 
(16); and the deletion of Akt1 in FcγRIIb-/- mice prevented IL-17A signaling and 
suppressed the development of renal inflammation (113). All of these studies 
utilized parental strains of mice that do not spontaneously develop a lupus-like 
disease and have no genetic predisposition to SLE other than the lpr mutation or 
engineered deficiency in FcγRIIb or Ro52. Although IL-17A is elevated in mice that 
spontaneously develop lupus-like disease, it is yet to be shown conclusively that 
IL-17A is associated with pathogenesis in these mice. It may be, therefore, that 
genetic factors influence the role of IL-17A in mouse models of SLE and that those 
focusing on the effect of IL-23 in lupus-prone mice may have overlooked the role 
of IL-22 and consequently overstated the importance of IL-17A (112,368,369). 
 
A recent study by Kuchroo and colleagues has comprehensively mapped the 
genes involved in the activation of Th17 cells (91) and suggested that complete 
activation of pathogenic Th17 cells required FAS signaling, although it is important 
to note that these observations were made in an in vitro setting and that such 
incompletely activated cells produced IL-17A as well as IL-10 but not IFNγ. These 
findings might suggest that pathogenic Th17 can cells not develop into pathogenic 
Th17 cells in MRL/lpr or B6lpr/lpr strains of mice, and that Th17 cells are unlikely to 
be the cellular source of pathogenic IL-17A in the MRL/lpr mouse. Indeed, at 12-
weeks of age, ES-62 increases the proportion of Th17 cells despite an overall 
reduction in the levels of IL-17A-producing cells including B, NK or Lin- cells. 
Furthermore, despite a clear modulation of IL-17A levels in the renal interstitial 
fluid by ES-62, there was no apparent decrease in the levels of PMA/iononomycin-
stimulated IL-17A-producing cells, perhaps suggesting that the cellular source of 
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IL-17A in the kidney may be neutrophils, which undergo apoptosis in response to 
this stimulus and have been reported to be responsible for the IL-17-mediated 
resolution of inflammation in the late phase of acute renal disease (401,402). 
Another potential IL-17A-producing population that appears to be modulated by 
ES-62 is of the Lin- phenotype that potentially comprises CD25+ (natural helper 
cells or neuocytes) or CD127+ (LTi) ILC (364,365).  
 
It is important to remember that these cytokine data represent cell populations 
undergoing pharmacological stimulation ex vivo and hence are not necessarily 
representative of what is occurring in vivo. Thus, in conclusion, ES-62 improves 
renal function in MRL/lpr mice and this may be due to a modulation of IL-17A and 
IL-22 production. These studies have identified that IL-22 is essential for the 
development of proteinuria in the MRL/lpr mouse and have highlighted a potential 
dual role for IL-17A in this model.  
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Figure 3.1. MRL/lpr mice develop a lupus like disease. ANA production in the 
serum of 21-week old MRL/MP and MRL/lpr mice was assessed by analysis of the 
intensity and pattern of staining of Hep-2 slides (A). Likewise, sections (7 µm) of 
kidneys from 21-week old MRL/MP and MRL/lpr mice were stained with H & E to 
asses glomerulopathology and cellular infiltration (B & C). Spleens and LN from 
21-week old MRL/MP and MRL/lpr mice were photographed (D) and the number of 
splenocytes (E) and lymphocytes (F; from pLN) were counted using a 
hemocytometer throughout the course of the MRL/lpr model.  
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Figure 3.2. ES-62 prevents the development of proteinuria in the MRL/lpr 
mouse. MRL/MP (n = 15) or MRL/lpr mice were maintained from 7-21 weeks of 
age. MRL/lpr mice were injected subcutaneously twice a week with either PBS (n= 
41) or ES-62 (n= 19; 2 µg/mouse). Proteinuria was measured using Siemens 
Multistix 10 SG. The protective effects of ES-62 are representative of 3 
independent experiments collated and the PBS data is representative of 5 
independent experiments collated. Statistical significance was determined by 2-
way ANOVA using the Tukey post-test analysis. Significance is shown as 
**=p<0.001 and ***=p<0.0001 where the colour of the asterisk reflect the group in 
comparison. 
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Figure 3.3. ES-62 does not improve renal histology in ES-62 treated mice. 
Kidney sections from 21-week old MRL/lpr mice treated with PBS or ES-62 were 
stained with H & E to determine glomerulonephritis, cellularity and infiltration; PAS 
to determine basement membrane thickness and FITC conjugated anti-IgG or anti-
C3 antibodies to determine immune complex or complement deposition (A). The 
number of cells inside or outside of the glomeruli from PBS (n=25) or ES-62 (n=18) 
treated mice were counted (B).  
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Figure 3.4. T cell dynamics in MRL/lpr mice. The number of cells in the spleens, 
pLN, rLN or kidneys from MRL/lpr mice at 12- (A; PBS n=5, ES-62 n = 5) and 21-
weeks (B; PBS, n = 11; ES-62, n = 18) was determined by cell counting using a 
hemocytometer. The proportions of CD4+, CD8+ and DN T cells were determined 
by flow cytometry (C + D; n = 5 at each time-point) throughout the time-course of 
the MRL/lpr mouse model. Absolute numbers were determined from total cell 
counts of the LN (E; n = 5). Statistical significance was determined using the 
student’s t-test (A & B) and two-way ANOVA (D & E): **=p<0.01 and ***=p<0.001 
where the colour of the asterisk reflect the group in comparison.  
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Figure 3.5. ES-62 modulates T cell levels in the LN. The proportion and 
absolute number of CD4+ T helper cells, CD8+ cytotoxic T cells, DN T cells and γδ 
T cells were determined in the pLN (A; 5 mice for each group) and rLN (B; 5 mice 
pooled for each group) of 12-week old mice; and the pLN (C) and rLN (D) of 21-
week mice. Black bars represent PBS treated mice (12-weeks n = 5 & 21-weeks n 
= 11) and grey bars represent ES-62 treated mice (12-weeks n= 5 & 21-weeks n = 
18). 21-week data is pooled from 3 independent experiments whereas the 12-
week data is representative of one experiment; statistical significance was 
determined using the student’s t-test (A-D). 
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Figure 3.6. ES-62 modulates T cell levels in the spleen and kidney. The 
proportion and absolute number of CD4+ T helper cells, CD8+ cytotoxic T cells, DN 
T cells and γδ T cells were determined in the spleens of 12-week (A) and 21-week 
(B) old mice; and the kidneys of 12-week (C) and 21-week (D) old mice. Black 
bars represent PBS treated mice (12-weeks n = 5 & 21-weeks n = 11) and grey 
bars represent ES-62 treated mice (12-weeks n= 5 & 21-weeks n = 18). 21-week 
data is pooled from 3 independent experiments whereas the 12-week data is 
representative of one experiment; statistical significance was determined using the 
student’s t-test (A-D). 
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Figure 3.7. T cells are retained in the blood of ES-62 treated mice. The blood 
and bone marrow (BM) of 4 mice, treated with PBS or ES-62, were pooled before 
the proportion of B220+CD3- B cells, CD3+B220-CD4+ T helper cells, CD3+B220-
CD8high and CD3+B220-CD8low cytotoxic T cells, CD3+B220+ DN T cells and 
CD3+B220-CD4-CD8-γδTCR+ γδ T cells were determined by flow cytometry. 
Numbers adjacent to terminal gates refer to the frequency of live cells for each 
population. Data are representative of two independent experiments. 
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Figure 3.8. ILC populations in the blood and bone marrow. The proportions of 
CD25+ and/or CD127+ (Lin; CD3, CD19, CD64 and CD11b)- cells were determined 
in the blood (A & B) or bone marrow (C & D) of PBS (A & C) and ES-62 (B & D) 
treated mice. Blood and bone marrow analysis was performed on cells pooled 
from 4 mice from each treatment group and the proportion of live cells is indicated 
in each population gate. Data is representative of 2 independent experiments.  
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Figure 3.9. ES-62 modulates the proportion of ILC found in lymphoid organs 
and the kidney in the MRL/lpr mouse. The proportions of CD25+ and/or CD127+ 
Lin- cells (CD3, CD19, CD64 and CD11b)- were determined in the spleen (A), pLN 
(B), rLN (C, 5 mice pooled) and kidneys (D) of 12-week MRL/lpr mice treated with 
PBS (black bar; n = 5) or ES-62 (grey bar; n = 5); and in the spleen (E), pLN (F), 
rLN (G) and kidneys (H) of 21-week MRL/lpr mice treated with PBS (black bar; n = 
7) and ES-62 (grey bar; n = 11). 21-week data is pooled from 3 independent 
experiments whereas the 12-week data is representative of one experiment; 
statistical significance was determined using the student’s t-test (A-H).  
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Figure 3.10. ES-62 does not modulate IFNγ  production. The proportion of IFNγ 
producing cells were determined in LN cells stimulated with PMA and ionomycin 
for 6 hours with BrefeldinA being added after 30 minutes. Cells were washed and 
stained for viability and surface markers before being analyzed by flow cytometry 
(A). The proportion and total number of IFNγ+ cells were determined in the pLN 
(B), rLN (C) and kidneys (D) of 21-week MRL/lpr mice treated with PBS (n = 4) or 
ES-62 (n = 8).  
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Figure 3.11. ES-62 suppresses early but enhances late IL-17A production. 
Cells were stimulated with PMA and ionomycin for 6 hours with BrefeldinA being 
added after 30 minutes. Cells were washed and stained for viability and surface 
markers before being analyzed by flow cytometry; IL-17+ gates was set based on 
fluorescent minus 1 (FMO) and isotype staining (A). The proportion and number of 
IL-17A producing cells were determined in pLN (B) and rLN (C) of 12-week mice 
treated with PBS (n=5) or ES-62 (n=5); and the pLN (D), rLN (E) and kidneys (F) 
of 21-week old MRL/lpr mice treated with PBS (n = 11) or ES-62 (n = 18). 21-week 
data is pooled from 3 independent experiments whereas the 12-week data is 
representative of one experiment; statistical significance was determined using the 
student’s t-test (B-F).  
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Figure 3.12. IL-17A may be protective in the MRL/lpr mouse. The 
concentration of IL-17A in the renal interstitial fluid from PBS (n = 28) or ES-62 (n 
= 18) treated mice, and 7-(n=5), 12-(n=5) and 21-week (n=5) MRL/MP mice, was 
measured by ELISA (A). The absolute number of IL-17A+ cells in the pLN of 21-
week old MRL/MP or MRL/lpr mice were determined by flow cytometry (B) and 
data from MRL/lpr mice was plotted against proteinuria level (C). Statistical 
significance was tested using the student’s t-test. 
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Figure 3.13. IL-17A may be protective in the MRL/lpr mouse. MRL/lpr mice 
received twice weekly injections of murine IgG (i.p.; 100 µg in 100 µl of PBS; until 
12 weeks of age), anti-IL-17A (i.p.; 100 µg in 100 µl of PBS; until 12 weeks of 
age), PBS (s.c.; 100 µl) or ES-62 (s.c.; 2 µg in 100 µl of PBS) from 7 weeks of age 
or rIL-17A (i.p.; 1 µg in 100 µl of PBS) from 12-21-weeks of age. Proteinuria was 
measured twice weekly. Kidneys from mice that received anti-IL-17A or rIL-17A 
were sectioned and stained with H & E (D) and serum from mice that received 
PBS, anti-IL-17A or rIL-17A was used to stain Hep-2 slides to assess ANA levels 
(E). Data is pooled from 3 independent experiments and statistical significance 
was tested by and two-way ANOVA. 
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Figure 3.14. ES-62 suppresses early and late IL-22 production. Cells were 
stimulated with PMA and ionomycin for 6 hours with BrefeldinA being added after 
30 minutes. Cells were washed and stained for viability and surface markers 
before being analyzed by flow cytometry (A). The proportion of IL-22 producing 
cells were determined in pLN (A) and rLN (B) of 12-week mice treated with PBS 
(n=5) or ES-62 (n=5); and the pLN (C), rLN (D) and kidneys (E) of 21-week old 
MRL/lpr mice treated with PBS (n = 11) or ES-62 (n = 18). 21-week data is pooled 
from 3 independent experiments whereas the 12-week data is representative of 
one experiment; statistical significance was determined using the student’s t-test 
(A-E).  
  
! 128!
 
  
! 129!
Figure 3.15. IL-22 is pathogenic in the MRL/lpr mouse. The concentration of IL-
22 in the renal interstitial fluid from PBS (n = 28) or ES-62 (n = 18) treated MRL/lpr 
mice, and 7-(n=5), 12-(n=5) and 21-week (n=5) MRL/MP mice, was measured by 
ELISA (A). The absolute number of IL-22+ cells in the pLN of 21-week old MRL/MP 
or MRL/lpr mice were determined by flow cytometry (B) and the MRL/lpr data was 
plotted against proteinuria level (C). Statistical significance was tested using the 
student’s t-test. 
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Figure 3.16. IL-22 is pathogenic in the MRL/lpr mouse. MRL/lpr mice received 
twice weekly injections of murine IgG (i.p.; 100 µg in 100 µl of PBS; from 12-21-
weeks of age), anti-IL-22 (i.p.; 100 µg in 100 µl of PBS; from 12-21-weeks of age), 
PBS (s.c.; 100 µl) or ES-62 (s.c.; 2 µg in 100 µl of PBS) from 7 weeks of age or 
rIL-22 (i.p.; 1 µg in 100 µl of PBS) from 12-21-weeks of age. Proteinuria was 
measured twice weekly. Kidneys from mice that received anti-IL-22 or rIL-22 were 
sectioned and stained with H & E (D) and serum from mice that received PBS, 
anti-IL-22 or rIL-22 was used to stain Hep-2 slides to assess ANA levels (E). 
Statistical significance was tested by two-way ANOVA (C).  
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Figure 3.17. ES-62 modulation of cells producing IFNγ . Cells were stimulated 
with PMA and ionomycin for 6 hours with BrefeldinA being added after 30 minutes. 
Cells were washed and stained for viability and surface markers before being 
analyzed by flow cytometry (A). The proportion of IFNγ+ CD4+ T, DN T, γδ T, B and 
Lin- cells were determined in pLN (B), rLN (C) and kidney (D) of PBS (black bars; n 
= 4) or ES-62 (grey bars; n = 8) treated MRL/lpr mice at 21-weeks. Statistical 
significance was tested using the student’s t-test (B-D). 
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Figure 3.18. ES-62 modulates the proportion of cells producing IL-17A. Cells 
were stimulated with PMA and ionomycin for 6 hours with BrefeldinA being added 
after 30 minutes. Cells were washed and stained for viability and surface markers 
before being analyzed by flow cytometry where the proportion of IL-17A+ CD4+ 
Th17, DN T, γδ T, B and Lin- cells (A) were determined in the pLN (B) & rLN (C) of 
12-week MRL/lpr mice treated with PBS (black bars; n = 5) or ES-62 (grey bars; n 
= 5) (B); and the pLN (D), rLN (E) and kidney (F) of PBS (black bars; n = 11) or 
ES-62 (grey bars; n = 18) treated MRL/lpr mice at 21-weeks. 12-week data are 
representative of 1 experiment whereas 21-weel data are representative of 3 
independent experiments; statistical significance was tested using the student’s t-
test (B-F).  
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Figure 3.19. ES-62 modulates the proportion of cells producing IL-22. Cells 
were stimulated with PMA and ionomycin for 6 hours with BrefeldinA being added 
after 30 minutes. Cells were washed and stained for viability and surface markers 
before being analyzed by flow cytometry where the proportion of IL-22+ CD4+ 
Th17, DN T, γδ T, B and Lin- cells were determined (A) in pLN (B) and rLN (C) of 
12-week MRL/lpr mice treated with PBS (black bar; n = 5) or ES-62 (grey bar; n = 
5); and the pLN (D), rLN (E) and kidney (F) of PBS (black bars; n = 11) or ES-62 
(grey bars; n = 18) treated MRL/lpr mice at 21-weeks. 12-week data are 
representative of 1 experiment whereas 21-week data are representative of 3 
independent experiments; statistical significance was tested using the student’s t-
test (B-F). 
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Figure 3.20. Adoptive transfer of DN T cells. In two independent experiments, 
DN T cells were purified from the pLN of 21-week old PBS (n = 4/3) or ES-62 (8/3) 
treated MRL/lpr mice were purified by depletion of CD19+, CD4+ and CD8+ cells 
using antibodies conjugated to magnetic beads (Miltenyi). Cell purity was checked 
by flow cytometry but found to be very inconsistent (A). 5 x 106 purified DN T cells 
were injected into the tail vein of 7-week old MRL/lpr mice which were maintained 
until 21-weeks of age.  
  
! 140!
 
4. ES-62 suppresses the generation of pathogenic B cell 
responses and promotes the development of IL-10-
producing B cells, in the MRL/lpr mouse 
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4.1. Introduction 
 
Systemic Lupus Erythematosus (SLE) is characterized by high titers of auto-
antibodies, against nuclear antigens (ANA), resulting in immune-complex 
mediated inflammation in the kidney, skin and joints as well as cardiovascular 
pathologies [5]. B lymphocytes are central to the pathogenesis of this disease, not 
only in terms of their production of autoantibodies, but also with respect to cytokine 
production and cellular interactions [6, 7][8]. Reflecting this, several B cell-specific 
genes have been associated with the development of SLE [9]. Moreover, whilst 
overexpression of the B cell growth factor, BAFF, promotes lupus-like pathology in 
mouse models [10], depletion of B cells ameliorates disease [6, 11].  The success 
of the B-cell-depleting monoclonal antibody, rituximab, as a therapy in a number of 
autoimmune conditions, as well as open-label studies in SLE, indicate that B cell 
depletion therapies are a rationale choice for treatment of Lupus. Despite this, 
Rituximab proved disappointing in clinical trials [12, 13] and Belimumab (anti-
BAFF) [14-16], the first SLE-specific treatment to be granted FDA approval in 50 
years, is successful in only 14% of patients. Nevertheless, associated mechanistic 
studies are suggestive of the future utility of such B cell-targeting therapies in more 
stratified lupus patient subsets. 
 
The ability of B-cell targeting therapies such as Rituximab to reset the imbalance 
between effector and regulatory B cells, which contributes to the pathology of 
autoimmune disease, [10, 17] has not only highlighted the important role of IL-10-
producing regulatory B cells (Bregs) in protecting against the development of 
autoimmunity, but has also identified their therapeutic potential in such disorders, 
including SLE [18-20]. It is therefore of interest to note that Breg populations are 
increased in patients with multiple sclerosis who are infected with parasitic worms 
[21], and that infection with Schistosoma mansoni prevents and reverses lung 
remodelling in a mouse model of asthma by induction of Bregs [22]. Moreover, ES-
62 exhibits therapeutic potential in both allergic [23, 24] and autoimmune [25-27] 
inflammatory disease, conditions in which it can induce hyporesponsive effector B 
cell responses [2, 25, 26, 28] and modulate antibody production (335) whilst 
stimulating IL-10 production by splenocytes [26, 29], responses consistent with the 
parasite product resetting the effector: regulatory B cell balance.  
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As ES-62 can protect against the development of proteinuria in the MRL/lpr 
mouse, it was the core aim of this chapter to determine whether protection is 
associated with a resetting of the balance of effector and regulatory B cell 
responses. Specifically, the aims of this section were to determine the effect of ES-
62 on the generation of pathogenic and regulatory B cell responses. Moreover, if 
ES-62 induced a regulatory population of B cells, it was also planned to determine 
whether transfer of such cells was sufficient to confer the protection afforded by 
ES-62.  
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4.2. Results 
 
4.2.1. ES-62 suppression of proteinuria is associated with suppressed 
effector B cell responses 
One of the striking features of the MRL/lpr mouse is the development of 
splenomegaly (Fig. 4.1A) due to the accumulation of DN T cells in MRL/lpr, but not 
MRL/MP, mice (Fig.3.1 & 3.4). In the parental MRL/MP strain the proportion of 
splenic CD19+ B cells remains constant, whereas, although the proportions of B 
cells decrease in MRL/lpr mice over time, the numbers of splenic CD19+ B cells 
actually increase around the time of onset of disease (Fig. 4.1B & C). This rise in 
the numbers of CD19+ B cells was reflected by increased levels of transitional type 
1, marginal zone (MZ), follicular (Fo) and germinal center (GC) B cell populations 
in the spleens of MRL/lpr, but not MRL/MP mice, with kinetics that correlated with 
onset and progression of disease (Fig. 4.1D-G).  By contrast, although the levels 
are generally lower than those in MRL/MP mice, following an initial rise, there is a 
decrease in the levels of marginal zone precursor (MZP) B cells in the spleens of 
MRL/lpr mice between 12-16 weeks (Fig. 4.1H), kinetics that may reflect their 
proposed role as IL-10-producing Bregs that can protect against development of 
disease in the MRL/lpr mouse [18, 19]. Interestingly, given that they also develop 
proteinuria after about 12 months, the levels of MZP cells in the spleens of 
MRL/MP mice drop dramatically to those of MRL/lpr mice by the time they reach 5 
months of age, perhaps indicating the initiation of pathology. 
 
Prior to the onset of disease, at 12-weeks of age, the proportion and number of B 
cells in the spleen and rLN were unchanged in ES-62 treated mice however they 
were significantly decreased in the pLN and significantly elevated in the kidneys 
(Fig. 4.2A and data not shown). The reduction in B cells in the pLN was due to 
reduced levels, both proportions and numbers of Fo1 and plasma B cells; (Fig. 
4.2B & F and data not shown) whilst the proportion and number of GC, memory B 
cells, plasmablasts, T1-3, MZP, MZ and B1 B cells were unaltered in pLN and rLN 
of ES-62 treated mice (Fig. 4.2 data not shown); however, the proportions and 
numbers of plasmablasts and plasma cells were both reduced in the rLN whilst the 
proportion and number of memory B cells was considerably increased at this site 
(Fig. 4.2D-F and data not shown). Moreover, the levels of plasmablasts and 
! 144!
plasma cells were significantly decreased in the kidneys. Taken together, these 
data suggest a decrease in the development of antibody producing cells in ES-62 
treated 12-week MRL/lpr mice.  
 
During established disease, at 21-weeks of age, ES-62-mediated protection was 
not reflected by suppression of the splenomegaly observed in MRL/lpr mice, 
indeed, the number of splenocytes was significantly increased in mice treated with 
the parasite product and this reflected a significant increase in both splenic CD19+ 
B cells (Fig. 4.3A & B) and DN T cells (Fig. 3.6B). The expansion of the B cell 
compartment was not due to a modulation of the T1-3 B cell (Fig. 4.3C-E), MZ or 
GC B cell (Fig. 4.4B & E) populations, but rather, the MZP and Fo B cell 
populations (Fig. 4.4A, C & D). Exposure to ES-62 did not modulate the levels of 
any of these populations in the pLN or rLN (Fig. 4.3 & 4.4). Although, several of 
these populations were not detected in the kidney,  cells of the MZ phenotype 
were found at increased levels at this site in ES-62 treated mice (Fig. 4.4B).  
Likewise, whilst ES-62 had no significant effects on CD138+B220+CD19+ pre-
plasma cells(354) or CD138+B220low/-CD19- plasma cell(352) at any of these sites, 
the proportions of CD138+B220low/-CD19+ plasmablasts were reduced in the 
kidneys of mice exposed to ES-62. Moreover, the proportions of plasmablasts and 
plasma cells were also reduced in the blood of ES-62-treated mice (Fig. 4.5D).  
 
The differential modulation of plasmablasts and plasma cells may reflect the ES-
62-mediated increase in IL-17A during established disease (see chapter 3), as this 
cytokine has recently been reported to drive the germinal centre reaction (403). 
Consistent with this, Szeto et al. recently reported that IL-17A mRNA levels in the 
urine of SLE patients inversely correlate with titers of anti-dsDNA antibodies (388), 
which are thought to be produced by plasmablasts (3,195). Thus, the potentially 
antagonistic roles reported for IL-17A and IL-22 in the pathogenesis of MRL/lpr 
mice in the previous chapter might suggest that IL-22 could also modulate the 
development of plasmablasts versus plasma cells. Indeed, this proposal was 
supported by preliminary data showing that treatment of MRL/lpr mice with 
neutralizing anti-IL-22 antibodies reduced the levels of plasmablasts, but not 
plasma cells, in the rLN and kidney (Fig. 4.6). Moreover, complementary data from 
mice treated with rIL-22 indicated that whilst rIL-22 also slightly suppressed the 
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levels of plasmablasts, but not plasma cells, in the kidney, it increased the levels 
of both plasmablasts and plasma cells in the rLN (Fig. 4.6).  
 
Finally, Despite being reduced in the pLN, the proportion and number of innate B1 
B cells were largely unaltered in ES-62 treated mice (Fig. 4.7).  
 
Consistent with proposals that B cells play both antibody-dependent and 
independent roles in the pathogenesis of lupus, increased signaling via B cell-
associated receptors (BAFF-R [32] and TLR4 [33]) and co-stimulatory molecules 
(CD40[34], CD80 and CD86 [35]) as well as loss of their immune complex-
mediated negative feedback regulatory mechanism (FcgRIIb [CD32] [35]) have 
been implicated as factors driving autoimmunity in this disease. Interestingly, 
therefore, whilst exposure to ES-62 downregulated expression of TLR4, CD40, 
CD80 and CD86, it upregulated that of FcγRIIB and BAFF-R, both in terms of the 
levels of expression and also the proportion of positive B cells circulating in the 
blood (Fig. 4.8A-F). Moreover, the levels of CD80 expression by B cells in the 
spleen, pLN, rLN and kidneys were similarly reduced (Fig. 4.8G) whilst those of 
BAFF-R expression were generally increased following treatment of MRL/lpr mice 
with ES-62 (Fig. 4.8H). Expression of FcγRIIb (CD32) by B cells was significantly 
increased in the spleens of ES-62 treated mice but unaltered elsewhere (Fig. 3.8I) 
whilst perhaps surprisingly, the level of expression of TLR4 was elevated on the B 
cells infiltrating the kidneys of ES-62 treated mice. By contrast, CD86 and CD40 
expression by B cells in the spleen, pLN, rLN and kidney was not modulated by 
ES-62 (Fig. 4.8J-L).  The expression of CXCR5, the receptor for the B cell-
attracting chemokine CXCL13, that is a marker for renal disease in patients with 
SLE [44], is down regulated on B cells in the spleens and pLN yet elevated in the 
kidneys of MRL/lpr mice treated with ES-62 suggesting that any reduction in the B 
cells infiltrating the kidneys of ES-62 treated mice was not due to their reduced 
expression of CXCR5, although the increased expression of this receptor on 
kidney B cells may indicate desensitization of its signaling in ES-62-treated mice 
(Fig. 4.8M). Similarly, although overexpression of BAFF has been proposed to 
play a pathogenic role in lupus by promoting B cell responses, the levels of this B 
cell survival factor are not decreased in the serum or kidney interstitial fluid of ES-
62-treated mice (Fig. 4.8N & O): thus the surprising increase in BAFF-R 
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expression by B cells in ES-62 treated mice may possibly suggest desensitization 
of this receptor (Fig. 4.8F & H) or alternatively, that such hyporesponsive B cells 
act as a sink for BAFF that would otherwise promote autoimmune B cell 
responses. Consistent with these findings, ES-62 has previously been shown to 
induce hyporesponsive signaling in B cells via uncoupling of the BCR to the ERK 
MAP kinase pathway via the recruitment of SHP-1 and Pac-1 (325). It was 
therefore hypothesized that ES-62 may alter BCR expression or signaling in the B 
cells of MRL/lpr mice. Although the responsiveness of B cells from ES-62 treated 
mice to BCR stimulation was not tested in this study, the surface expression of 
IgM and IgD was found to be unaltered by the parasite product (Fig. 4.9).  
 
Collectively, these data suggest that whilst ES-62 does not act to prevent the 
maturation or migration of all B cells, it induces a more hypo-responsive 
phenotype of effector B cells and renders them more susceptible to negative 
feedback inhibition by immune complexes and this is perhaps reflected in the 
reduction of pathogenic plasmablasts.  
 
4.2.2. ES-62 modulates effector B cell responses 
As ES-62-mediated protection was associated with modulation of the levels  and 
responsiveness of effector B cells the ability of the parasite product to modulate 
autoantibody responses was investigated. Rather surprisingly, ES-62 did not 
modulate the levels of total IgM, IgG1 or IgG2a in the serum of MRL/lpr mice (Fig. 
4.10A-C). However, and consistent with the earlier observation that ES-62 reduced 
the proportion of plasmablasts, which are responsible for the production of 
pathogenic anti-dsDNA antibodies(3,195), ES-62 significantly suppressed the 
production of anti-nuclear antibodies (ANA) in the serum of 12- and 20-week 
MRL/lpr mice (Fig. 4.10A & B) and in the renal interstitial fluid from 20-week mice 
(Fig. 4.11C). As expected, ANA were not detectable at the same intensity in the 
serum or renal interstitial fluid of age-matched MRL/MP mice, however, by 20-
weeks of age, nuclear ANA staining was detectable in some mice (Fig. 4.10A-C). 
The modulation of ANA production by ES-62 was evidenced not only in terms of 
intensity of staining, but also in the pattern of reactivity. For example, whilst serum 
from PBS strongly reacted with antigens in the nucleus and cytoplasm of Hep-2 
cells, serum from ES-62 treated mice appeared to recognise the cell membranes 
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of the Hep-2 cells. Although, the reasons for this altered specificity have not been 
defined, it is possible that it reflects the anti-phosphorylcholine antibody responses 
induced by the PC-moieties on ES-62; both IgM and IgG antibodies against PC 
were significantly elevated in the serum of ES-62 treated mice and it is likely that 
these recognise phosphatidylcholine in plasma membranes (Fig. 4.11D & E). 
Although the high titers of these anti-PC antibodies may also have masked the 
effects of ES-62 on total IgM and IgG (auto) antibody production, they further 
indicate that the parasite product does not act to suppress all antibody production 
but rather, acts selectively to target pathogenic ANA and cytoplasmic specificities.  
 
B cell production of IL-6 has recently been shown to be required for Th17 
mediated autoimmunity in mice (235) and consistent with its ability to suppress 
polarization of Th17 responses in mice with CIA, ES-62 is known to reduce IL-6 
production by macrophages and DC (see chapter 5) (331,336). It was surprising 
therefore to find that the number of IL-6 producing cells was elevated in the 
spleens and rLN, but not the pLN and kidney, of ES-62 treated mice (Fig 4.12A-E). 
However, the proportion of B cells that were producing IL-6 was significantly 
reduced in the spleen and pLN although they were significantly increased in the 
rLN. This latter finding may indicate a modulation of the migration of pathogenic 
cell types from the renal LN into the kidney.    
 
4.2.3. ES-62 induces IL-10-producing Bregs with a MZP phenotype  
The reduction of the levels of IL-6-producing B cells as well as the elevated levels 
of MZP B cells in the spleen induced by treatment with ES-62 (Fig. 4.4A) could 
suggest that this subset contains representatives of the Breg population previously 
shown to have the capacity to suppress development of pathology in the MRL/lpr 
mouse and patients with SLE [18, 19], especially as the kinetics of the decline of 
this population in MRL/lpr mice correlates with disease development (Fig. 4.1H). 
Supporting this, the proportion (and number) of IL-10 producing B cells was 
significantly increased in the spleen, rLN and kidneys, but not pLN, of ES-62-
treated MRL/lpr mice (Fig. 4.13A-D). Moreover, these IL-10-producing B cells 
predominantly comprised the MZP phenotype that was increased in the spleen 
(Fig. 4.4A); interestingly, this population was also elevated in the blood of mice 
treated with ES-62 in vivo (Fig 4.13E).  Reflecting this induction of IL-10-producing 
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B cells, exposure to ES-62 also increased the levels of IL-10 found in the 
interstitial fluid of the kidneys from MRL/lpr mice (Fig. 4.13F).  
 
Follicular T helper (Tfh) cells have recently been shown to promote the 
development of IL-10-producing regulatory B cells via the provision of IL-21 (405). 
This role is perhaps surprising as Tfh cells are also required for the development 
of pathogenesis in lupus prone mice (406), suggesting that it is the precise 
functional phenotype of Tfh cells that is important. Nevertheless, it was interesting 
to observe that the number of splenic Tfh cells was significantly increased in ES-
62 treated mice and correlated with the increased levels of IL-10 producing B cells 
in the spleens of ES-62 treated mice. By contrast the levels of Tfh cells in the pLN, 
rLN or kidneys of MRL/lpr mice were not modulated by exposure to ES-62 (Fig. 
4.14A & B). Tfh cells are also found in the blood of SLE patients and may be 
linked to the survival and function of antibody secreting cells(407); these cells 
were present in the blood of MRL/lpr mice but were unaltered in ES-62 treated 
mice (Fig. 4.14C). Interestingly, the proportion and number of Tfh cells were not 
modulated by treatment with ES-62 prior to the onset of disease; this 
corresponded with no effect on the levels of IL-10 producing B cells and perhaps 
suggests that this putative Breg population cells are sufficient at suppressing the 
immune response prior to the onset of disease (data not shown). 
 
IL-10-producing Bregs have been proposed to mediate their effects, at least in 
part, via the induction of regulatory T cells, particularly IL-10-producing CD4+ T 
cells (Tr1 cells), in MRL/lpr mice [18, 19]: however, the Breg-dependent induction 
of either Tr1 or Foxp3 Tregs has also been reported depending on the model of 
rheumatoid arthritis [37, 38] and asthma (353). Consistent with the reported role 
for Tregs in protecting against development of lupus (408,409), preliminary data 
showed that the proportion of Foxp3+CD4+ Tregs in the LNs of MRL/lpr, but not 
MRL/MP, mice declined with age and with kinetics that correlated with the initiation 
and progression of proteinuria (McGrath, Harnett & Harnett, unpublished data). 
However, treatment with ES-62 did not reverse this trend and did not induce 
enhanced levels of CD4+CD25+Foxp3+ T cells  (Fig. 4.15A & B) or IL-10-producing 
Tr1 cells (Fig. 4.15A & C) in the spleens, LNs or kidneys of MRL/lpr mice; indeed, 
at some sites ES-62 reduced the proportion of T cells with a regulatory phenotype. 
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Collectively, therefore, these data suggest that if ES-62-mediated protection is 
associated with the induction of Bregs, they do not mediate their effects via the 
induction of regulatory T cells.  
 
IL-10-producing regulatory B cells have been reported to modulate T helper cell 
responses and in particular, suppress the development of pathogenic Th17/Th1 
responses in mouse models of rheumatoid arthritis (345). Although such 
suppression was reported to be dependent on the induction of regulatory T cells, it 
was decided to investigate whether the increase in IL-10 producing B cells in the 
pLN, rLN and kidneys of ES-62 treated mice correlated with the modulation of IL-
17A and IL-22 production in the spleen as in the LN and kidney (Fig. 4.16; see 
chapter 3). This analysis revealed that the increase in IL-10-producing B cells in 
the spleen indeed correlated with a reduction in the IL-22-producing and an 
increase in the IL-17-producing population of splenocytes during the established 
phase of disease in spleens of ES-62 treated mice; although there was a 
significant increase in the levels of lin- cells producing IL-22, this differential 
modulation of IL-17A and IL-22 production appeared to reflect a general effect on 
cytokine production rather than targeting of a specific phenotype (Fig. 4.16). 
 
4.2.4. Adoptive transfer of splenic B cells from ES-62-treated MRL/lpr mice 
mimics the ability of ES-62 to suppress development of proteinuria in 
recipient MRL/lpr mice 
 
In order to directly test whether protection afforded by exposure to ES-62 reflected 
resetting of the effector: regulatory B cell balance, in particular by inducing 
regulatory B cells, we examined the effect of adoptively transferring purified 
splenic B cells (~83.55% ± 4.17), harvested from 21-week-old MRL/lpr mice, 
treated with either PBS or ES-62, into recipient 7-week old MRL/lpr mice. Analysis 
of the composition of the transferred B cells (Table 4.1) revealed that the B cell 
population from ES-62-treated mice was enriched in MZP B cells and reduced in 
plasmablasts/plasma cells relative to that of PBS-treated mice, albeit these 
differences did not reach significance. Strikingly, the transfer of B cells from ES-62, 
but not PBS, treated MRL/lpr mice was sufficient to provide significant protection 
against the development of proteinuria in the recipient mice (Fig. 4.17A & B). 
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Interestingly, although they did not confer protection, transfer of the B cells from 
the PBS-treated mice resulted in a profile of proteinuria that was of a somewhat 
remitting and relapsing nature perhaps reflecting the existence of some "regulatory 
B cells" that were induced in the donor mice in attempt to control inflammation 
during the established phase of pathology (Fig. 4.17B). As with treatment with ES-
62, there was no substantial improvement in kidney histology (Fig. 4.18).  
 
Consistent with their ability to mimic the action of ES-62, transfer of B cells from 
ES-62-treated mice similarly resulted in suppressed levels of pathogenic ANA in 
recipient mice, as indicated by the reduction in nuclear and cytoplasmic staining 
relative to antibodies from "control" MRL/lpr mice (PBS i.v.) or MRL/lpr mice 
receiving B cells from PBS-treated mice (Fig. 4.19A): indeed, serum from mice that 
received B cells from PBS-treated donor mice contained higher levels of ANA as 
indicated by elevated staining intensity. Likewise, the reduction in nuclear and 
cytoplasmic staining by the serum from mice receiving B cells from ES-62 treated 
mice was associated with strong plasma membrane staining which presumably 
reflected the ES-62-mediated switch to anti-PC responses.  
 
The transfer of B cells from ES-62 treated mice resulted in an reduction of 
splenocytes and lymphocytes, although there were more cells found in the kidneys 
(Fig. 4.20A). Consistent with a role for Il-10-producing regulatory B cells, 
protection, as with ES-62 treatment, was associated with increased levels of IL-10-
producing B cells of the MZP phenotype in the rLN, but not the spleen, albeit these 
did not reach statistical significance (Fig. 4.20B-E). As in mice treated with ES-62, 
the transfer of B cells from ES-62 treated donor mice appeared to have no effect 
on the proportion or number of regulatory T cells in the spleen or rLN (Fig. 4.20F & 
G).  
 
Intriguingly, preliminary data suggest the transfer of B cells from ES-62 treated 
donor mice appeared to increase the proportion of cells producing IL-17A in the 
spleen and rLN, albeit not significantly in the latter case whilst decreasing the 
numbers of IL-22-producing cells in the spleen and rLN. As with treatment with ES-
62, no clear IL-17A-producing population was modulated by ES-62, although the 
proportion of IL-17A producing B cells in the spleen was significantly elevated in 
! 151!
the mice that received B cells from ES-62 treated donors; however, whilst the 
proportions of CD4+ T cells producing IL-22 were rather surprisingly elevated, the 
proportion of IL-22 producing DN T cells was significantly reduced in the rLN of 
mice that received B cells from ES-62 treated donors, a finding reminiscent of mice 
treated with ES-62 (Fig. 4.21).  
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4.3. Discussion   
 
In the search for novel, safe and effective treatments for autoimmune disease, 
much research has focused on the ability of parasitic helminths to suppress the 
mammalian immune system via the production of immunomodulatory molecules. 
One such molecule, ES-62, suppresses disease is mouse models of autoimmune 
arthritis (335,336) and allergic airway hyper-responsiveness (228,338) via 
modulation of IL-17A responses. ES-62 has now also been shown to suppress the 
development of proteinuria in the MRL/lpr mouse model of SLE via modulation of 
the IL-17A/IL-22 axis (Chapter 3). In this chapter, the impact of ES-62 on effector 
and regulatory B cell populations in the MRL/lpr mouse was also investigated. ES-
62 was found to promote the expansion of IL-10-producing B cells whilst 
suppressing the development of pathogenic plasmablast populations and 
associated ANA production. Furthermore, the protective effect of ES-62 was 
mimicked by adoptive transfer of CD43- B2 B cells from ES-62-treated donor 
MLR/lpr mice (21-week old) to recipient (7-week old) MRL/lpr mice.   
 
The MRL/lpr mouse model of SLE portrays several pathologies associated with the 
human disease and as in other models of SLE, B cells are essential for the 
development of disease (162,410). In support of this, the proportions and numbers 
of several mature B cell populations, mainly the marginal zone and follicular B 
cells, expand in a manner that correlates with disease. As ES-62 modulates BCR 
and NFκB signaling, both of which being important in the peripheral development 
and activation of B cells in the spleen (174) it was hypothesized that the parasite 
product exerted its protective effects, at least in part, by modulating the levels 
and/or responsiveness of peripheral B cell subsets. Treatment with ES-62 was 
indeed found to modulate the proportions and numbers of MZP, Fo1 and Tfh cells 
in the spleen. The increase in Fo1 cells suggested that ES-62 may prevent these 
cells from entering the germinal center reaction, however, the level of GC B cells 
or downstream antibody producing populations, in the spleen, were not reduced by 
ES-62.  
 
Although the proportion of CD138+B220-CD19- long-lived plasma cells (352) were 
slightly reduced in the blood of mice treated with ES-62, their levels were 
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maintained in the spleen, pLN and rLN and, if anything, were slightly elevated in 
the kidneys of treated mice. Similarly, ES-62 did not modulate the levels of 
CD138+B220+CD19+ pre-plasma cells, which have been reported to secrete 
autoantibodies and break tolerance in the absence of control by DC or 
macrophages (356). By contrast, the proportions of CD138+B220lowCD19+ B cells 
were reduced in the blood, kidney and renal draining LN of ES-62 treated mice. 
These cells, which are reported to have plasmablast-like qualities (355,411) but 
may also represent short-lived plasma cells (352), are associated with disease 
flares in SLE patients and are thought to be the source of pathogenic anti-dsDNA 
antibodies (3,195,226). Interestingly, therefore, their reduced levels were reflected 
by a reduction in the levels of ANA in both the serum and renal interstitial fluid of 
the ES-62-treated mice.  
 
Despite reducing ANA production, ES-62 had no effect on total antibody levels, 
perhaps reflecting its lack of modulation of the plasma cell population. However, 
the parasite product has been shown in the past to induce anti-PC responses in 
mice and ES-62 treated MRL/lpr mice exhibited significantly elevated levels of anti-
PC IgG and IgM antibodies, which may mask the loss of some specificities 
produced in PBS-treated mice. Moreover, the high concentration of anti-PC 
antibodies possibly explains the atypical cell membrane staining of Hep-2 ANA 
slides by the serum from ES-62 treated mice. Interestingly, anti-PC responses 
have been proposed to be protective in SLE, particularly with respect to 
atherosclerotic complications, by inhibiting inflammatory phospholipids such as 
PAF(412), which have been implicated in the pathogenesis (413) and promoting 
the clearance of oxidised lipids and apoptotic cells that is defective in SLE. Such 
oxidized lipids may be involved in the activation of Th1 cells (414)  and have been 
shown to promote monocyte recruitment to sites of inflammation via the activation 
of MCP-1 production (415). Anti-PC antibodies may also promote the clearance of 
apoptotic cell debris by binding to phosphatidylserine; they are therefore believed 
to be beneficial in SLE as well as other autoimmune diseases (412). In addition, 
ES-62 has previously been shown to induce high levels of IgG1, but not IgG2a, 
antibodies to non-PC-epitopes of the parasite molecule in naive wild type BALB/c 
mice and such antibodies may also mask a decrease in total immunoglobulin 
responses to lupus-relevant antigens. Interestingly, given that these current 
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studies show that ES-62 can induce IL-10-producing B cells that appear to 
contribute to the protective effects of ES-62 in the MRL/lpr mouse, in IL-10-/- Balb/c 
mice, ES-62 induces both IgG1 and IgG2a antibodies, suggesting that IL-10 plays 
an important role in the suppression of IgG2a specificities by ES-62 (327).  
 
There is increasing evidence that protection against immune mediated disease by 
some helminth products may be, at least in part, via the activation of regulatory B 
cell function. Indeed, multiple sclerosis patients infected with helminths exhibit less 
severe disease and this appears to be associated with elevated levels of IL-10 
producing B cells. Support for this has also been provided by experimental studies 
where, for example in a mouse model of asthma, IL-10 producing B cells induced 
by the helminth S. mansoni can suppress disease (353,416,417). Interestingly, 
therefore, whilst it has previously been reported that ES-62 stimulates production 
of IL-10 by peritoneal B cells, suppression of pathogenic antibody production, by 
the parasite product, in both the collagen induced model of arthritis and the 
ovalbumin induced model of asthma is associated with elevated levels of IL-10 
producing B cells (chapter 6 and Rodgers, Coltherd Harnett & Harnett, 
unpublished data) (326,335,338). Thus, taken together with the results of this 
study in MRL/lpr mice, there is increasing evidence that ES-62 may protect against 
harmful inflammation by promoting IL-10-producing (regulatory) B cells.  
 
CD19+CD21+CD23+ T2-MZP B cells, have previously been shown to be protective 
in the MRL/lpr mouse and in vitro or in vivo stimulation of these cells by anti-CD40 
can enhance the suppressive qualities of this population (244). This present study 
has shown that this population declined from 12-weeks of age, the dynamics of 
which inversely correlated with the rise in proteinuria, providing a cellular rationale 
for the report by Shlomchik and colleagues that Bregs in the MRL/lpr mouse are 
ineffective (418). Furthermore, treatment with ES-62 significantly increased the 
proportion of such MZP B cells in the spleen and blood of MRL/lpr mice and 
consistent with these cells having regulatory capabilities, the majority of IL-10-
producing B cells in ES-62-treated mice had this phenotype. It has been reported 
that Bregs act upon regulatory T cells (Treg or Tr1 cells) (345,419), however, ES-
62 had no effect on any of the regulatory T cell phenotypes evaluated and this may 
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suggest that in response to ES-62, Bregs can disseminate around the body to act 
directly at the site of inflammation.  
 
Consistent with the proposed protective roles for Bregs, IL-10 is an important 
regulatory cytokine in SLE: indeed, disease is exacerbated in IL-10-/- MRL/lpr mice 
[51]. However, IL-10 is not always protective in lupus due to its ability to promote B 
cell antibody production. Thus, the precise effect of IL-10 (and other cytokines) is 
likely determined by the immunological context in which the cytokine is released, 
for example the immunological receptors engaged in cell-cell interactions at the 
site of inflammation. It is interesting to note therefore that ES-62 reduces the 
surface expression of co-stimulatory molecules that are likely to promote 
autoimmune responses whilst increasing that of negative feedback receptors, such 
as FcγRIIb, on B cells circulating in the blood, spleen and kidney. The upregulation 
of FcγRIIb expression is particularly interesting as polymorphisms of this negative 
feedback antibody receptor (15) are associated with the development of lupus in 
patients (420); indeed, the loss of this receptor in C57BL/6 and MRL/MP mice 
causes a lupus-like phenotype that is characterized by the development of anti-
dsDNA responses (15,229,421). Thus, by increasing the expression of FcγRIIb on 
B cells in the spleen and circulating in the blood, ES-62 may promote tolerance by 
controlling the expansion of autoreactive B cells. The down regulation of CD80 
may also be interesting as ligation of CD80 has been shown to reverse the 
suppressive action of human CD19+CD24hiCD38hi regulatory B cells [19] and to be 
important in the regulation of Tfh development, consequent GC B cell survival and 
plasma cell production[36]. Thus, collectively, the increase in BAFF-R by B cells, 
along with the decrease in pro-inflammatory receptors, may indicate that ES-62 
promotes the survival of hypo-responsive B cells which may act as ‘sinks’ for 
circulating BAFF and hence indirectly suppress autoimmunity promoted by the 
elevated levels of BAFF found in MRL/lpr mice. 
 
Recently it has been proposed that follicular helper T cells promote the 
development of regulatory B cells via the production of IL-21 (405): it is interesting 
therefore that this population in the spleen was expanded by ES-62. Although it is 
not clear whether the remainder were enriched in IL-21-producing cells, that can 
promote Breg induction, it is tempting to speculate therefore that ES-62 may 
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modulate B cell hypo-responsiveness via such T cells. However, such hypo-
responsiveness could also be promoted by DC or macrophages, as ES-62 
suppresses pro-inflammatory responses by these cells, which have also been 
reported to be involved in the regulation of B cell activation (173).  
 
To determine whether the protective effects of ES-62 in the MRL/lpr mouse were 
predominantly B cell mediated, CD43- B2 B cells were adoptively transferred from 
PBS or ES-62 treated 21-week old MRL/lpr mice into recipient 7-week old MRL/lpr 
mice: such B cells were sufficient to almost completely abrogate development of 
proteinuria in recipient mice. This protection, rather surprisingly given that by the 
cull date these B cells had not been exposed to the parasite product for 3 months, 
essentially mimicked that afforded by treatment with ES-62 as indicated by 
decreased ANA and atypical plasma membrane staining of Hep2 cells, as well as 
an increased proportion of IL-10-producing B cells and modulation of IL-17A- and 
IL-22-producing splenocytes. Although it is tempting to attribute the success of this 
treatment to IL-10-producing (regulatory) B cells that were enriched in the 
population derived from ES-62-treated mice, it should be noted that 
plasmablasts/plasma cells were depleted from this population relative to that 
derived from PBS-treated mice. Thus, although it is possible that the transfer of IL-
10 producing B cells protected the recipient mice, as the ANA staining from mice 
that received B cells from ES-62 treated donors replicated that of the ES-62-
treated donor mice, it is also possible that protection reflects, at least in part, the 
transfer of anti-PC plasmablasts/plasma cells or MZ, Fo1 or GC B cells with 
differential specificities and/or hyporesponsive phenotype that compete with 
pathogenic specificities for survival factors such as BAFF. 
 
B cell depletion therapy is protective in some SLE patients; however, the 
therapeutic promise of B cell depletion in SLE patients has not materialized as 
Rituximab (anti-CD20) failed to meet its primary outcomes in phase III clinical trials 
and Belimumab (anti-BAFF) is only effective in approximately 14% of patients (38). 
An explanation for the ineffectiveness of these pan-B cell depletion strategies in 
SLE may be that they target protective regulatory B cells as well as pathogenic 
populations. However, as regulatory B cells appear to be ineffective in SLE 
patients and mouse models, this may not be the case (247,418). Nevertheless, 
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studies in mouse models of autoimmunity have revealed that the effect of B cell 
depletion depends upon timing and the status of disease (54) as indicated in lupus 
prone mice where B cell depletion in 4 week old NZB/W mice exacerbates disease 
(422), perhaps suggesting that Bregs antagonising inflammation prior to onset of 
pathology are being targeted in this case: this suggestion resonates with data 
presented here, that show that the highest levels of MZP cells, which are the 
candidate IL-10 producing population induced by ES-62,  are found in MRL/lpr 
mice at 12-weeks, immediately prior to onset of pathology. Moreover, as B cells 
produce the pathogenic autoantibodies associated with SLE, they remain a valid 
therapeutic target for further development (244,423), perhaps especially if they 
incorporate information exploiting mechanisms utilised by helminths to promote 
enhanced levels of IL-10-producing (regulatory) B cells and/or targeting antibody-
producing plasma cells. 
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Table 4.1: cellular composition of adoptively transferred B cells. The 
proportions ± SEM of T1-3, transitional 1-3; MZP, marginal zone precursor; MZ, 
marginal zone; Fo, follicular; GC, germinal center; pPc, pre-plasma cell; Pb, 
plasmablast and P, plasma cells over two independent experiments. Statistical 
significance was shown using the student’s t-test.  
 
 
 PBS ES-62 P value 
T1 2.40 ± 0.44 1.97 ± 0.28 0.21 
T2 1.07 ± 0.16 0.79 ± 0.11 0.086 
T3 6.03 ± 0.60 4.53 ± 0.65 0.058 
MZP 5.37 ± 1.71 6.45 ± 1.46 0.31 
MZ 1.95 ± 0.73 1.42 ± 0.39 0.26 
Fo1 4.16 ± 0.61 4.76 ± 0.54 0.23 
Fo2 0.29 ± 0.07 0.42 ± 0.07 0.1 
GC 0.83 ± 0.14 0.90 ± 0.25 0.4 
Pb 0.44 ± 0.05 0.33 ± 0.05 0.07 
P 2.14 ± 0.78 1.68 ± 0.30 0.29 
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Figure 4.1. Splenic B cell dynamics in the MRL/lpr mouse. The number of cells 
from the spleens of MRL/lpr mice (n=5 for each time point) were counted (A) and 
the proportion (B) and the number (C) of CD19+ B cells were determined. The 
number of Transitional 1 (T1; D; CD19+CD23-CD21-IgM+IgD-), marginal zone (MZ; 
E; CD19+CD23-CD21+IgM+IgD-), follicular (Fo; F; CD19+CD23+CD21low/-IgM+/-IgD+), 
germinal center (GC; G; CD19+CD43-CD24+GL7+) and marginal zone precursor 
(MZP; H; CD19+CD23+CD21+IgM+IgD+) B cells were determined by multicolor flow 
cytometry. The data are representative of one experiment and the student’s t-test 
was used at each time point to determine statistical significance; *=p<0.05, 
**=p,0.01 and ***=p<0.001. 
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Figure 4.2. The effect of ES-62 on peripheral B cell populations, prior to the 
onset of disease. The number of CD19+ B cells from the spleen, pLN, rLN and 
kidney of 12-week MRL/lpr mice treated with PBS (black bar, n=5) or ES-62 (grey 
bar, n=5) was determined by flow cytometry (A). The proportion of follicular type 1 
(B; CD19+CD23+CD21low/-IgM-IgD+), germinal centre (C; CD19+CD43-CD24+GL7+), 
memory (D; CD19+B220+IgM-IgD-IgG+), plasmablast (E; Dump-B220-CD19+) and 
plasma (F; Dump-B220-CD19-) cellslwas determined by flow cytometry; where the 
dump channel contained antibodies against CD3, CD4, CD8, CD11c, CD11b, F4/80 
and GR1. The data are presented as the mean values of individual mice ± SEM, 
except for the rLN, which are the values for cells pooled from the 5 mice due to 
limitations of cell numbers at this time point. The data are representative of three 
independent experiments and presented as the mean values of individual mice ± 
SEM and statistical significance was determined using the students t-test where 
*=p<0.05.  
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Figure 4.3. The effect of ES-62 on transitional B cell populations during 
established disease. The number of total cells (A) and CD19+ B cells (B) from 
the spleen, pLN, rLN and kidney of 21-week old MRL/lpr mice treated with PBS 
(black bar, n=11) or ES-62 (grey bar, n=18) was determined by flow cytometry. 
The proportion and number of T1 (C; CD19+CD23-CD21-IgM+IgD-AA4.1+), T2 (D; 
CD19+CD23+CD21-IgM+IgD+AA4.1+) and T3 (E; CD19+CD23+CD21-IgMlow/-
IgD+AA4.1+), was determined by flow cytometry. The data are representative of 
three independent experiments and presented as the mean values of individual 
mice ± SEM and statistical significance was determined using the students t-test 
where *=p<0.05.  
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Figure 4.4. The effect of ES-62 on marginal zone precursor, marginal zone, 
follicular and germinal centre B cell populations during established disease. 
The proportion and number of MZP (A; CD19+CD23+CD21+IgM+IgD+), MZ (B; 
CD19+CD23-CD21+IgM+IgD-), Fo1 (C; CD19+CD23+CD21low/-IgM-IgD+), Fo2 (D; 
CD19+CD23+CD21low/-IgM+IgD+) and germinal center (E; CD19+CD43-CD24+GL7+) 
was determined by flow cytometry in the spleen, pLN, rLN and kidney of 21-week 
old MRL/lpr mice treated with PBS (black bar, n=11) or ES-62 (grey bar, n=18). 
The data are representative of three independent experiments and presented as 
the mean values of individual mice ± SEM and statistical significance was 
determined using the students t-test where *=p<0.05.  
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Figure 4.5. The effect of ES-62 on antibody-producing B cell populations 
during established disease. The proportion and number of pre-plasma (A; 
Dump-CD138+B220+CD19+), plasmablast (B; Dump-CD138+B220-CD19+) and 
plasma cells (C; Dump-CD138+B220-CD19) in the spleen, pLN, rLN, kidney (A-C) 
and blood (D; data representative of two independent experiments) of 21-week old 
MRL/lpr mice treated with PBS (black bar, n=11) or ES-62 (grey bar, n=18) was 
determined by flow cytometry. The dump channel contained antibodies against 
CD3, CD4, CD8, CD11c, CD11b, F4/80 and GR1. The data are representative of 
three independent experiments, unless otherwise stated, and presented as the 
mean values of individual mice ± SEM and statistical significance was determined 
using the students t-test where *=p<0.05.  
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Figure 4.6. Treatment of MRL/lpr mice with anti-IL-22 suppresses the level of 
plasmablasts in rLN and the kidney. The proportion Dump-CD138+B220-CD19+ 
plasmablasts and Dump-CD138+B220-CD19- plasma cells was determined, by flow 
cytometry, in the rLN (A) and kidneys (B) of 21-week MRL/lpr mice treated with 
PBS (black bar, n=4), anti-IL-22 (dark grey bar, n=4) or rIL-22 (light grey bar, n=4). 
The data are representative of one experiment and presented as the mean values 
of individual mice ± SEM and statistical significance was determined using the 
students t-test where *=p<0.05 and ***=p<0.0001.  
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Figure 4.7. The effect of ES-62 on B1 B cell populations during established 
disease. The proportion and number of CD19+IgM+CD43+CD5+ B1a (B) and 
CD19+IgM+CD43+CD5- B1b (C) B cells in the spleen, pLN, rLN and kidney of 21-
week old MRL/lpr mice treated with (grey bar, n=18) or without (black bar, n=11) 
ES-62 was determined by flow cytometry (A). The data were representative of 3 
independent experiments and are presented as the mean values of individual mice 
± SEM and statistical significance was determined using the students t-test where 
*=p<0.05.  
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Figure 4.8. ES-62 promotes a hyporesponsive B cell phenotype. The 
expression level of CD80 (A), CD86 (B), CD40 (C), TLR4 (D), CD32 (E) and 
BAFF-R (F) was determined on B cells circulating in the blood in MRL/lpr mice 
treated with (blue line; 4 mice pooled) or without (red line, 4 mice pooled) ES-62 
relative to appropriate isotype controls (grey histogram). The expression levels of 
CD80 (G), BAFF-R (H), CD32 (I), TLR4 (J), CD86 (K), CD40 (L) and CXCR5 (M) 
on B cells in the spleen, pLN, rLN and kidney of MRL/lpr mice treated with (grey 
bar, n=18) or without (black bar, n=11) ES-62 was determined by flow cytometry. 
The concentration of BAFF was measured in the serum of MRL/MP mice, or 
MRL/lpr mice treated with or without ES-62 (N), or renal interstitial fluid of mice 
treated with or without ES-62 (O) by ELISA (R&D). The data are representative of 
three independent experiments (except M-O) and are presented as the mean 
values of individual mice ± SEM and statistical significance was determined using 
the students t-test where *=p<0.05.   
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Figure 4.9. ES-62 does not modulate the levels of IgM or IgD expression. The 
mean fluorescence intensity (MFI) of IgM (A-D) and IgD (E-H) expression by B 
cells was measured, by flow cytometry, in the spleen (A & E), pLN (B & F), rLN (C 
& G) and kidneys (D & H) of 21-week old MRL/lpr mice. The data are 
representative of three independent experiments and are presented as the mean 
values of individual mice ± SEM. 
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Figure 4.10. ES-62 does not modulate total antibody production. The levels of 
IgM (A), IgG1 (B) and IgG2a (C) antibodies in serum from 21-week old MRL/MP 
mice (grey line) or 21-week old MRL/lpr mice treated with ES-62 (blue line) or PBS 
(red line) was measured by ELISA.  
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Figure 4.11. ES-62 suppresses pathogenic ANA responses. Hep-2 slides 
(Antibodies incorporated) were incubated with serum from 12-week (A) and 20-
week (B) MRL/MP or MRL/lpr mice treated with PBS or ES-62.The ANA staining 
intensity of 3 biological replicates of the serum from each mouse was scored in the 
nucleus and cytoplasm as: none (0), ± (1), positive (2) and bright (3); for MRL/MP 
(n=10), PBS treated MRL/lpr (n=6) and ES-62 treated MRL/lpr (n=11) mice. Hep-2 
slides were also stained with renal interstitial fluid from 21-week old MRL/MP or 
MRL/lpr mice treated with PBS (n=5) and ES-62 (n=3) treated MRL/lpr mice and 
the ANA staining intensity was scored in the nucleus and cytoplasm (C).  The level 
of anti-PC IgG (D) IgM (E) antibodies were measured by ELISA by Dr. Lamyaa Al-
Riyami as described in Chapter 2. Statistical significance was determined using 
the students t-test where *=p<0.05 and ***=p<0.001.  
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Figure 4.12. The effect of ES-62 on IL-6 production by B cells. Cells were 
stimulated with PMA and ionomycin for 6 hours, BrefeldinA was added after 30 
minutes to block intracellular trafficking. Cells were stained with the Live/Dead cell 
discrimination fixable dye, washed and then stained for surface markers, fixed, 
permeablized and incubated with anti-mouse-IL-6 antibodies. Cells were analysed 
by flow cytometry (A) and the proportion and number of IL-6+ cells were 
determined in the spleen (B), pLN (C), rLN (D) and kidney (E). In each organ, the 
proportion of B220+CD3- B cells, B220-CD3+ T cells, B220+CD3+ double negative T 
cells and B220-CD3- Lin- cells in mice treated with (grey bar, n=8) or without (black 
bar, n=4) ES-62 was determined by flow cytometry. The data are presented as the 
mean values of individual mice ± SEM and statistical significance was determined 
using the students t-test where *=p<0.05.    
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Figure 4.13. The effect of ES-62 on IL-10-producing B cells. Cells were 
stimulated with LPS, PMA and ionomycin for 6 hours, BrefeldinA was added after 
30 minutes to block intracellular trafficking. Cells were stained with the Live/Dead 
cell discrimination fixable dye and stained for surface markers. Cells were then 
fixed and permeabilized and incubated with anti-mouse-IL-10 antibodies. Cells 
were analysed by flow cytometry and the proportion and number of IL-10+CD19+ 
cells were determined in the spleen (A), pLN (B), rLN (C) and kidney (D) of PBS 
(n=10) or ES-62 (n=13) treated MRL/lpr mice. In each organ, the phenotype of the 
IL-10+ B cells was further analyzed by measuring CD21 and CD23 expression. 
The data are presented as the mean values of individual mice ± SEM and 
statistical significance was determined using the students t-test where *=p<0.05. 
Blood from mice treated with or without ES-62 were pooled (4 per group) and the 
proportion of CD19+CD21+/-CD23+/- B cells circulating in the blood was determined 
(E); data are representative of two independent experiments (E). The 
concentration of IL-10 in the renal interstitial fluid of individual was measured by 
ELISA (F). Statistical significance was determined using the students t-test where 
*=p<0.05 and ***=p<0.001. 
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Figure 4.14. The effect of ES-62 on T follicular helper cells. The proportion 
and number of CD3+CD4+ICOS+CXCR5+ T follicular helper cells (Tfh) was 
determined by flow cytometry (A) in the spleen, pLN, rLN, kidney (B) and blood (C; 
cells were pooled from 4 mice in each group) of 21-week old MRL/lpr mice treated 
with (grey bar, n=10) or without (black bar, n=7) ES-62. Data are represent 2 
independent experiments, apart from the analysis of the blood, and are presented 
as the mean values of individual mice ± SEM and statistical significance was 
determined using the students t-test where *=p<0.05.   
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Figure 4.15. The effect of ES-62 on regulatory T cells. Unstimulated cells were 
assessed for FoxP3 expression whilst for the analysis of IL-10 producing T cells, 
cells were stimulated with PMA and ionomycin for 6 hours with Brefeldin A being 
added after 30 minutes to block intracellular trafficking. Cells were stained with the 
Live/Dead cell discrimination fixable dye and stained for surface markers before 
being fixed and permeabilized, incubated with anti-mouse-IL-10 antibodies and 
analyzed by flow cytometry (A). The proportion and number of FoxP3+B220-
CD3+CD4+CD25+ regulatory T cells (B; Tregs) or IL-10+B220-CD3+ Tr1 cells (C) 
was determined in the spleen, pLN, rLN and kidney of mice treated with PBS (n=4) 
or ES-62 (n=8). The data are presented as the mean values of individual mice ± 
SEM and statistical significance was determined using the student’s t-test. 
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Figure 4.16. The effect of ES-62 on IL-17- and IL-22-producing cells in the 
spleen. Splenocytes were stimulated with PMA and ionomycin for 6 hours with 
BrefeldinA being added after 30 minutes to block intracellular trafficking. Cells 
were stained with the Live/Dead cell discrimination fixable dye and stained for 
surface markers before being fixed, permeablized and incubated with anti-mouse-
IL-17A or anti-mouse-IL-22 antibodies. The proportion and number of IL-17+ or IL-
22+ cells in the spleens of individual mice treated with PBS (n=11) or ES-62 (n=18) 
was determined by flow cytometry. The data are presented as the mean values of 
individual mice ± SEM and statistical significance was determined using the 
students t-test where *=p<0.05 and **=p<0.01.  
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Figure 4.17. Adoptively transferred B cells from ES-62 treated mice prevent 
the development of proteinuria in recipient mice. Splenocytes were pooled 
from 21-week old MRL/lpr mice treated with ES-62 (n=8) or PBS (n=8) and CD43- 
B cells were purified (Table 1; approximately 85% ± 4.17 pure) and injected (5 x 
106 cells in 100µl of sterile PBS) into the tail veins of 7-week old MRL/lpr mice. 
Proteinuria of the recipient mice (i.v. PBS, n= 6; PBS B cells, n= 8; ES-62 B cells, 
n=8) was measured twice weekly until 21-weeks of age at which point the mice 
were sacrificed.  
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Figure 4.18. Adoptively transferred B cells do not suppress the development 
of glomerulonephritis. The kidneys from 21-week old MRL/lpr mice that received 
B cells from PBS or ES-62 treated donors, were fixed and snap frozen before 
being sectioned (7µm) and stained by either H&E or PAS. 
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Figure 4.19. Adoptive transfer of B cells from ES-62 treated mice 
suppresses pathogenic ANA responses. Hep-2 slides (Antibodies incorporated) 
were incubated with serum from 21-week MRL/lpr mice that received i.v. B cells 
from PBS- or ES-62-treated donors or i.v. PBS as a control (A). The ANA staining 
intensity of 3 biological replicates of the serum from each mouse was scored in the 
nucleus and cytoplasm as: none (0), ± (1), positive (2) and bright (3); for MRL/lpr 
mice that received B cells from PBS (n=4) or ES-62 (n=4) treated donors. 
Statistical significance was shown using the student’s t-test where *=p<0.05. 
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Figure 4.20. The effect of the adoptive transfer of B cells from ES-62 treated 
donor mice on regulatory B and T cell populations. The number of cells in the 
spleen, pLN (n=4 pooled), rLN and kidney (n=4 pooled) of 21-week MRL/lpr mice, 
that received B cells from PBS (black bar, n-10) or ES-62 (grey bar, n=10) treated 
donors, were counted (A). Cells were the stimulated with PMA and ionomycin for 6 
hours, BrefeldinA was added after 30 minutes to block intracellular trafficking. 
Cells were stained with the Live/Dead cell discrimination fixable dye and stained 
for surface markers. Cells were then fixed, permeablized and incubated with anti-
mouse-IL-10 antibodies. For the analysis of regulatory T cells, unstimulated cells 
were stained with the Live/Dead cell discrimination fixable dye. The surface 
markers of cells were stained before the cells were washed, fixed and 
permeablized and stained for FoxP3 using a FoxP3 staining kit (eBioscience, CA). 
Cells were analysed by flow cytometry and the proportion of IL-10+ B cells were 
determined in the spleen (B) and rLN (C). The proportion of IL-10+ B cells with a 
MZ (CD21+CD23-), MZP (CD21+CD23+), Fo (CD21low/-CD23+) or CD21-CD23- 
phenotype was determined in the spleen (D) and rLN (E) where data are 
presented as the mean values of individual mice ± SEM. The proportion of 
CD3+CD4+CD25+FoxP3+ regulatory T cells was determined in the spleen (F) and 
rLN (G) by flow cytometry. Data are representative of 2 independent experiments 
and statistical significance was determined using the student’s t-test. 
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Figure 4.21. The effect of the adoptive transfer of B cells from ES-62 treated 
donor mice on IL-17A and IL-22 production. Cells from the spleen or rLN of 21-
week MRL/lpr mice that received B cells from PBS (n=4) or ES-62 (n=4) treated 
donors were stimulated with PMA and ionomycin for 6 hours, BrefeldinA was 
added after 30 minutes to block intracellular trafficking. Cells were stained with the 
Live/Dead cell discrimination fixable dye and stained for surface markers. Cells 
were then fixed, permeablized and incubated with anti-mouse-IL-17A or anti-
mouse-IL-22 antibodies before being washed and analysed by flow cytometry. The 
proportion, number and phenotype of IL-17+ (A & B) or IL-22+ (C & D) cells was 
determined in the spleen (A & C) and rLN (B &D). The data are representative of 
two independent experiments and are presented as the mean values of individual 
mice ± SEM and statistical significance was determined using the students t-test 
where *=p<0.05.   
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5. ES-62 induces hypo-responsiveness of renal cells to 
pro-inflammatory stimuli 
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5.1. Introduction 
 
SLE is a systemic autoimmune disease mediated by the deposition of immune 
complexes in target organs: the kidney is a major site of pathology and 
glomerulonephritis a serious manifestation that presents in patients (1,2). In terms 
of immune complexes, those involving anti-dsDNA autoantibodies are particularly 
associated with disease severity (3). These antibodies usually bind to DNA 
released from necrotic cells, however in the kidney, due to interactions with 
collagen type IV or heparin sulphate at the glomerular basement membrane, 
circulating DNA becomes embedded in the glomerular matrix and provides a 
focused source of antigen for the circulating anti-dsDNA antibodies, allowing 
formation of large immune complexes (4,5). Consequent activation of antibody 
receptors (6), in concert with complement (7,8) and toll-like (9,424) receptors, 
drives inflammation in the kidney.  The resulting proinflammatory cytokine 
response leads to the infiltration of innate and adaptive cells that drive pathology 
by the production of antibodies, cytokines and the failed clearance of apoptotic or 
antigenic debris; the collateral damage of which perpetuates further inflammatory 
responses (2,10). 
 
The data presented in the preceding chapters suggest that ES-62-mediated 
suppression of proteinuria in the MRL/lpr mouse model of SLE appears to be 
associated with resetting of the IL-17A/IL-22 inflammatory axis and the effector: 
regulatory B cell balance. However, surprisingly, histological analysis of the 
kidneys from such ES-62-treated mice did not reveal any striking improvement in 
glomerular proliferation, cellular infiltration, basement membrane thickening or 
complement and antibody deposition. It was therefore the aim of this chapter to 
determine whether the protection against proteinuria afforded by ES-62 reflected 
desensitisation of renal cells to pathogenic pro-inflammatory stimuli, in particular 
those targeting TLRs, FcRs and complement receptors.  
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5.2. Results 
 
5.2.1. The upregulation of pro-inflammatory receptor expression by kidney 
cells during disease progression is suppressed in MRL/lpr mice treated with 
ES-62 
Prophylactic treatment of MRL/lpr mice with ES-62 prevents the development of 
proteinuria: however, this is not associated with any global improvement in renal 
histology as evidenced by glomeruloproliferation, glomerular basement membrane 
thickening, cellular infiltration, immune complex or complement deposition (Fig. 
3.3). It was therefore hypothesized that ES-62 might act to desensitize effector 
cells, both resident and infiltrating, to inflammatory signals in the kidneys and thus 
a more comprehensive analysis of the responses of such kidney cells was carried 
out. Consistent with reports that signaling via TLR, FcR and complement receptors 
perpetuate chronic inflammation in the kidney (6-9,424), analysis of kidney cells 
from MRL/MP (21-week), MRL/lpr (7-week) and MRL/lpr (21-week) mice showed 
that the levels of expression of these receptors, as well as that of the co-
stimulatory molecule CD86, increased with disease progression (Fig. 5.1A-E). 
Expression of MyD88, the key signal transducer for IL-1R/TLR family that is 
involved in the response to endogenous DAMPs in lupus (425) and a known target 
of ES-62 mediated immune modulation (322,336,337), was similarly increased 
(Fig. 5.1F). This is consistent with previous findings that MyD88 is essential for 
disease development in lupus-prone mice (426,427) and required for renal graft 
rejection (428). Interestingly, therefore, expression of MyD88 was significantly 
reduced in cells from the kidneys of ES-62 relative to PBS treated mice (Fig. 5.2A 
& B). Moreover, ex vivo culture of the kidney cells from 21-week old MRL/lpr mice 
overnight with ES-62 resulted in a clear inhibition of LPS (as a surrogate of 
endogeneous DAMPs) stimulated up regulation of MyD88, TLR4, C5aR and C3aR, 
but not CD16/32 expression (Fig. 5.2C-G). To address whether these observations 
reflected ES-62 mediated hyporesponsiveness of resident kidney cells, explant 
cultures of renal fibroblasts were expanded from the kidneys of PBS or ES-62 
treated MRL/lpr mice for two weeks and then, again as a surrogate for DAMP 
signaling, cultured with and without LPS for a further 24 hours before being 
examined for pro-inflammatory receptor expression. This analysis revealed that 
renal fibroblasts from ES-62 treated mice exhibited reduced expression of MyD88, 
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C5aR and CD64 (FcgRI), albeit not significantly, but not CD16, CD86 or TLR4 
(Fig. 5.3A-C and data not shown). The finding that fibroblasts from ES-62-treated 
mice produced less IL-6 in response to LPS than those from PBS-treated mice 
highlighted the potential functional relevance of the modulation of MyD88 (Fig. 
5.3D). Moreover, renal fibroblasts from both ES-62 and rIL-17A treated mice 
exhibited reduced MyD88 expression compared to those from PBS and rIL-22 
treated mice and this reflected a reduction in LPS-stimulated MCP-1 (CCL2) 
production (Fig. 5.3E & F). To further explore the functional relevance of such 
receptor modulation, renal fibroblasts were also cultured with a variety of 
potentially disease-relevant pro-inflammatory stimuli including rIL-6, rIL-17, rIL-22, 
rC3a, rC5a and in addition, FcγIIIR (CD16) was activated by antibody-mediated 
cross-linking; however, all of these stimuli failed to elicit MCP-1 or IL-6 production.   
 
5.2.2. Renal fibroblast proliferation and wound healing  
One of the pathological features of glomerulonephritis is hyper-cellularity but no 
significant difference in this parameter could be detected between ES-62- or PBS-
treated mice by histological analysis (H & E staining). Interestingly therefore, it was 
observed that ex vivo expansion of fibroblasts from ES-62-treated mice routinely 
resulted in lower yields of cells which proliferated less (as indicated by their DNA 
synthesis) than those from PBS-treated MRL/lpr mice (Fig. 5.4A & B). To address 
whether this potentially reflected differences in the regulation of epithelial barrier 
permeability, the ability of renal fibroblasts from PBS and ES-62 treated mice to 
heal artificial wounds was evaluated over 72 hours (Fig. 5.4C). Despite their 
reduced capacity for proliferation, renal fibroblasts from ES-62 treated mice 
initiated wound repair significantly earlier than cells from either PBS- or rIL-22-
treated mice (Fig. 5.4C). Nevertheless, and perhaps reflecting that IL-22 has been 
implicated in wound repair of epithelial cells (132,429), significantly higher levels of 
"healing" was observed with the cells from rIL-22 treated mice between 48-72 h. 
However, it appeared that these cells were insensitive to contact inhibition as they 
were observed to visually exceeded the confines of monolayer confluency (Fig. 
5.4C). Although these observations do not reconcile the apparent discrepancies 
between fibroblast proliferation and histological hyper-cellularity, they may suggest 
that cells from ES-62-treated mice retain wound healing properties that promote 
the maintenance of barrier permeability without exhibiting the deregulated 
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fibroblast hyperplasia observed with renal fibroblasts from rIL-22 treated mice that 
could lead to fibrosis and contribute to kidney pathology 
 
5.2.3. Analysis of infiltrating kidney cells  
 
The observed desensitization of pro-inflammatory cytokine and chemokine 
responses by resident kidney cells from ES-62-treated mice suggested that this 
could result in reduced recruitment of inflammatory cells to this site of 
inflammation, breaking the perpetuating cycle of chronic inflammation. Thus, as 
ES-62 did not appear to induce any striking decrease in cellular infiltration as 
evidenced by H & E histological staining of kidney sections (Fig. 3.3), it was 
decided to determine whether the improvement in proteinuria reflected changes in 
the composition and/or functional phenotype of the cellular infiltrates.  
 
Indeed, as reported in Chapters 3 & 4, it was found that the levels of effector T 
cells (Fig. 3.6), ILC (Fig. 3.9) and effector B cells (Fig.4.5) were reduced in the 
kidneys of ES-62 treated mice. These data are consistent with ES-62 resetting the 
effector: regulatory balance of B and T cell responses (Chapter 3 and 4). 
Moreover, analysis of granulocyte populations revealed that whilst the proportion 
of CD11bhiGR1hi cells were considerably elevated in the blood (Fig. 5.5A), the 
proportions of CD11bhiGR1hi, CD11bhiGR1low and CD11bhiGR1- cells were 
significantly reduced in the kidneys of ES-62 treated mice at 21-weeks (Fig. 5.5B). 
As there were no significant differences in their levels in spleen, pLN, rLN or bone 
marrow at this time point, these data may suggest a block in their survival or 
migration to the kidney (Fig. 5.5C & F). By contrast, prior to the onset of disease at 
12-weeks, when IL-17A production was generally reduced by ES-62, although 
these granulocytes could not be detected in the kidneys, the levels of 
CD11bhighGR1low cells in the spleen, CD11bhighGR1low and CD11bhighGR1- cells in 
pLN and CD11bhighGR1low and CD11bhighGR1- cells in rLN were reduced in ES-62-
treated mice (Fig. 5.5G-I), perhaps suggesting that ES-62 prevents the early 
recruitment and activation of pathogenic granulocytes. However, although the 
levels of CD45+F4/80+CD11b+ macrophages in the spleen and LNs were largely 
unaltered in ES-62 treated mice at 21-weeks (Fig. 5.6A-C), the levels of 
macrophages were raised in blood and kidneys of ES-62 treated mice (Fig. 5.6D & 
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E), which, as an imbalance in the ratio of M1: M2 macrophages has been reported 
in lupus prone mice (430), may reflect a modulation of the functional phenotype of 
these macrophages. 
 
ES-62 has previously been reported to suppresses PAMP-driven pro-inflammatory 
responses by macrophages (320,331,333) and so to address whether it indeed 
modulated the functional phenotype of macrophages in lupus,  bone marrow-
derived macrophages (BMM) from MRL/lpr mice were cultured for 24 hours with 
our without LPS. Such BMM from MRL/lpr mice produced large quantities of 
TNFα, IL-1β, IL-6, IL-27, IL-10, IL-12p70 and IL-23 in response to LPS. 
Interestingly, pre-treatment with ES-62 for only 2 hours resulted in inhibition of LPS 
induced IL-1β, IL-6 and IL-12p70 production (Fig. 5.7A-G). Furthermore, in the 
BMM as is the renal fibroblasts, ES-62 reduced LPS up-regulated the expression 
of MyD88 (Fig. 5.7H). 
 
5.2.4. Small molecular analogues of phosphorylcholine suppress proteinuria 
in the MRL/lpr mouse 
 
ES-62 is a large immunogenic molecule and therefore not an ideal therapeutic 
candidate. The complexity of the lifecycle required to produce this 
immunomodulatory molecule further questions its feasibility as a therapy. Small 
molecular analogues (SMA) based on the immunomodulatory moiety of ES-62, 
phosphorylcholine (PC), have therefore been derived and tested in a variety of 
inflammatory settings (International Patent Application No. PCT/GB2013/051988). 
Two lead compounds, S3 and S5 (Fig. 5.8A), identified from initial screens of anti-
inflammatory properties against BMM (reduction of LPS-, BLP- and CpC-mediated 
IL-12p40 and IL-6 production and down-regulation of MyD88), were examined for 
their therapeutic potential in the MRL/lpr model alongside SMA15, a structurally 
related molecule that did not exhibit anti-inflammatory activity or down-regulate 
MyD88 expression in this screen (Fig. 5.8B and Al-Riyami, Rzepecka, Rodgers, 
Harnett & Harnett; unpublished data). To address their therapeutic potential in 
lupus, MRL/lpr mice were monitored for 16 weeks until they began to show signs 
of pathology (proteinuria ~3 mg/ml) before administering the SMAs (each mouse 
received 1 µg of S3, S5 or SMA15 s.c., twice-weekly until 21-weeks). Both S3 and 
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S5 significantly suppressed the development of proteinuria (Fig. 5.9A) and rLN 
lymphadenopathy (Fig. 5.9B); interestingly, therefore, both S3 and S5 also 
reduced MyD88 levels in the kidney cells (Fig. 5.9C). By contrast, the mice treated 
with SMA15, if anything, experienced exacerbated disease that was associated 
with mild to severe skin inflammation at the site of injection.  
 
Interestingly, as with ES-62, the suppression of proteinuria in the MRL/lpr mouse 
was not associated with substantial improvements in renal histology in terms of 
glomerulonephritis, cellular infiltration and glomerular basement membrane 
thickening (Fig. 5.10A). Nor was it associated with a consistent reduction in ANA 
responses (Fig. 5.10B), although it is interesting to note that some of the mice 
(3/5) receiving S5 showed a similar Hep2 staining pattern to ES-62 suggesting that 
they may have switched to developing antibodies that recognized/cross-reacted 
with membrane, as opposed to nuclear or cytoplasmic antigens: however this 
propensity did not appear to be linked to proteinuria level. By contrast, serum from 
mice that received SMA15 showed strong nuclear staining indicating high titers of 
anti-DNA responses and all of these mice exhibited high levels of proteinuria.  
 
To further address their mechanism of action, the effect of the SMAs on the other 
key immunoregulatory sites modulated by ES-62 were investigated but these 
preliminary studies did not identify any clear target. Nevertheless, they suggested 
that S3 and S5 did not act by inducing IL-10 producing B cell or regulatory T cell 
populations (Fig. 5.11A & B). Moreover, although there was some evidence that 
S3 and S5 reduced the levels of IL-17A-producing cells in the rLN and kidney and 
S3 had similar effects on IL-22-producing cells (Fig. 5.11C & D), there was no 
significant effect of either S3 or S5 on the levels of IL-10, IL-17A or IL-22 in the 
renal interstitial fluid of these mice (Fig. 5.10E-G). Surprisingly, however, those 
treated with SMA15 contained significantly higher concentrations of IL-22 and 
significantly lower concentrations of IL-10 and IL-17A, findings perhaps consistent 
with their high levels of proteinuria and skin inflammation. Reflecting the late 
administration after the onset of disease pathology, collectively these data suggest 
that, rather than targeting pathogenic events resulting in the breaking of tolerance, 
the therapeutic effects of S3 and S5 may be mediated predominantly through their 
effects on the renal cells, perhaps by modulation of MyD88 expression.  
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5.3. Discussion 
 
Lupus nephritis is the major cause of mortality in SLE patients and occurs in 
approximately 50% of patients; thus novel therapies to improve efficiency with 
reduced toxicity in treating this pathology are urgently required (431,432). In the 
MRL/lpr mouse model of SLE, ES-62 suppresses the development of proteinuria 
and therefore improves the functions of the kidneys, despite any apparent 
substantial effect on renal histology. Rather, this appears to be due to a reduction 
in the production of the pro-inflammatory cytokine IL-22, and the resultant 
recruitment of inflammatory leukocytes that infiltrate the kidneys, as well as 
reduced generation of ANA. However, as the parasite product does not appear to 
suppress the level of immune complex and complement deposition that is 
generally associated with ANA production, other factors may be involved such as 
modulation of signaling of their proinflammatory receptors (C3aR, C5aR, FcgRI 
and FcgRIII) in the inflamed kidneys by the parasite product. Perhaps, as ES-62 
appears to modulate the repertoire of antibodies in the MLR/lpr mouse, favoring 
development of anti-PC over ANA responses (Fig.4.11), the resultant immune 
complexes deposited in the kidneys of MRL/lpr treated with ES-62 may be smaller 
and/or less pathogenic than those formed by interactions with the DNA embedded 
in the glomerular basement membrane. Nevertheless, such immune complexes 
would still be expected to stimulate renal cells via their cross-linking of FcR: thus, 
by suppressing the expression of FcRs, such as CD16 and CD64, ES-62 may 
render these renal cells hyporesponsive to such inflammatory stimuli. Moreover, 
the accompanying suppression of MyD88 expression by ES-62 would further 
reduce their responsiveness, as immune complex-mediated renal damage has 
been reported to require synergistic signaling via FcRs and TLRs (433).  
 
Both the classical and alternative complement pathways are active in the nephritic 
kidneys of SLE patients. The classical pathway appears to be involved in 
regulating the clearance of apoptotic debris and hence, is generally viewed as a 
positive factor in lupus nephritis (32). The alternative pathway, on the other hand, 
is generally thought to contribute towards lupus nephritis by the activation and 
recruitment of inflammatory cells (35) and consistent with this, inhibition of the 
alternative pathway can prevent glomerular nephritis in the MRL/lpr and NZB/W F1 
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mouse models of SLE (434,435). Thus, although ES-62 does not appear to 
suppress the deposition of complement in the kidneys of MRL/lpr mice, by 
reducing the expression of C3aR and C5aR, the parasite product may render renal 
cells hyporesponsive to these pro-inflammatory stimuli. Indeed, suppression of 
C3aR signaling has been shown to prevent the induction of pathogenic IL-23 
responses (436,437) and this may be relevant to the reduction of pathogenic IL-
22-producing cells (126) observed in the kidneys of ES-62 treated mice (Chapter 
3). Likewise, C5aR signaling acts in synergy with TLR4 and MyD88 signaling to 
drive IL-17F production by macrophages (438), and in addition, drives IL-17A 
production by activating DC production of IL-6 and TGFβ (439): thus, suppression 
of C5a responses may play a role in desensitizing the kidney to the pathogenic 
effects of IL-17A in the initiation phase of disease.  
 
TLR1-9 and TLR11 are expressed and upregulated in the kidneys of lupus prone 
mice (440). Reflecting this, TLR signaling aggravates glomerulonephritis (441-443) 
presumably as a result of its role in neutrophil recruitment to the kidney (443,444). 
Furthermore, TLR signaling via MyD88 promotes IL-1α, IL-1β, IL-6, TNFα and 
MCP-1 production in the kidney (433,445) and is required for the development of 
pristane-induced nephropathy (446). Collectively, therefore, the reduction of 
MyD88 observed in BMM, renal fibroblasts and kidney cells from ES-62-treated 
MRL/lpr mice would provide a mechanism, by preventing neutrophil recruitment 
and proinflammatory cytokine production, to explain, at least in part, improved 
renal function in such mice.  
 
Indeed, TLR4 expression has been shown to correlate with levels of MCP-1 and 
IL-6 in the kidneys of patients suffering from chronic kidney disease (447). 
Similarly, serum and urinary levels of MCP-1 correlate with disease activity, and 
suppression of synthesis of this chemokine prevents mesangial cell proliferation 
(448,449). As IL-17A promotes the recruitment of inflammatory cells, such as 
monocytes and neutrophils, to the kidney through the induction of CCL2 (MCP1) 
(450), it was perhaps surprising to find that whilst ES-62 increased the 
concentration of IL-17A in the renal interstitial fluid of 21-week MRL/lpr mice, this 
did not result in an increase in infiltrating neutrophils or monocytes. However, this 
may be explained by the observation that LPS induced production of MCP1 was 
! 210!
lower in renal fibroblasts from either ES-62- or rIL-17-treated mice, presumably 
reflecting the decreased expression of MyD88 by such cells. This latter finding 
perhaps suggests that ES-62 exploits a homeostatic (IL-17-mediated) mechanism 
for first initiating and then limiting and resolving inflammation in the kidney.  
 
The biological function of the kidney glomerulus is to filter the blood of nitrogen-
containing urea, water and salt. In order to prevent the escape of macromolecules 
and cells into the urine, the glomerular basement membrane must form a tight 
barrier (451). The reduced development of proteinuria in MRL/lpr mice treated with 
ES-62 is an indication that the parasite product improves renal function; ES-62 
must therefore promote epithelial barrier function, potentially by affecting tight 
junctions and this could be achieved by several potential mechanisms. Firstly, 
whilst MyD88 signaling appears to be important, via MyD88-ARNO-ARF6 
signaling, for the disruption of vascular stability (452), it has also been found to 
promote epithelial cell homeostasis (453), with recent findings demonstrating that 
MyD88, MAL and PKC signaling is required for the maintenance of epithelial tight 
junction barriers (454). Whilst ES-62 has been shown to modulate MyD88 and 
PKC isoform in a number of cell types (311), it appears that the parasite product 
does not influence MAL expression (Tay, Eason & Harnett; unpublished data). It 
may be possible therefore that whilst suppressing pro-inflammatory TLR signaling, 
unbalanced MyD88 and Mal signaling in the kidneys of ES-62 treated mice may 
enhance tight barrier formation. Alternatively, inhibition of C5aR signaling has 
been shown to promote the maintenance and viability of the blood brain barrier in 
the MRL/lpr mouse (455,456) and hence, suppression of C5a signaling, by 
reducing C5aR expression, may allow ES-62 to exert similar effects in the kidney. 
Finally, resetting of the balance of IL-17A and IL-22 production by ES-62 may also 
have affected tight barrier formation, as IL-23 has been reported to be required for 
the development of glomerulonephritis in the anti-glomerular basement membrane 
(αGMB) model (457). Although, IL-22 has been shown to promote epithelial barrier 
formation and resistance to injury in the lung (132), it has been widely reported to 
play both protective and pathogenic roles depending on the inflammatory context 
and hence during chronic IL-22 signaling the fibroblast proliferation required for 
wound healing may lead to fibrosis and act to disrupt barrier formation.  
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ES-62 is a large immunogenic compound that is unsuitable as a therapeutic and 
therefore small molecular analogues (SMAs) have been designed, based on the 
PC-moiety that appears to be responsible for most of the immunomodulatory 
actions of the parasite product. Two of these compounds, S3 and S5, suppressed 
the development of proteinuria in MRL/lpr mice even although they were 
administered following the onset of pathology: although their mechanism of action 
has not yet been defined, as with ES-62, protection was associated with reduction 
of MyD88 expression by renal cells. Interestingly, the SMAs did not improve renal 
histology or appear to reduce ANA production, although serum from some of the 
mice receiving S5 exhibited a similar pattern of membrane staining as that from 
ES-62 treated mice. As glomerulonephritis remains a major problem for SLE 
patients, new drugs to prevent kidney failure are urgently required. Exploitation of 
the natural relationship between parasite immunomodulatory proteins and the 
immune system may therefore provide the basis for the development of novel 
immunomodulatory drugs. As ES-62 can improve renal function despite clear 
kidney pathology, drugs based on its mechanism of action may therefore prolong 
the working life of such kidneys and subsequently have a clear impact on the 
quality of life of SLE patients. 
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Figure 5.1: Pro-inflammatory receptor expression by renal cells. Kidney cells 
from 21-week old MRL/MP, 7- or 21-week old MRL/lpr mice were pooled (4 mice 
per group) and the expression of TLR4, CD16/32, C3aR, C5aR, MyD88 and CD86 
evaluated by flow cytometry. Exemplar plots are shown for 21-week MRL/lpr mice, 
positive stains are represented as open histograms and the isotype as a filled grey 
histogram. The data are presented as MFI of expression of each marker relative to 
its isotype control.  
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Figure 5.2: The expression of pro-inflammatory receptors by renal cells is 
reduced in mice treated with ES-62. MyD88 expression was evaluated in renal 
cells from MRL/lpr mice treated with or without ES-62 by flow cytometry (A & B). 
Kidney cells from PBS treated MRL/lpr mice (n=4 pooled) were pre-treated with 
(blue line) or without (red line) ES-62 and then cultured for 18 hours in the 
presence of LPS (1µg/ml), the expression of MyD88 (C), TLR4 (D), C5aR (E), 
C3aR (F) and CD16/32 (G) was the determined by flow cytometry and compared 
to relevant isotype controls (grey histogram). Data are representative of two 
independent experiments and the student’s t-test was used to show statistical 
significance (B).  
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Figure 5.3: ES-62 renders renal fibroblasts hypo-responsive. Renal fibroblasts 
were expanded from the kidneys of ES-62 (blue line) or PBS (red line) treated 
MRL/lpr mice, the expression of MyD88 (A), C5aR (B) and CD64 (C) were 
evaluated by flow cytometry and compared to an appropriate isotype control. 
Representative plots are shown alongside graphs of three biological replicates 
from one of two independent experiments (A-C). The concentration of IL-6 (D) and 
MCP-1 (E) were measured in the supernatants from renal fibroblasts stimulated 
with LPS for 18 hours. The total mean fluorescence intensity (total MFI) of MyD88 
in these cells was measured by flow cytometry (F). The student’s t-test (D) and 
one-way ANOVA (E) tests were used to show statistical significance where 
**=p<0.001 and ***=p<0.001. 
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Figure 5.4: Renal fibroblast proliferation is altered in ES-62 treated mice. 
Renal fibroblasts expanded from the kidneys of 21-week old PBS or ES-62 treated 
MRL/lpr mice were photographed after 10 days, using the Olympus IX51 light 
microscope at x10 optical zoom (A). Renal fibroblasts were cultured with [3H] 
thymidine for 24 hours before the cells were harvested and and incorporation into 
DNA measured by a microbeta plate reader. Renal fibroblasts from mice treated 
with PBS, ES-62 or rIL-22 were cultured in a 96-well plate until they reached 80-
90% confluency, at which point a 10 µm wound was created using a pipette tip; the 
rate of recovery (C) was then scored over 72 hours on the basis of clean cut (0), 
cellular extensions across cut (1), cellular extensions and wound narrowing (2), 
narrow wound, almost closed (3) and healed (4) (D). Statistical significant was 
shown using the 2-way ANOVA where *=p<0.05 and ***=p<0.0001. 
  
! 220!
 
  
! 221!
Figure 5.5: ES-62 modulated the population dynamics of myeloid cells. Cells 
from 21-week old PBS (black bar, n=11) or ES-62 (grey bar, n=18) treated MRL/lpr 
mice were stained with anti-GR1 and anti-CD11b antibodies to resolve the 
CD11bhighGR1high, CD11bhighGR1int, CD11bhighGR1low and CD11bhighGR1- 
granulocyte populations in the blood (A, sample pooled from 4 mice for each group 
and is representative of 2 independent experiments), kidneys (B), spleens (C), 
pLN (D), rLN (E) and bone marrow (F, 4 mice pooled from each group); and the 
spleen (G), pLN (H) and rLN (I, 4 mice pooled from each group) of 12-week 
MRL/lpr mice. 
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Figure 5.6: Macrophages populations in PBS and ES-62 treated mice. The 
proportion of CD45+F4/80+CD11b+CD64+ macrophages present in the spleen (A), 
pLN (B), rLN (C), kidney (D) and in the blood (E) of 21-week MRL/lpr mice treated 
with or without ES-62 was determined by flow cytometry; where live cells were first 
identified as being CD45+ (red line = PBS, blue line = ES-62, grey histogram = 
isotype) and then selected on the basis of being F4/80+CD11b+.  
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Figure 5.7: ES-62 suppresses pro-inflammatory cytokine production by bone 
marrow derived macrophages. Macrophages derived from bone marrow 
precursors from the femur and tibia of 21-week old MRL/lpr mice, were pre-treated 
with media or ES-62 for 2 hours before being cultured with LPS for 18 hours. The 
concentration of TNFα (A), IL-1β (B), IL-6 (C), IL-27 (D), IL-10 (E), IL-12p70 (F) 
and IL-23 (G) was then measured in the culture supernatants by ELISA; data are 
from duplicate biological replicates and are representative of 3 independent 
experiments. The level of MyD88 expression was determined by Western blot, 
using the ab2068 antibody (Abcam), and the protein level, relative to β-actin, was 
measured using the ImageJ software package from 7 independent experiments; 
statistical significance was shown using the 1-way ANOVA with the Tukey post-
test where *=p<0.05 and **=p<0.001  (H).   
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Figure 5.8: The effect of S3, S5 and SMA15 on MyD88 protein levels in BMM. 
Diagrams of the chemical structures of S3, S5 and SMA15 (A). BMM from MRL/lpr 
mice were cultured with media, LPS, S3 (at 1µg/ml or 5µg/ml), S5 (at 1µg/ml or 
5µg/ml) or SMA15 (at 1µg/ml or 5µg/ml) for 18 hours; cells were washed, lysed 
and the relative intensity of MyD88 (ab2068), relative to β-actin, was analyzed in 
protein lysates by Western blotting. Image J analysis from 5 experiments showed 
that S3 and S5 significantly downregulate MyD88 expression  (A).   
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Figure 5.9: S3 and S5 prevent the development of proteinuria in the MRL/lpr 
mice. Female MRL/lpr mice were monitored for onset (1-3 mg/ml) of proteinuria 
which occurred at 16-weeks of age (arrow), at which point the mice began to 
developed proteinuria levels of approximately 1-3 mg/ml. Mice received 1µg of S3 
(n=6), S5 (n=6), SMA15 (n=3, one of these mice died at week 18) (all at 1 µg in 
100µl) or PBS (n=4; 100 µl) injected sub-cutaneously twice weekly. Proteinuria 
was measured twice weekly throughout the model and mice were culled at week 
22 (A). The number of cells in the spleen, pLN, rLN and kidney was counted using 
a hemacytometer (B) and the level of MyD88 expression by kidney cells was 
determined by flow cytometry (B). The two-way ANOVA and student’s t-test 
statistical analysis were used to determine statistical significance where *=p<0.05, 
**=p<0.01 and ***=p<0.001. 
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Figure 5.10: Treatment with S3 or S5 does not improve renal histology. 
Kidney sections from mice treated with PBS, S3 or S5 were stained by H & E or 
PAS and visualized using the Olympus IX51 light microscope at x10 optical zoom 
(A). Serum from the mice treated with PBS, S3, S5 or SMA15 was used to stain 
Hep-2 slides for analysis of ANA:staining intensity was then evaluated using an 
axiovert fluorescence microscope at 10x optical zoom (B).  
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Figure 5.11: Treatment with S3 or S5 does not modulate the key 
immunological parameters targeted by ES-62. Cells from the spleen, pLN, rLN 
or kidneys of 21-week female MRL/lpr mice treated with PBS, S3 or S5 were 
stimulated with PMA plus ionomycin (and LPS for IL-10 (A)) for 6 hours, with 
BrefeldinA added after 30 minutes to block intracellular trafficking. Cells were 
stained with the Live/Dead cell discrimination fixable dye and stained for surface 
markers. Cells were then fixed and permeabilized and incubated with the relevant 
anti-mouse-cytokine or FoxP3 antibodies. Cells were analyzed by flow cytometry 
and the proportion and number of IL-10+CD19+ (A), CD3+CD4+CD25+FoxP3+ 
Tregs (B), IL-17+ (C) and IL-22+ (D) cells were determined. The concentration of 
IL-10 (E), IL-17A (F) and IL-22 (G) in the interstitial fluid of PBS, S3, S5 and S15 
treated mice was measured by ELISA. The student’s t-test was used to determine 
statistical significance where *=p<0.05, **=p<0.01 and ***=p<0.001. 
  
! 234!
6. ES-62 modulation of collagen-induced arthritis in mice 
is associated with an increase in IL-10-producing B cells 
and reduced plasma cell infiltration of the joints 
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6.1. Introduction 
 
The data presented in the previous chapters demonstrates that ES-62 protects 
against the development of autoimmune lupus-like pathology in the MRL/lpr 
mouse, by resetting the balance of effector: regulatory B cells and consequently 
IL-17A/IL-22 responses. Moreover, transfer of B cells from ES-62-, but not PBS-
treated MRL/lpr mice was sufficient to recapitulate the protection afforded by ES-
62.  Protection was determined in terms of proteinuria, but such mice may 
sometimes also exhibit arthritis and this was also prevented by exposure to ES-62 
(McGrath, Harnett & Harnett, unpublished data). Thus, as the mice in the cohorts 
involved in the B cell transfer studies did not develop arthritis, and also to 
determine whether this action of ES-62 was specific to the B cell-driven pathology 
in Lupus, it was decided to determine whether ES-62 generally acted to reset the 
effector: regulatory B cell balance in other autoimmune pathologies such as the 
mouse collagen-induced arthritis (CIA) model of Rheumatoid Arthritis (RA) in 
which it has been previously shown to confer protection by acting to suppress 
pathogenic Th1/Th17 responses (336). This model was chosen as the success of 
rituximab as a therapy for autoimmune disease had refocused interest on the 
pathogenic and protective roles of B cells in RA (458) with recent studies 
highlighting the importance of IL-10-producing regulatory B cells (Bregs) in the 
prevention and amelioration of CIA and also antigen-induced arthritis (AIA), via the 
suppression of Th1/Th17 responses and the promotion of Tr1 and Treg 
differentiation (245,345,458,459). In this context, it was interesting, therefore, that 
previous studies had found that whilst exposure to ES-62 resulted in enhanced 
spontaneous ex vivo production of IL-10 by splenocytes from mice with CIA, it 
induced hypo-responsiveness of normal and CIA-derived splenic B cells and 
reduced the levels of pathogenic collagen-specific IgG2a antibodies (319). It was 
therefore the aim of this chapter to determine whether the protective effects of ES-
62 in CIA are associated with an increase in the levels of IL-10-producing B cells 
and suppression of effector B cells, to address whether ES-62 may act, at least in 
part, to modulate the balance between effector and regulatory B cell responses in 
this mouse model of RA. 
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6.2. Results  
 
6.2.1. ES-62 reduces the levels of Germinal Centre B cells in the spleens of 
mice with CIA    
 
The associated between ES-62-mediated protection against CIA (Fig. 6.3A & B) 
and the modulation of B cell populations was investigated (Fig. 6.1 & 2). There 
was no significant modulation by the helminth product of either the proportion or 
number of CD19+ B cells in the spleen (Fig. 6.4A; numbers (x106) ± SEM: Naive, 
25.13 ± 2.26; PBS, 26.86 ± 1.76; ES-62, 28.27 ± 2.68) or draining LN (dLN) 
(results not shown) and consistent with this, no significant changes were observed 
in the transitional (T1-T3), marginal zone precursor (MZP) or marginal zone (MZ) 
populations in the spleen (Fig. 6.4B & C and results not shown). However, ES-62 
significantly increased the levels of CD19+CD21low/-CD23high follicular B cells (Fo; 
Fig. 6.4B & C) and further analysis showed that whilst exposure to ES-62 had no 
effect on follicular type-2 (Fo2) B cells (results not shown), it increased the levels 
of follicular type-1 B cells (Fo1; Fig. 6.4 D; numbers (x106) ± SEM: PBS, 6.08 ± 
0.64; ES-62, 7.97 ± 0.91). The reduction in Fo1 B cells was associated with 
corresponding reductions in germinal centre B cells (GC; Fig. 6.4E; numbers 
(x106) ± SEM are: PBS, 6.28 ± 1.36; ES-62, 2.95 ± 0.39) and 
CD3+CD4+ICOS+CXCR5+ follicular helper T cells (Tfh; from 2.42 to 1.49% of live 
splenocytes; Fig. 6.4F) in the spleen. By contrast, ES-62 had no effect on the 
levels of CD19+B220+IgM-IgD-IgG+ cells, which may represent a subset of memory 
B cells and were generally reduced in mice with CIA (Fig. 6.3G). Collectively, 
these data suggest that ES-62 may act to reduce the generation of pathogenic 
antibodies by blocking the activation of follicular B cells and their consequent 
differentiation into GC B cells (460). 
 
6.2.2. ES-62 modulates the recruitment of B cells to the joints of mice with 
CIA 
 
As pathogenic B cells migrate to the joints and even form ectopic germinal centres 
in response to B cell recruitment and survival factors such as BAFF, CXCL12 and 
CXCL13 secreted by synovial fibroblasts (458), whether the above effects of in 
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vivo exposure to ES-62 on the profile of B cells were reflected in the arthritic joint 
was investigated. This revealed that both the proportion (Fig. 6.5A & B) and 
absolute numbers (Fig. 6.5C) of CD19+ B cells found in the joints were significantly 
reduced by ES-62 treatment. This reduction was reflected in a CD19+CD23+ B cell 
population (Fig. 6.5D & E), which further analysis revealed to be follicular type 1 B 
cells (Table 6.1). There was also a clear decrease in CD19-CD138+ (from 9.27 to 
2.47% live cells) and CD19+CD138+ (from 15.6 to 6.51% live cells) cells infiltrating 
the joints of mice treated with ES-62 (Fig. 6.5F & G) suggestive of a reduction in 
plasma cells.  Consistent with this, further analysis, excluding the myeloid and T 
cell lineages expressing CD138 (Fig. 6.5H), revealed that exposure to ES-62 
indeed suppressed the proportions  (Fig. 6.5I-J) and numbers (Table 6.1) of CD19-
B220-CD138+ (from 8.31 to 3.69% live cells) and CD19+B220low/-CD138+ (from 
1.37 to 0.72% live cells) plasma cell respectively phenotypically similar to the long-
lived plasma cell and short-lived plasma cell/plasmablast functional populations, 
reported previously (352,355,411).  This presumably reflected reduced 
development and/or migration of such cells, as suggested by the significant 
increases in the levels of Fo1 (Fig. 6.4D) and CD19-B220-CD138+ plasma cells 
(numbers (x106) ± SEM: Naïve, 0.75 ± 0.22; PBS, 1.28± 0.31; ES-62, 1.58± 0.26) 
found in the spleen, since ES-62 did not modulate the levels of early 
CD19+B220+CD138+ "pre-plasma cells" which have been reported are subject to a 
tolerance checkpoint that is defective in the autoimmune-prone MRL/lpr mouse 
(354) (Fig. 6.4K). 
 
In addition to investigating its effects on the levels of B cells found in the joint, 
modulation of the functional phenotype of such infiltrating cells was also assessed. 
Thus, whilst ES-62 did not significantly modulate the expression of BAFF-R, CD80, 
CD86 or TLR4 (either in terms of percentage positive cells or levels of expression) 
on splenic CD19+ B cells, expression of CD80, TLR4 and, to a lesser extent, 
CD86, but not BAFF-R, by CD19+ B cells in the joint was down-regulated (Fig. 6.6 
and data not shown), mirroring a tendency towards a decrease in expression of 
both CD80 and TLR4 by CD19+ DLN cells (Data not shown).  Further analysis 
revealed that this reflected selective down-regulation of TLR4, CD80 and CD86 
expression on CD19+CD23highCD21low/- follicular B cells but not CD19+CD23-
CD21high or CD19+CD23highCD21high B cells (Fig. 6.6A). Moreover, although B1, 
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GC and plasma cells also expressed TLR4, such expression was not modulated 
by exposure to ES-62 (Fig. 6.6A)  
 
Collectively, therefore, these data suggest that ES-62 may act to prevent 
development and migration of pathogenic B cells to the site of inflammation, with 
the residual B cells that infiltrate the joint being rendered functionally hypo-
responsive.  
 
6.2.3. IL-10-producing B cells are elevated in the spleens of mice with CIA 
receiving ES-62 
 
IL-10 producing regulatory B cells (Bregs) have been reported to curb pathogenic 
Th1/Th17 responses in CIA and it has been proposed that these cells protect 
against disease by promoting the development of Tr-1 regulatory T cells (345). 
Although the ES-62-mediated suppression of B cell development and migration 
(Fig. 6.4 & 6.5) and consequent inhibition of generation of pathogenic IgG2a 
responses observed in CIA (335) might reflect the ability of the parasitic worm 
product to induce hypo-responsiveness of B2 cells by uncoupling the BCR from 
ErkMAPkinase signalling, both in vitro and in vivo, it is also interesting to note that 
it has previously been shown to induce the production of IL-10 by peritoneal B1 B 
cells (324). As B1 cells are not thought to play a central role in systemic 
autoimmunity and autoantibody production in CIA (461), although there is no 
unambiguous phenotype for B1 cells in the spleen (199), it is therefore possible 
that the reduced levels of CD19+IgM+CD43highCD5+ and CD19+IgM+CD43highCD5+ 
cells, that have been reported to be B1a and B1b cells respectively 
(200,353,462,463), found in the spleens (Fig. 6.7A-C) and DLNs (Fig. 6.7D) of ES-
62-treated mice with CIA could reflect their egress and migration to the joints to 
mediate IL-10-dependent anti-inflammatory effects. Perhaps consistent with this, 
although the levels of B cells infiltrating the joint were reduced following treatment 
with ES-62, the proportion of such B1-like cells was slightly increased (PBS: 
1.42%, 1.3%; ES-62: 1.58%, 1.51%, where data are expressed as the proportion 
(%) of live cells, that are CD43+CD19+IgM+ B1-like cells, harvested from the joints 
of 6-7 mice/group in 2 independent experiments).   
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Analysis of IL-10-producing B cells (Fig. 6.8A) revealed that whilst induction of CIA 
resulted in a significant reduction in the levels of these cells, relative to naïve mice, 
this was not the case for those treated with ES-62. Indeed, exposure to ES-62 led 
to a significant enhancement in the level of IL-10-producing B cells in mice with 
CIA, restoring them to levels comparable with those found in healthy naive mice 
(Fig. 6.7C; numbers (x106) ± SEM: Naïve, 1.81 ± 0.22; PBS, 1.48 ± 0.12; ES-62, 
1.99 ± 0.26). CD19+IL-10+ B cells in the spleens of naïve and CIA mice (Fig. 6.8A) 
reflected a mixed population comprising phenotypes consistent with marginal zone 
precursor, marginal zone, follicular B cells and CD19+CD21low/-CD23+ B cells (Fig. 
6.8B). Almost all of these cells expressed CD1d with the highest expression on the 
MZ (CD21+CD23-) and MZP (CD21+CD23+) populations (Fig. 6.8E) and some of 
the IL-10+ cells expressed CD5 with the highest expression on the follicular and IL-
10+CD19+CD21-CD23- populations; both of these markers have previously 
associated with certain IL-10-producing B cells (464,465). Rather surprisingly, the 
ability of ES-62 to return the levels of IL-10-producing B cells towards that existing 
in naïve, non-arthritic mice, did not appear to involve a preferential increase of any 
of these phenotypes, perhaps suggesting it acts rather to regulate B cell 
responses in a  "homeostatic" manner. Although the protective effects of IL-10-
producing B cells in CIA have previously been reported to be associated with the 
induction of Tr-1 regulatory cells (345), our analysis showed the IL-10 production 
by splenocytes to be predominantly B cell-derived (Fig. 6.8A) and that the CD19-
IL-10+ population was not increased by treatment with ES-62 (Fig. 6.8D), 
suggesting that Tr-1 cells were not being induced in this case.  Likewise, and 
consistent with the previously reported lack of Breg-mediated induction of Tregs in 
the CIA model (345), further investigation indicated that in vivo treatment with ES-
62 did not result in enhanced levels of FoxP3-expressing CD4+ regulatory T cells 
in the DLN (McGrath, Harnett & Harnett, unpublished data), as shown following 
induction of Bregs in AIA (419).  
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6.3. Discussion 
 
The successful clinical implementation of B cell-depletion therapies in recent years 
has reignited interest in the pathogenic and protective roles of B cells in RA. In 
particular, much interest has focused on the ability of IL-10-producing regulatory B 
cells to prevent development of pathogenic Th1/Th17 responses and induce 
regulatory T cells that result in the suppression of disease in the antigen 
(methylated BSA)-induced arthritis  (AIA) and CIA mouse models of RA 
(245,345,419). Interestingly, therefore it has recently emerged that one of the 
strategies exploited by parasitic helminths to dampen host immune responses and 
hence promote their survival is the induction of IL-10-producing Bregs: moreover, 
the protection afforded against allergic inflammatory disease by such worms has 
also been associated, at least in part, by their induction of Bregs(353,466-469). 
Thus, the current findings that exposure to ES-62 results in elevated levels of IL-
10-producing B cells may provide a rationale for previous findings that the parasite 
product exerts its protective effects in CIA via suppression of Th1, Th17 and IL-17-
producing gd T cell responses, as well as being consistent with an earlier 
observation that it promotes spontaneous IL-10 production by splenocytes from 
mice with CIA (319,335,336). Interestingly, although regulatory B cells have been 
proposed to mediate at least some of their protective effects in experimental 
arthritis via the generation of natural Tregs (AIA) and/or induced Tr1 (AIA and CIA) 
cells (245,345,419), there was no evidence that ES-62 induces any IL-10-
producing regulatory T cells in DBA/1 mice with CIA. Although perhaps surprising, 
this failure to induce Tregs is supported by preliminary data from the C57BL/6 
model of chronic CIA (470), in which in vivo exposure to ES-62 does not increase 
the levels of either FoxP3+ or IL-10-producing CD4+ T cells in the DLN of such 
mice (McGrath & Harnett, unpublished data) and is consistent with their lack of 
induction in previous studies investigating ES-62-mediated hyporesponsiveness to 
the model antigen Ovalbumin (OVA) in both the DO.11.10 transfer model (37) and 
the OVA-induced airway inflammation model (338) of asthma. Nevertheless, whilst 
ES-62 does not increase the levels of Tregs in mice with CIA, it is not possible to 
rule out at this stage that it may act to reverse/overcome the impaired (cell contact-
mediated) suppressive ability of Tregs reported in RA (471).  
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Perhaps surprisingly, the increase in IL-10-producing B cells resulting from 
exposure to ES-62 did not reflect induction of a particular phenotype of B cells 
associated with regulatory function: although modest, these statistically significant 
increases in IL-10 producing B cells are consistent with the numbers seen in other 
studies in the absence of enrichment by anti-CD40 or LPS/IL-21 stimulation 
(244,405,472) and suggest that ES-62 may be acting in a homeostatic manner to 
reset the balance of effector and regulatory B cells back towards that observed in 
healthy DBA/1 mice.  However, and consistent with this proposal, whilst the ES-
62-mediated suppression of the level of GC B cells was associated with a 30-40% 
reduction of Tfh cells, preliminary data suggest that the residual Tfh cells produced 
higher levels of the cytokine, IL-21 that appears to be critical to for the generation 
of functional Bregs that combat autoimmunity (405).  Thus, as regulatory function 
of these IL-10 producing B cells has not been formally demonstrated in this study, 
it is not possible at this stage to rule out that ES-62 is also reversing the defective 
regulatory function of one or more Breg phenotypes observed in CIA and RA 
patients (418,473).  Nevertheless, it was shown previously that whilst ES-62 
induces high levels of IgG1, but not IgG2a, antibodies in naive wild type BALB/c 
mice, in IL-10-/- mice the helminth product induces both IgG1 and IgG2a 
antibodies. This suggests that IL-10 plays an important role in the suppression of 
IgG2a antibodies directed against ES-62 (345). Interestingly, therefore, neither the 
ES-62-mediated suppression of DC-priming of OVA-specific Th1 responses(330) 
nor the suppression of TLR-mediated IL-12 responses of macrophages exposed to 
ES-62 either in vitro or in vivo (331) appears to be due to autocrine production of 
IL-10 by APC. By contrast, whilst exposure to ES-62 in vivo induces hypo-
responsiveness of splenic B2 cells, peritoneal B cells from such mice produced 
enhanced spontaneous and BCR-stimulated IL-10 responses (324,326) and 
although these peritoneal cells will predominantly comprise B1 cells, there is 
increasing evidence that they likely also included some B2 cells (463).  
 
Collectively, therefore, these data suggest that exposure to ES-62 leads to hypo-
responsiveness of effector B2 cell responses and an increase in IL-10-producing B 
cells that in CIA, given the complex interplay between B cell-derived IL-10 and 
pathogenic IL-17Aresponses in the regulation of inflammation and autoantibody 
responses (103,244,247,345,403,405,419), results in the reduction of plasma cells 
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that may contribute to the suppression of pathogenic autoantibodies and 
inflammation associated with the ES-62-mediated protection against CIA. For 
example, the ability of B cell-derived IL-10 to impact on APC such as DC in vivo 
may contribute to the effects of ES-62 on the DC-dependent priming of Th1/Th17 
and IL-17-producing gd T cells (330,336,338). Alternatively, such IL-10 may 
suppress effector B cell activation with consequent induction of T cell hypo-
responsiveness, as the reduction of GC B cells and TFH cells observed in the 
spleens of ES-62-treated mice is reminiscent of that reported for mast cell-derived 
IL-10-mediated suppression of TFH cell function (474). This could be particularly 
important at the site of inflammation with the profound down-regulation of CD80 
expression on follicular B cells impacting on the functionality of ectopic GCs given 
that expression of this B7 molecule by B cells has been shown to be important in 
the regulation of Tfh development, and consequent GC B cell survival and plasma 
cell production (475), the latter population being significantly reduced in the joints 
of ES-62-treated mice. Interestingly therefore, blocking of B7-CD28 interactions 
has been reported to be sufficient to prevent development of CIA (476).  Finally, 
the strong down-regulation of TLR4 is similarly likely to suppress B cell activation 
and plasma cell generation at this site (477), and in this way, disrupt the 
destructive chronic inflammation resulting from cells in the joint expressing 
upregulated levels of TLRs, including TLR4, and responding to DAMPs,  such as 
HSP22 and tenascin-C (478) found in the synovium of RA patients. 
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Table 6.1: Exposure to ES-62 in vivo suppresses infiltration of the joints by 
B2 cells and plasma cells. Data (number of cells x 106) are presented from 2 
independent experiments where CD19+B220low/-CD138+ and CD19-B220-CD138+ 
plasma cell and CD19+CD21low/-CD23+AA6.1-IgMlowIgDhigh Fo1 B cell populations 
infiltrating the joints were analysed by flow cytometric analysis of joint cells 
harvested from 6-7 mice from each group. 
 
 
Group CD19+B220low/-CD138+ CD19-B220-CD138+ Fo1 
Exp 1 2 1 2 1 2 
PBS 0.24 0.67 1.5 0.74 0.029 0.11 
ES-62 0.035 0.32 0.18 0.36 0.009 0.033 
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Figure 6.1: Gating strategy for analysis of B cell subsets and phenotyping of 
populations. Cell populations were initially selected on the basis of "Lymphocyte" 
size and granularity and "doublets" and dead cells were excluded. The 
conventional method for the analysis of marginal zone precursor (MZP), marginal 
zone (MZ) and follicular B cells is to resolve CD19+ cells by their CD21 and CD23 
expression (A). To improve resolution of these subsets we initially gated on 
CD19+CD23- and CD19+CD23+ cells (B) to resolve MZP (CD21hiCD1dhi) from Fo 
(CD21low/-CD1dint/-) B cells (C) and MZ (CD21+IgM+) and T1 (CD21-IgM+) cells (D), 
respectively, allowing more clearly defined populations of MZ (IgMhighIgDlow/-), MZP 
(IgMhighIgDhigh) and Fo(IgMlow/-IgDhigh) B cells. This modified method improved the 
resolution of these populations and the IgM IgD expression profiles between the 
conventional and contemporary methods: panel E compares the populations from 
panel A and F compares the populations from panels C and D, Fo1 cells are 
represented by grey dots, MZP with black dots and MZ with black contour lines.  
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Figure 6.2: Gating strategy for analysis of B cell subsets and phenotyping of 
populations. The follicular (Fo) population identified (Fig6.1C; CD21low/-CD1dlow) 
is a heterogenous population that contains the functionally distinct follicular type 1 
(Fo 1: IgDhighIgMlow/-AA6.1-) and follicular type 2 (Fo 2: IgDhighIgMhighAA6.1-) as well 
as the transitional 2 (T2: IgDhighIgMhighAA6.1+) and transitional 3 (T3: IgDhighIgMlow/-
AA6.1+) populations. These populations are first separated on the basis of their 
expression of IgM and IgD (A) and then, AA6.1 (B & C). For the identification of 
germinal centre (GC) B cells we first identify CD19+CD43- cells (D) and then 
exclude contaminating non-B cells by gating on the GC cell specific marker GL7 
along with the pan B cell marker CD24 (E) before confirming expression of FAS by 
essentially all (>90%) CD19+CD43-CD24+GL7+ GC B cells; we have therefore not 
included this redundant marker in our analysis (F).   
! 248!
 
  
! 249!
Figure 6.3: ES-62 prevents the development of disease in the CIA mouse 
model of RA. CIA was induced, as described in the materials and methods 
section, by Dr. Miguel A Pineda. Mean articular scores (± SEM) of CIA mice 
treated with PBS (n=34) or ES-62 (n=18) between day 16 and 28 (A) and at time 
of cull at day 28 (B). The student’s t-test was used at each time point to show 
statistical significance where *=p<0.05 and **=p<0.01. 
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Figure 6.4: ES-62 reduces the levels of Germinal Centre B cells in the 
spleens of mice with CIA The percentage of CD19+ B cells (A); representative 
plots (B) and proportions (C; mean values ± SEM of individual mice where naive, 
n=16; PBS, n= 31; ES-62, n=12) of MZP, MZ and Fo B cells derived by the 
conventional method; follicular type 1 B cells (D: CD19+CD23+CD21low-
/CD1dintIgMlowIgDhiAA6.1-) and germinal centre (E: CD19+CD43-CD24+GL7+), as 
derived by the gating strategy in presented in Fig. 1, in spleens from mice 
undergoing CIA are shown. The proportion of CD3+CD4+ICOS+CXCR5+ T follicular 
helper cells were determined by FACS with representative plots shown alongside 
a graph of the absolute numbers (F) and the proportion of memory B cells in the 
spleens of naïve mice and CIA mice treated with PBS or ES-62 (G).   
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Figure 6.5: ES-62 modulates the recruitment of B cells to the joints of mice 
with CIA. Cells extracted from the joints of mice with CIA were analysed for the 
proportion (A & B) and number (C) of infiltrating CD19+ B cells (A-C; data in C are 
presented as the means ± SEM of 4 biological replicates pooled from two 
independent experiments) and consequently for the relative proportions of 
CD19+CD23+ (D & E); plasma cells on the basis of CD19 CD138 expression (F & 
G); exclusion of myeloid and T cell-expressing CD138 cells by use of Dump 
channel (CD4+CD8+GR1+F4/80+CD11b+ CD11c +; H); Dump-CD19-B220-Cd138+ 
plasma cells and Dump-CD19+B220low/-CD138+ plasma cells (I & J; values give 
refer to the % of live cells). The proportion of Dump-CD138+B220±CD19± cells in 
the spleen, LN and paws are presented (K). The student’s t-test was used to show 
statistical significance where *=p<0.05 and **=p<0.01.  
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Figure 6.6: ES-62 modulates expression of TLR4 and costimulatory 
molecules on follicular B cells. TLR4 (A), CD86 (B) and CD80 (C) expression 
by B cells in the joints of PBS and ES-62 treated mice are presented as 
expression levels relative to isotype control (grey area), for CIA mice treated with 
ES-62 (blue line) or PBS (red line).  Cells from at least 5 mice/group were pooled.  
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Figure 6.7: ES-62 modulates the levels of B1-like cells in the spleen of mice 
with CIA.   
There is no unambiguous phenotype for B1 cells in the spleen but they have been 
described as CD19highCD23-CD43+IgMhighIgDlow/-CD5± cells where CD5+ B1a and 
CD5- B1b comprise ~2% and 1% of cells in the spleen respectively 6. However, 
following gating on CD19+IgM+(A), analysis of CD43+CD5± cells has been widely 
used to describe B1 cells 25, 26 whilst CD19+CD5+ gating has been used to 
describe B1a cells 28. Moreover, whilst CD43 can be upregulated on B2 cells, this 
is usually expressed at a lower level than on B1 cells 27 and we have thus chosen 
to gate only on CD43high cells (B) in order to exclude any potential CD43+ B2 cells.  
We have therefore phenotyped CD19highCD43+IgMhighIgD- B cells as CD5+ B1a-like 
cells and CD5- B1b-like cells and the data show their relative proportions in the 
spleen (C; naïve, n=10; PBS, n=13 and ES-62, n=11) and DLN (D; naïve, n=4; 
PBS, n=8 and ES-62, n=8) of the indicated groups of mice.    
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Figure 6.8: ES-62 induces IL-10-producing B cells in the spleen of mice with 
CIA. IL-10-producing CD19+ B cell (A & C) and IL-10-producing CD19-  (A & D) 
subsets in the spleen were analysed with the proportions of these cells, in spleens 
of individual naive mice and PBS- and ES-62-treated mice with CIA respectively.  
Representative plots of the phenotypes of CD19+IL-10+ B cells based on their 
expression of CD21 & CD23 (B) and the level of CD1d (E) and CD5 (F) expression 
on IL-10+ MZ (blue line), MZP (red line), Fo (green line) and CD21-CD23- (black 
line) B cells are shown for spleens of mice with CIA. The student’s t-test was used 
to show statistical significance where *=p<0.05 and **=p<0.01. 
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7. General discussion 
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7.1. Developing drugs from parasitic immunomodulators 
 
Filarial nematodes are parasitic helminths that can cause debilitating conditions 
such as elephantiasis and river blindness (302-304). The low prevalence of 
autoimmunity in developing countries that are endemic for such parasitic worms 
may reflect the ability of the parasites to modulate the immune system, a 
characteristic that has likely evolved to promote survival of the parasite whilst 
limiting host pathology (1,2,4,5). This relationship has generated interest in the 
anti-inflammatory products of helminths and consequently, their therapeutic 
potential. Indeed, understanding the mechanisms by which these helminth-derived 
molecules modulate the immune response may identify novel pathways for future 
manipulation (311). Thus, parasite-derived immunomodulatory molecules may 
provide a platform for the development of novel immune modulating drugs, which 
would potentially treat disease in a safe and balanced manner, reducing the 
debilitating side effects associated with conventional therapies. 
 
It is now widely established that infection with parasitic worms can suppress 
disease in mouse models of autoimmune and allergic inflammatory disease 
(298,307,308,353). Consistent with this, helminth-infected patients suffering from 
multiple sclerosis present with less severe disease compared to uninfected 
multiple sclerosis patients (416). Furthermore, there is a striking negative 
correlation between the rates of rheumatoid arthritis and incidence of helminth 
infection in parts of the world where both diseases are common (479). The 
successful modulation of disease in mouse models has culminated in clinical trials 
evaluating the benefit of live T. suis helminths in the treatment of irritable bowel 
disease (298,480). These clinical trials have shown promise, however, the 
potential dangers of prescribing live pathogens to patients and the perception of 
“eating worms” may prevent the widespread uptake of these treatments. A safer, 
more controlled and palatable alternative to the therapeutic use of whole worms 
would therefore be to identify the specific components of the worms that are 
responsible for the modulation of the immune system (311). 
 
ES-62 is the major excretory-secretory product secreted by the filarial nematode A. 
viteae (481), a PC-containing glycoprotein that exhibits therapeutic potential in 
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mouse models of RA (collagen-induced arthritis) (335) and asthma (ovalbumin-
induced airway hypersensitivity) (228). In both diseases, the suppression of 
disease was due to modulation of pathogenic IL-17A responses. Consistent with 
this targeting of IL-17A responses (336,338), in this thesis, ES-62 has been shown 
to have therapeutic potential in a mouse mode of SLE, which is known to have a 
mixed Th1/Th2/Th17 phenotype. 
 
7.2. ES-62 suppresses the development of proteinuria in the MRL/lpr mouse 
 
SLE is a chronic autoimmune disease with a clear unmet clinical need that affects 
5 million people worldwide. SLE is usually treated with immunosuppressive drugs; 
however, such therapies are not always effective and long-term usage can lead to 
serious side effects such as infection and cancer (1,2). The exact etiology of SLE 
is unknown however the disease is largely thought to be due to a defect in the 
clearance of apoptotic cell debris, resulting in prolonged activation of the innate 
immune system and activation of auto-reactive lymphocytes. Consistent with this, 
SLE is characterized by autoantibody responses to double stranded DNA as well 
as other nuclear and cytoplasmic antigens. The resulting deposition of 
autoantibody-immune complexes induce localized inflammation in tissues with 
dense capillary networks, most commonly the skin, joints and kidneys. 
Consequently, lupus nephritis is one of the major causes of morbidity and mortality 
in SLE patients (10). 
 
To study the therapeutic potential of ES-62 in SLE, we utilized the MRL/lpr mouse, 
a naturally occurring mutant of the parental MRL/MP mouse, the genome of which 
contains several mutations in SLE disease susceptibility loci that result in the 
development of lupus-like disease within 12-18 months that exhibits characteristics 
of human disease including inflammation of the kidney, joints, skin and 
cardiovascular system. The lpr mutation results in accelerated disease, due to a 
loss of FAS signaling, with the mice developing severe disease within 5 months, 
with lupus nephritis the major cause of death in this animal model of SLE (14). The 
concentration of protein in the urine (proteinuria) directly correlates with 
glomerulopathy and leukocyte infiltration into the kidney; the twice-weekly 
prophylactic administration of ES-62 significantly reduces development of 
! 263!
proteinuria in the MRL/lpr mouse. Remarkably, however, despite such a drastic 
improvement in renal function, the level of glomeruloproliferation, glomerular 
basement membrane thickening, cellular infiltration, complement and immune 
complex deposition appeared relatively unaffected by the parasite product.  
 
Thus, as ES-62 did not substantially protect against these pathological signs of 
renal inflammation, it was hypothesized that the parasite product may act to 
modulate the functional responses of effector cells in the kidney to these pro-
inflammatory stimuli. Indeed, the expression of the C3aR, C5aR, FcγRI and FcγRIII 
by the renal cells and renal fibroblasts was reduced by both the in vitro and in vivo 
administration of ES-62. ES-62 has previously been shown to target TLR signaling 
via the adaptor protein MyD88 (320,322), which has been strongly implicated in 
the renal pathology of SLE (428,482). It was therefore of interest to also observe a 
reduction in the level of MyD88 in the renal cells and renal fibroblasts from ES-62 
treated mice. Such a reduction would likely perturb the responsiveness of kidneys 
to TLR ligands including DAMPs such as dsDNA and HGMB1 (26,462,482,483).  
The biological function of the kidney is to filter the blood and thus, tight barrier 
formation of glomerular basement membrane is paramount to ensure that 
macromolecules and cells are not lost into the urine; the level of proteinuria is 
therefore inextricably linked to the integrity of the glomerular basement membrane 
(443). Modulation of MyD88 signaling in the kidneys of ES-62 treated mice may 
therefore explain how renal function is maintained in the presence of such strong 
pro-inflammatory pathology, as whilst MyD88-ARNO-ARF6 signaling increases 
vascular permeability MyD88-MAL signaling promotes the maintenance of 
epithelial tight junctions (3,5,6,9). Thus, exposure to ES-62 may promote MyD88 
signaling via MAL over that coupled to ARNO-ARF6, to maintain the viability of the 
renal barrier function (Fig. 7.1); indeed, ES-62 has been observed to suppress 
PLD signaling in T cells and mast cells, which has been linked to the ARNO-ARF6 
pathway, whereas it has no effect on the expression of MAL (Ball, Eason, Tay, 
Harnett & Harnett unpublished data). Furthermore, ES-62 suppression of C5aR 
expression by renal fibroblasts may also contribute to the maintenance of renal 
barrier function as antagonizing this receptor has been reported to promote the 
viability of the blood-brain barrier in the MRL/lpr mouse (455) (Fig. 7.1).  
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7.3. ES-62 modulates cell infiltration of the kidneys of MRL/lpr mice 
 
Consistent with them expressing lower levels of proinflammatory receptors and 
signal transducing adaptor molecules, renal fibroblasts from ES-62 treated mice 
produced less MCP-1 in responses to TLR stimulation. MCP-1 is involved in the 
recruitment of effector leukocytes to sites of inflammation and is directly linked to 
lupus disease activity and renal involvement (14). The reduction in MCP-1 
expression was perhaps surprising given that histological analysis of the kidneys 
from ES-62 treated mice failed to identify any substantial reduction in cellular 
infiltration, however, analysis of the phenotype of the cells infiltrating the kidneys of 
ES-62 treated mice, indicated that the parasite product modulated the composition 
of the leukocyte population in the kidney. Indeed, the levels of pro-inflammatory 
effector cells such as CD11bhiGR1hi neutrophils, CD11bhiGR1int/low monocytes, 
CD4+ T helper cells, CD8+ and CD8low cytotoxic T cells, CD3+B220+CD4/8- DN T 
cells, γδ T cells, ILC and plasmablasts were significantly reduced in the kidneys of 
ES-62 treated mice. Interestingly, a common feature with the reduction of these 
cell populations was an apparent retention or increase of these populations at 
distal sites such as the spleen, LN or blood. This may suggest that ES-62 
modulates leukocyte migration and although preliminary data presented 
throughout this thesis supports this theory, further investigation is required to 
confirm this theory and characterize the mechanisms involved.  
 
7.4. ES-62 modulates the IL-17A/IL-22 axis in the MRL/lpr mouse 
 
ES-62 suppression of disease in mouse models of RA and asthma is via 
modulation of the IL-17A:IL-22 axis (336,338); as both of these cytokines have 
been implicated in the pathogenesis of SLE, the effect of ES-62 on these 
parameters was assessed in the MRL/lpr mouse. Prior to the onset of disease, 
ES-62 suppressed the level of IL-17A and IL-22 producing lymphocytes, 
suggesting that these two cytokines were involved in promoting initiation of 
pathogenesis. ES-62 also suppressed the levels of IL-22 producing lymphocytes in 
the LN and kidney during established disease, the latter of which correlated with a 
reduction in the concentration of IL-22 in the renal interstitial fluid. Interestingly, 
therefore the number of IL-22 producing cells in the pLN the MRL/lpr mice 
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positively correlated with proteinuria, whilst IL-22 producing cells were 
undetectable in the pLN of MRL/MP mice. Thus it appeared that IL-22 was 
associated with both initiation of pathogenesis and development of chronic kidney 
pathology in the MRL/lpr mouse. Indeed, neutralization of IL-22 from 12-weeks of 
age completely ablated the development of proteinuria in the MRL/lpr mouse 
whereas the administration of rIL-22 significantly accelerated and exacerbated 
disease, supporting this proposal and suggesting that IL-22 was sufficient and 
essential for disease pathogenesis in the MRL/lpr mouse. Thus, suppression of IL-
22 production provides a mechanism that contributes to the protection against 
proteinuria afforded by ES-62. 
 
In direct contrast to its effect on IL-22-producing cells, ES-62 significantly 
increased the proportion of IL-17A+ cells in mice during established disease. 
Although few IL-17A producing cells were detected in the kidney, the concentration 
of IL-17A was also significantly increased in the renal interstitial fluid of ES-62 
treated mice, suggesting that the stimulation with PMA and ionomycin, typically 
used to identify cytokine-producing T cells by flow cytometry, was inducing death 
of cells, such as neutrophils, that may have been a predominant source of this 
cytokine (41,98) at this site. Nevertheless, there was an inverse correlation 
between the number of IL-17A producing cells in the pLN and the level of 
proteinuria; moreover, high levels of IL-17A producing cells were also found in the 
pLN of MRL/MP mice at 20 weeks, a time point at which these mice do not exhibit 
pathology, suggesting, perhaps controversially, that IL-17A does not play a solely 
pathogenic role in the MRL/lpr mouse. This possibility was confirmed, as whilst the 
neutralization of IL-17A production prior to the onset of disease, slowed the onset 
and reduced the severity of proteinuria, it did not block it completely, indicating that 
such early production of IL-17A was not sufficient for pathogenesis.  Moreover, the 
administration of recombinant IL-17A during the established phase of disease 
partially mimicked the protective effects of ES-62 in suppressing development of 
proteinuria. Although these data suggest that IL-17A can indeed exert protective 
effects in the MRL/lpr mouse, together with recent findings that neutralization of IL-
23 in MRL/lpr mice suppresses disease (368,369), collectively the data presented 
here suggest it is possible that IL-17A plays dual roles in the MRL/lpr mouse 
promoting pathogenesis prior to the onset of disease and acting to resolve 
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inflammation during established disease, such a precedent having been set for IL-
17A in asthma (118,338).  
 
The finding that IL-17A can protect against proteinuria in the MRL/lpr mouse runs 
contradictory to the current literature, which suggests an essential role of the 
cytokine in pathogenesis (103). However, closer scrutiny of previous reports 
examining IL-17A in SLE patients may reconcile this contradiction. Thus, IL-17A is 
undoubtedly elevated in SLE patients compared to healthy controls (103,373,374) 
however, few publications have reported a direct correlation between IL-17A and 
SLEDAI (114,375-378). On the other hand, considerably more groups have found 
that IL-17A is not associated with SLEDAI and may in fact be associated with 
protection in SLE patients (379-383,385,386). For example, an informative study 
by Szeto et al. measured the levels of IL-17A mRNA in the urine of SLE patients 
over time, and discovered that in the weeks preceding a disease flare, IL-17A 
mRNA levels in the urine declined significantly (388,389). Supporting evidence for 
a protective role for IL-17A is provided by its suppression by IFNα, a cytokine 
strongly implicated in the pathogenesis of SLE (38,484). Moreover, whilst in SLE 
models using mouse strains that are not genetically susceptible to develop the 
disease spontaneously, such as the FcγRIIb-/-, Ro52-/- or the B6lpr/lpr models, there 
is strong evidence that IL-17A promotes pathogenesis (15,16,112), such a role for 
IL-17A has not been definitively demonstrated in lupus-prone strains, such as the 
NZB/NZW F1 or the SNF1 mouse. In the MRL/lpr mouse, which is genetically 
predisposed to develop lupus-like disease, IL-17A can demonstrably be protective 
during established disease. Thus, although others have demonstrated IL-17A 
producing cells in the MRL/lpr model, these may reflect the potential protective 
effects of the cytokine during established disease (112,369) as reported in other 
models of autoimmune and allergic inflammatory disease (118,485) and perhaps 
most pertinently, during renal host versus graft disease (98) and models of 
glomerular nephritis. Altogether, these data suggest that IL-17A may be important 
in the induction of SLE, perhaps by promoting germinal center-dependent 
generation of autoantibody-producing plasma or memory B cells (403): however, 
during established disease IL-17A may act to suppress generation of pathogenic 
anti-dsDNA producing plasmablasts by promoting GC formation and production of 
less pathogenic auto-antibodies by long-lived plasma cells. Furthermore, IL-22R 
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has recently been identified as a marker for GC stromal cells, tempting speculation 
that IL-17A and IL-22 may be involved in counter-regulation of the GC reaction and 
by resetting the balance of these cytokines, ES-62 may modulate GC function. 
Indeed, preliminary data presented in Chapter 4 suggested that IL-22 plays a role 
in the generation of extra-follicular plasmablasts, as the neutralization of IL-22 
reduced the levels of these cells in the kidneys (Fig. 7.2).  
 
7.5. ES-62 modulates the effector/regulatory B cell balance in the MRL/lpr 
mouse 
 
As the producers of the pathogenic autoantibodies, B cells have long been heavily 
implicated in the pathogenesis of SLE; however, B cells contribute towards the 
pathogenesis in the MRL/lpr mice via both antibody dependent and independent 
mechanisms (162,232). Consistent with this, the onset of disease in the MRL/lpr 
mouse correlates with the expansion of MZ, Fo1 and GC effector B cell 
populations in the spleen. As ES-62 is known to modulate TLR, NFκB and BCR 
signaling; it was predicted that the parasite product might modulate the population 
dynamics of peripheral B cells in vivo (305,324,325), as all three of these signaling 
pathways can determine the fate of B cells (174). Although ES-62 did not seem to 
favor the development of a particular B cell subset, for example marginal zone 
over follicular, the parasite product did appear to specifically expand the MZP and 
Fo B cell populations. This suggested that ES-62 could block the development of 
these mature effector cells: however, this proved at least not entirely to be case as 
although the proportion of Dump-CD138+B220low/-CD19+ plasmablasts, was 
significantly reduced in the kidney, the levels of MZ, GC and plasma B cells were 
unaltered in the ES-62 treated mice.  
 
Plasmablasts, rather than long-lived plasma cells, have been associated with 
pathogenesis in SLE as they have been predicted to be the main source of the 
pathogenic anti-dsDNA responses associated with disease flares (159,194-196). 
In this study, such anti-nuclear autoantibodies (ANA) were detected in the serum 
of MRL/lpr mice, but not MRL/MP mice, from 12-weeks of age, and treatment with 
ES-62 significantly suppressed the development of ANA responses, both prior to 
and following onset of disease. The suppression of ANA in ES-62 treated mice 
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was associated with a reduction of the levels of plasmablasts in the blood and 
kidneys and this likely contributes to the protective effect of ES-62 in MRL/lpr 
mouse. Interestingly, the serum from ES-62 treated mice stained the cell 
membranes of the Hep-2 cells, rather than the cyptoplasmic and nuclear antigens 
characteristic of lupus, and this may reflect a switch to anti-PC specificities that 
elicited by ES-62. As anti-PC antibodies are thought to be protective in SLE, by 
acting to improve clearance of apoptotic cells, this may provide another 
mechanism by which ES-62 protects against disease (412,486). By contrast, ES-
62 did not alter the levels of plasma cells in the blood, kidney or rLN in the MRL/lpr 
mice, and this possibly explains why no alteration in serum IgG1, IgG2a and IgM 
antibody levels were observed; however, a reduction in pathogenic specificities of 
these plasma cells may be masked by the significantly elevated levels of anti-PC 
produced.  
 
The reduction in effector B cell responses was associated with ES-62-mediated 
induction of a hypo-responsive phenotype of B cells, as indicated by reduced 
surface expression of activation or co-stimulatory molecules such as CD40, CD80 
and CD86 and the pro-inflammatory receptor, TLR4. Interestingly the up-regulated 
expression of the negative feedback inhibition receptor, FcγRIIb as well as the 
receptor for the B cell survival factor, BAFF suggested that ES-62 promoted the 
survival of such hypo-responsive cells. The increase of the inhibitory antibody 
receptor, FcγRIIb, on B cells is of particular interest, as FcγRIIb-/- mice develop a 
lupus-like disease (15,420), and hence the up-regulation of its expression likely 
contributes to the reduction in ANA responses. 
 
The success of targeting B cells in mouse models of disease has been testament 
to the role of these cells in pathology; however, the translation of these strategies 
into the clinic has only been moderately successful. Rituximab, an anti-CD20 
monoclonal antibody that depletes B cells, showed promise in mouse models of 
SLE but failed to meet its primary end points in two independent phase III clinical 
trials (275,281,293). Belimumab, a monoclonal antibody that binds to and reduces 
the bioavailability of BAFF, the B cell activating factor, was more successful and 
became the first drug in 50 years to receive FDA approval for the treatment of SLE 
(487). The failure of rituximab, an off-label therapy favored by many 
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rheumatologists to treat SLE patients that do not respond to conventional 
therapies, can easily be put down to poor clinical trial design due to inadequate 
patient characterization, an issue with SLE patients that has previously likely 
obstructed beneficial drugs receiving FDA approval for this disease. However, the 
ineffectiveness of Belimumab suggests that alternative B cell therapies are 
required for the treatment of SLE and dictates that alternative approaches should 
be considered (38).  
 
One possible reason for the low success rates of B cell depleting therapies may be 
that they generally do not discriminate between effector and regulatory B cells 
(281). Regulatory B cells (Bregs) can suppress the development of pathogenic T 
and B cell responses in autoimmune disease via IL-10- dependent mechanisms, 
with such Bregs being reported to suppress disease in mouse models of MS 
(EAE) (488), RA (CIA) (245) and SLE (MRL/lpr) (244). Similarly, populations of IL-
10 producing B cells have also been identified in humans and indeed, the ability of 
these cells to suppress T cell responses has been reported to be reduced in SLE 
patients (247).  
 
Interestingly, therefore, several studies have implicated a role for Bregs in the 
helminth-mediated suppression of autoimmune disease in both mouse and man 
(353,416). Perhaps reflecting this, it has previously reported that ES-62 induces 
IL-10 production by peritoneal B1 B cells (326). The effect of ES-62 on regulatory 
B cells in the MRL/lpr mouse were therefore evaluated and it was found that ES-62 
increased the proportion of IL-10-producing B cells in the spleen, pLN, rLN and 
most importantly, the kidney. The major phenotype of these Bregs was that of the 
MZP B cells (244,245), a population that declined with kinetics mirroring the 
development of proteinuria in the MRL/lpr mouse. Moreover, during established 
disease, exposure to ES-62 increased the proportion of MZP B cells in the spleen 
and also circulating in the blood and interestingly, healthy 20-week old MRL/MP 
mice had substantially higher levels of B cells of the MZP phenotype relative to 
MRL/lpr mice. 
 
To determine whether the suppression of proteinuria by ES-62 was B cell 
mediated, B2 B cells were purified from 20-week old ES-62 or PBS treated 
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MRL/lpr mice and transferred into 7-week old MRL/lpr recipients. Remarkably, the 
B cells from ES-62 treated mice suppressed the development of proteinuria 
whereas the mice that received B cells from PBS treated donors developed 
disease that was not significantly different to those receiving PBS alone. ES-62-B 
cell mediated suppression of disease was associated with a reduction in renal 
lymphadenopathy and suppression of ANA levels. Mechanistically, such protection 
was associated with an increase in the levels of rLN Bregs, a switch in Hep-2 
staining indicative of anti-PC responses as well as elevated levels of IL-17A+ and 
reduced IL-22+ cells in the spleen and rLN. These data imply that ES-62 resets the 
IL-17A/IL-22 axis via B cell dependent mechanisms and suggest that transfer of 
ES-62-treated B cells is sufficient to mimic the protective actions of ES-62 (Fig. 
7.3).  
 
7.6. Is modulation of the effector/regulatory B cell balance a generality of the 
action of ES-62 in inflammatory disease? 
 
ES-62 mediated suppression of collagen-induced arthritis, a mouse model of 
rheumatoid arthritis, is also associated with a modulation of the IL-17A/IL-22 axis 
(336,338). Unlike the MRL/lpr model, however, in the CIA model IL-17A drives 
pathogenesis whereas IL-22 plays dual pathogenic and protective roles (Pineda, 
Harnett & Harnett unpublished data). To address whether resetting of the effector: 
regulatory B cell balance is general to the anti-inflammatory action of ES-62 in IL-
17A-associated autoimmune inflammation, the effect of ES-62 on the population 
dynamics of B cells in CIA was also investigated. As in the MRL/lpr mouse, the 
proportion of follicular B cells was elevated in the spleens of CIA mice treated with 
ES-62: however, the, proportions of GC B and Tfh cells were decreased, whereas 
in the MRL/lpr mouse, GC B cells were unaffected by the parasite product and the 
proportion of Tfh cells in the spleen was significantly increased. This may be due 
to the different roles of IL-17A/IL-22 and plasma cells/plasmablasts in the CIA 
mouse as the levels of both plasma cells and plasmablasts appeared to be 
affected by ES-62 being reduced in the paws of treated mice. Crucially, the levels 
of IL-10-producing B cells were also increased by exposure of CIA mice to ES-62 
although in this case there didn't appear to be a preferential induction of a 
particular subset such as those of the MZP phenotype, but rather a homeostatic 
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resetting to the levels observed in naive mice.  Interestingly, therefore, preliminary 
experiments in the ovalbumin-induced airway hypersensitivity model of asthma, in 
which the protective effects of ES-62 are also associated with suppression of 
pathogenic Th17/Th2 responses (338), revealed that such immunomodulation was 
also associated with increases in the levels of splenic IL-10-producing B cells 
(Rodgers, Coltherd, Harnett & Harnett, unpublished data). Collectively, therefore, it 
appears that the protective action of ES-62 in both autoimmune and allergic 
disorders involves resetting of the effector: regulatory B cell balance.     
 
7.7. Developing drugs from ES-62 
 
In order to facilitate translating the therapeutic potential of ES-62 to the clinic, 
small molecular analogues of ES-62, based around the structure of the active 
immunomodulatory phosphorylcholine moiety, were tested for their ability to 
suppress lupus-like pathology in the MRL/lpr mouse. Two lead compounds, S3 
and S5, were selected on the basis that they suppressed TLR-mediated 
production of IL-6 and IL-12p40 by bone marrow derived macrophages, 
proinflammatory cytokines that promote IL-17A and IL-22 responses (Rzepecka, 
Al-Riyami, Suckling, Harnett & Harnett). The anti-inflammatory potential of these 
compounds was confirmed in the MRL/lpr mouse as both molecules suppressed 
the development of proteinuria. Consistent with their administration after disease 
had begun to be established, neither molecule seemed to affect the induction of 
regulatory B or T cell populations or IL-17A or IL-22 production, responses likely to 
have been initiated prior to the onset of pathology. However, as with ES-62, 
suppression of disease was associated with the modulation of MyD88 expression 
in effector cells at the site of inflammation. This finding is potentially exciting as 
there is an urgent requirement for drugs to treat lupus nephritis in SLE patients. 
Conventional therapies are effective but cause unacceptable collateral damage to 
the patient. Preliminary data suggest that S3 and S5 have good tolerability profiles 
and low toxicity (Rzepecka, Al-Riyami, Harnett & Harnett, unpublished data): 
furthermore, given that these compounds target mechanisms that have been 
selected through host-parasite evolution to result in safe immune modulation, it is 
possible that optimized derivatives of these compounds could suppress renal 
inflammation with limited side-effects.  
! 272!
 
In the study of parasite immunomodulatory mechanisms and host-parasite 
interactions, it is important to realize that these naturally evolved relationships do 
not solely provide material to be therapeutically manipulated, but rather and 
perhaps more importantly, they should also be viewed as tools that provide 
interesting insights into the mechanisms of the immune system in health and 
disease. By exploring the therapeutic potential of ES-62 in the MRL/lpr mouse 
model of SLE, several interesting discoveries have been made that may impact on 
our understanding of the human disease. Firstly, that IL-22 appears to pathogenic 
whilst IL-17A may have dual pathogenic and protective roles in disease. Secondly, 
that B cells may control such immune responses to regulate the development of 
autoimmunity. And finally, that modulation of pro-inflammatory signaling can 
suppress tissue inflammation, even in the presence of substantial kidney 
histopathology.  
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Figure 7.1: Proinflammatory signaling in the glomerulus. MyD88 signals via 
ARNO-ARF6 to destabilize epithelial barriers (452) and hence as the suppression 
of proteinuria in ES-62 treated MRL/lpr mice is associated with a reduction in the 
levels of MyD88 expression in the kidney, this may indicate that this ARNO-ARF6 
pathway is suppressed. Alternatively, ES-62 may promote signaling of this residual 
pool of MyD88 via the MAL-dependent pathway reportedly involved in maintaining 
epithelial tight barriers (454).  
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Figure 7.2: ES-62 modulation of IL-17A and IL-22 may affect the 
development of pathogenic B cell responses. Activated B cells can develop 
into long-lived plasma cells via the germinal center reaction or via extra-follicular 
development, into plasmablasts/short-lived plasma cells. This cell fate decision is 
dependent on several factors such as the affinity and signal strength of the BCR 
and the cytokine milieu: thus, IL-17A promotes and drives the germinal center 
reaction in lupus-prone mice (403). Prior to the onset of disease IL-17A appears to 
contribute to pathogenesis in the MRL/lpr mouse; this may reflect its ability to 
promote the break in tolerance and the early development of autoantibody-
producing plasma cells (Pc) and memory B cells (Mc). IL-22 is also pathogenic 
prior to the onset of disease and may be involved in the activation of naturally 
occurring dsDNA-specific follicular B cells (Fo1) or the reactivation of dsDNA-
specific memory B cells (Mc) into anti-dsDNA producing plasmablasts/short-lived 
plasma cells (Pb). By suppressing both IL-17A and IL-22 at this time point, ES-62 
may prevent or perturb these pathogenic B cell responses. During the established 
disease phase, however, ES-62 suppresses IL-22 production whilst promoting that 
of IL-17A. This may result in the preferential entry of memory B cells into the 
germinal centre reaction rather than the extra-follicular development of dsDNA-
specific plasmablasts. Thus by suppressing IL-22 at this time point, ES-62 may 
prevent the development of pathogenic plasmablast production of anti-dsDNA that 
is associated with the human disease (195). 
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Figure 7.3: ES-62 modulation of pro-inflammatory responses in the MRL/lpr 
mouse. ES-62 modulates disease in the MRL/lpr mouse by modulating the 
balance of effector and regulatory cells. Most notably, the parasite product 
suppresses the production of the pro-inflammatory cytokine IL-22 and the 
generation of pathogenic ANA producing plasmablasts, whilst inducing counter-
balancing IL-17Aresponses and promoting the development of IL-10 producing 
regulatory B cells. ES-62 also suppresses the ability of B cells to interact with T 
cells, via the induction of hypo-responsive phenotype. Furthermore, the parasite 
product has been shown to have anti-inflammatory effects on macrophages and 
also renal cells. Remarkably, the majority of these effects may be B cell dependent 
as they are observed in recipient mice that receive B cells from ES-62 treated 
donors induce the reduction of ANA producing and elevation of anti-PC producing 
cells, suppression of IL-22 producing and elevation of IL-17Aproducing cells and a 
suppression of lupus nephritis.  
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